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ABSTRACT 
 
Low-middle income countries are experiencing greater increases in cancer incidence due to 
changes in lifestyle. Colorectal cancer is one cancer that reflects this increase [1, 2]. As cancer 
incidence increases so do the costs associated with treatment. Although chemotherapy is not 
the only cost contributor, it increases costs considerably. This problem is not unique to low-
middle income countries and requires further research [3]. Therefore this research was 
conducted to ascertain the cost of colorectal cancer chemotherapy in South Africa for both 
public and private healthcare sectors and to determine if treatment is equitable between the 
sectors. Clinical pathways were developed and compared to clinical practice by conducting a 
retrospective drug utilisation review to determine any variation from the pathways. A costing 
model was developed to include chemotherapy, supportive medicines, administration fees  
and administrative fees. The cost was calculated for the developed pathways and the 
retrospective drug utilisation review allowed for comparison between the sectors and with 
expected costs. Observations indicate private sector treatments are similar to international 
standards due to the availability of biological agents however public sector patients have 
limited access to newer therapies. Comparing the two sectors indicates a higher cost of 
chemotherapy in the private sector and one such example is the cost difference observed for a 
commonly prescribed regimen CAPOX for advanced CRC. The observed cost per cycle was 
R 6 068,28 (public sector) vs. R 9 480,93 (private sector). This is largely due to different 
access as well as acquisition costs. Nevertheless these patients do have access to newer 
biological agents. In conclusion, South Africa’s two healthcare sectors differ in access to 
treatment with the public sector per capita cost for therapy being lower.   
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1. CHAPTER ONE – INTRODUCTION 
 
1.1 General Introduction 
 
South Africa’s healthcare system is divided into two sectors based on socioeconomic factors, 
namely the public non-insured (~85% of population) and private insured (~15% of 
population) healthcare sectors. The healthcare provisions range from basic primary healthcare 
services to highly specialised healthcare services. While the two sectors may offer similar 
services there is a notable difference in funding as well as in the population which makes use 
of the healthcare services. Even though a larger population makes use of the public healthcare 
sector, the overall expenditures incurred between the two sectors are actually comparable [4]. 
 
The comparable expenditures result in an unequal per capital healthcare spending [4]. This 
means that South African private healthcare sector patients cost more than public healthcare 
sector patients. Research also shows that this gap between the two healthcare sectors is ever-
increasing thus concerns are arising as to whether or not medical schemes and their 
beneficiaries receive cost effective care whereas public sector patients receive inadequate 
care. One such area of concern is with the use of chemotherapeutic medicines.  
 
Chemotherapeutic medicines are well known to be of high cost, not only in South Africa but 
globally. Some of the reasons for these huge costs are due to the fact that these medicines 
circulate in a non-competitive market and newer agents are not used to replace older ones but 
rather as add on therapies. In addition many cancers are incurable and patients may be treated 
with all the available medicines even though there is insufficient evidence to support their 
usage [3].  
 
Additionally, the financing of the two healthcare sectors differ which ultimately influences 
the price of medicines within each sector. The private healthcare sector in South Africa is 
unable to acquire these medicines at lower rates unlike the public sector due to the 
implementation of a transparent pricing system in 2004 known as single exit pricing [5].The 
single exit price (SEP) is the price that the manufacturer must sell the medicine to dispensing 
healthcare professionals regardless of the volume that is ordered. This also applies to the sale 
of medicines by dispensing healthcare professionals to patients. This transparency ensures 
that no perverse incentives including rebates or discounts apply thereby ensuring equitable, 
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availability, affordability and quality of all medicines sold within the country [6]. In addition 
to the SEP of medicines a dispensing fee may be added by the pharmacist or dispensing 
doctor based on a scale-base calculation. The high costs of medicines consequently are often 
carried over to the patients in the form of co-payments as medical schemes are often 
unwilling to cover all costs. There are also instances where patients cannot afford medical 
schemes but do not access the public sector in which case they fund their treatment fully out-
of-pocket.  
 
On the other hand however, through tender procurement processes and adherence to the 
Essential Medicines Lists as used in the public sector, patients do not always have access to 
all the available medicines which circulate within the private healthcare sector. Healthcare 
financing will be discussed in more detail in section 1.5.7.  
 
Hence given the discrepancies in funding and availability of the medicines in the two sectors, 
it is important to establish whether or not patients in the private sector are paying more for the 
same medications available to public sector patients and also to ascertain whether or not 
access to treatment is at all equitable between the two sectors. Moreover it is unclear as to 
whether or not patients are treated according to evidence-based clinical pathways as clinical 
guidelines are lacking in South Africa for a disease such as colorectal cancer.  
 
Therefore the aim of this study was to calculate and compare the costs between the public and 
private healthcare sectors of South Africa for the treatment of colorectal cancer according to 
the accepted treatment pathways and formularies such as the standard treatment guidelines 
and essential medicine lists, which are currently used in practice both in the public and private 
sectors. Moreover the study will compare the treatment patients receive to the evidence-based 
clinical pathways available.  
 
1.2 Study Objectives 
 
1. To determine the accepted treatment pathways, based on treatment guidelines, used in the 
past 12 months in the public and private sectors for systemic treatment of early and late 
colorectal cancer.  
2. To analyse retrospective drug utilisation data of the chemotherapeutic medicines from 
both sectors based on a sample drawn from a tertiary/quaternary public hospital in 
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Gauteng (representing the public sector) and a major medical scheme (representing the 
private sector). 
3. To determine the costs included of the chemotherapeutic agents used in the treatment of 
colorectal cancer per sector and then calculate the total costs, administrative costs (facility 
fees associated with receiving chemotherapy), administration costs (medicines and costs 
directly related to the administration of the chemotherapy) and supportive care medicine 
costs. 
4. To compare the costs of chemotherapeutic treatment for the various pathways between the 
two sectors. 
 
1.3 Study Setting 
 
The public healthcare sector setting is the Charlotte Maxeke Johannesburg Academic 
Hospital, a tertiary/quaternary hospital in Gauteng, South Africa in which the selected patient 
cohort represents public healthcare sector patients whereas the private healthcare sector 
patient cohort is represented by a major medical  scheme, Discovery Health, within South 
Africa.
 4 
1.4 Background 
 
Cancer is a broad term used to describe diseases that arise from uncontrolled cellular growth 
and proliferation that result in abnormal cell morphology. These cancerous cells are able to 
invade and spread to other tissues and organs if undetected (metastasis). Metastasis is the 
major contributor to cancer deaths as treatment of advanced cancer can be difficult [7, 8]. 
 
Recent cancer data shows that global cancer incidence rates are changing. Namely High 
Income Countries (HICs) show a decrease in incidence while Low-Middle Income Countries 
(LMICs) show increases [2]. In 2016, it is still expected that 1,685,210 new cancer cases and 
595,690 cancer-related deaths will be recorded in the United States despite the decreases 
literature cites [9]. This increase, as cited in literature, is due to increasing westernisation 
which influences an increase in cancers such as colorectal. This adoption of an unhealthy 
lifestyle, influences factors such as reproduction, diet, metabolism and hormone determinants. 
These increase the risk of such cancers in LMICs [1, 2]. Assuming constant social and 
economic development, global cancer incidence is projected to be 22.2 million by 2030 as 
opposed to the estimated 12.7 million in 2008 [1]. Moreover cancer is one of the leading 
causes of death worldwide with 8,2 million cancer-related deaths recorded in 2012. 
Furthermore cancer cases are expected to increase to 22 million over the next two decades, 
despite the growing HIV/Aids epidemic and cardiovascular disease [10-12]. 
 
 
Figure 1.1 New cancer cases and deaths for 2008 and 2012 (excludes non-melanoma skin 
cancer) [11, 13] – Dark grey (reported new cancer cases) and light grey (reported cancer 
deaths) 
 
A comparison of GLOBOCAN data taken between 2008 and 2012 displays an increase in 
new cancer cases as well as cancer deaths (Figure 1.1). According to GLOBOCAN 2012 data, 
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more than half of the 14,1 million new cases of cancer (excluding non-melanoma skin cancer) 
occurred in LMICs [11]. This is similar for cancer deaths.  
 
1.4.1 The origins of Cancer  
 
Cancer begins with the deregulation of normal cellular processes. Cells are required to grow 
and divide in a controlled manner in order to sustain the body in a healthy state. When cells 
become old or damaged, they die and are replaced [7, 14]. This process is known as the cell 
cycle. The cell cycle consists of a systematic series of events in which the cells replicate [7]. 
It is this cellular cycle that allows cells to achieve the task of passing on their genetic material 
to the next generation of cells. In order to produce two genetically identical daughter cells, the 
DNA found in the nucleus must replicate fully via a process known as the synthesis phase (S 
phase) of the cell cycle. The duplicated DNA is then evenly separated into two cells during 
mitosis (M phase) [7]. A human cell spends 8% of a 24-hr period in mitosis, 29% 
synthesizing its cellular contents and the remainder of the time in a growth phase [15]. 
 
The cell cycle control system is very important in regulating cellular progression via many 
regulatory proteins and signaling pathways [7]. When this system malfunctions it leads to 
uncontrolled cell divisions and the development of tumours. These tumours can become 
cancerous resulting in cancer development. The cell cycle control system ensures that these 
sequential events occur correctly and at the correct time preventing tumour development. If 
however the environment becomes unfavourable, such as when there are insufficient growth 
factors, or when a cell fails to complete an important process, the control system will arrest 
the cell cycle. This cell cycle arrest is crucial in preventing tumours. The central proteins 
involved in this control system are cyclin-dependent kinases (CDKs), which are dependent on 
the cyclins for their activation [7]. The changes in the activities of these various cyclin-CDK 
complexes are what control the cell cycle phases as well as the mechanism. These changes 
include phosphorylation, binding of inhibitors such as CDK inhibitor proteins [16], 
proteolysis of cyclins and changes in the transcription of the genes, which encode these CDK 
regulatory proteins [7].  
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1.4.2 APC/C pathway and other ubiquitin ligases 
 
The cell cycle control system is also dependent on APC/C (anaphase-promoting 
complex/cyclosome) and other ubiquitin ligases. The APC/C is an important regulator in cell 
cycle progression. The complex allows for the transition from metaphase-to-anaphase during 
mitosis. These types of enzyme complexes catalyze ubiquitylation and proteolytic destruction 
of certain regulatory proteins that control the cell cycle phases. The first major target for 
APC/C is a protein that secures the linkages between sister chromatids in early mitosis. The 
second target (Figure 1.2) S- and M-cyclins will inactivate most of the CDKs. It is these 
CDKs, which play a critical role in the control mechanism.  
 
The mitogen stimulation pathway leads to the activation of MYC and E2F [7]. Mitogens 
stimulate cell division by eliminating intracellular molecular hitches, which would restrain 
cell progression in the G1 phase. The mechanism by which mitogens do so is via cell-surface 
receptor activation.  The activated mitogen receptor will lead to the activation of a GTPase, 
RAS. The activation of RAS causes downstream activation of RAF via phosphorylation. This 
in turn leads to the activation of the MAP kinase pathway (MAPK pathway) and results in an 
increased expression of the immediate early genes, such as those, which encode the regulatory 
protein MYC (Figure 1.2). MYC will lead to an increased expression of the delayed response 
genes including those that lead to an increase in the activity of the G1-Cdk. This allows for 
phosphorylation of the Retinoblastoma (RB) family of proteins. By phosphorylating RB, it 
allows for the protein to become inactive and free the E2F gene regulatory protein, which it 
binds. The activation of E2F leads to the transcription of the G1/S genes as well as the G1/S 
cyclin and S cyclin genes. Once the S-CDK is activated DNA synthesis can occur as seen in   
Figure 1.2 below [7]. 
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Figure 1.2 Control of the cell cycle [7] – DNA synthesis is activated via the activation of the 
MAPK pathway. The MAPK pathway activates the gene expression of MYC leading to the 
expression of the MYC protein. MYC causes a delayed response of G1-Cdk expression 
allowing for inactive E2F to be activated. S phase gene transcription is subsequently activated 
allowing for DNA synthesis.  
 
1.4.3 Abnormal proliferation signals 
 
 
If abnormal proliferation signaling occurs, cell-cycle arrest or apoptosis is induced, however, 
this is not the case in all cells. Cancer cells are an example where apoptotic signals are absent. 
This is as a result of gene mutation These cancer-promoting genes are referred to as 
oncogenes. This response by normal cells is one way to prevent the survival and proliferation 
of cells containing oncogenes [7]. 
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An example of these mutations is seen in a single amino acid mutation encoding the RAS 
protein (KRAS and NRAS). This causes the protein to become overactive leading to a 
constant stimulation of the RAS pathway. This occurs even when there is an absence of 
mitogenic stimulation. Mutations have also been seen in MYC, where the corresponding 
protein becomes overexpressed stimulating unwarranted cellular growth and proliferation and 
in so doing promoting tumour development [7]. Other unwarranted mitogenic stimulation also 
leads to the overproduction of a cell-cycle inhibitor protein, ARF. This inhibitor protein binds 
to MDM2 and inhibits it, which leads to the inhibition of P53 degradation. The increased 
levels of P53 increases the level of cell-cycle arrest or apoptosis, which is evident in normal 
cells [7]. 
 
Apoptosis is a process whereby cells undergo “suicide” in response to cellular signals. 
Apoptosis involves a morphological change by the cell including cytoskeleton collapse and 
nuclear envelope disassembly together with chromatin condensation and fragmentation. Cells 
undergoing apoptosis form apoptotic bodies, which are engulfed by macrophages so as to 
eliminate them quickly without any inflammation. Necrosis is another method in which cells 
can undergo cell death however, unlike apoptosis these cells die in response to trauma or lack 
of blood supply. The necrotic cells will swell and burst, spilling all their cellular contents into 
the neighbouring area. This results in an inflammatory response [17]. 
 
1.4.4 Types of Cancer  
 
There are over 100 different types of cancer, which can be grouped into categories ( 
Table 1.1) based on the origin of the cancer cells [14, 18]. 
Table 1.1 Classification of the different types of Cancer [14, 18]. 
Category Description 
Carcinoma Cancer cells arising in the skin or tissues that line or cover 
the internal organs. 
Sarcoma Cancer cells arising in the bone, cartilage, fat, muscle, 
blood vessels or any other connective/supportive tissue. 
Leukemia Cancer cells arising in blood-forming tissue such as the 
bone marrow. 
Lymphoma and myeloma Cancer cells arising in the cells of the immune system. 
Central nervous system cancers Cancer cells arising in the tissues of the brain and spinal 
cord.  
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Carcinomas are the most common types of cancer, which cause most of the cancer deaths 
each year, including lung,  prostrate, cervix, stomach, liver, colorectal and breast cancer [11, 
12].  
 
1.4.5 Incidence of cancer based on geographical region 
 
The incidence of a cancer type also appears to vary based on the geographical region. Recent 
cancer mortality data (mortality is influenced by incidence [19] shows that different 
geographical regions have increased mortality of certain cancers as opposed to other regions. 
While cancer mortality is decreasing globally, liver cancer mortality is still on the rise and 
lung cancer mortality in females is also on the increase. A recent analysis of 60 countries 
from 6 continents  showed stomach cancer mortality is greatest for regions such as the former 
Soviet Union, Japan and Korea whereas colorectal cancer mortality is the greatest in the 
Oceania region (tropical Pacific Ocean Islands) [20].  
 
The only African country included in the analysis was South Africa and in comparison to 
other regions, cancer mortality is second lowest however, stomach, lung and uterine cancer 
are among the highest cancer mortalities. Africa was however grouped with Asia and 
therefore it can’t be directly translated as South Africa’s mortality statistics [20].  
 
Research such as this does indicate that geographical region is important as to the cancer type 
a population may well be at risk of developing as the disparities between the regions are based 
on the populations characteristics, risk factor prevalence within the population, screening and 
treatment access [20].   
  
1.4.7 Colorectal Cancer 
 
Colorectal cancer (CRC) is cancer that originates in the large intestine (colon) or the rectum 
(end of the colon) (Figure 1.3). CRC is most commonly found as carcinomas however rare 
cases do include lymphomas, carcinoid tumors, melanomas or sarcomas [21].   
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Figure 1.3 Anatomy of the lower gastrointestinal tract [22] 
1.4.7.1 Stages of Colorectal Cancer 
 
CRC is staged according to the American Joint Committee on Cancer (AJCC). Stage 1 to 3 
cancer (early CRC) is localised where stage 4 cancer (advanced CRC) has spread to other 
parts of the body (Figure 1.4) [23].  
 
Figure 1.4 AJCC staging of cancer [23] – Stage 1 to 3 is localised where stage 4 has spread 
to other parts of the body.   
 
1.4.7.2 Causes of Colorectal Cancer 
 
There is no single cause related to CRC however, it is a highly treatable and often curable 
disease when localised to the bowel area [24, 25]. Most CRCs begin with benign polyps or 
tumors. These polyps can become cancerous if undetected or ignored. The major problem is 
that CRC progresses slowly from these benign polyps. This means that symptoms may not be 
present for many years until the cancer is progressively further along which reduces the 
survival rate [21, 26]. As the cancer is progressively further along, it will grow into the inner 
cell layer of the colon or rectum, allowing it to grow into nearby blood or lymph vessels. The 
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cancer is then able to move to more distant parts of the body, such as the liver, through 
metastasis [21, 26]. It is the metastasis of CRC that makes it difficult to treat and therefore not 
surprising to see the survival rate drop. From the latest published data survival rates decrease 
as the CRC progresses further but there has also been greater increases in survival rates 
compared to previously published data by SEER (Surveillance, Epidemiology and End 
Results Programme) [27]. 
 
1.4.7.3 Risk factors, symptoms and incidence of Colorectal Cancer 
 
A risk factor is anything that can affect a person’s chance of getting a disease such as cancer. 
It has to be noted that different cancers have different risk factors however, one factor can be 
a risk for more than one type of cancer, such as smoking [24]. Also if a person has a risk 
factor, it does not mean that they will develop the disease nor does it mean if a person has no 
risk factors that will not develop the disease [26].  There are known to be several risk factors 
associated with developing CRC. These can be grouped into lifestyle related risk factors and 
risk factors that a person cannot change such as genetics. 
  
1.4.7.4 Lifestyle related risk factors 
 
1.4.7.4.1 Diet 
 
A diet high in red meat such as beef, lamb or pork as well as processed meat (luncheon meats) 
can increase the risk. Cooking meats at very high temperatures which includes frying, boiling 
and grilling can result in the formation of carcinogens. Research has also shown that a diet 
high in fruits, vegetables and whole grains can decrease a person’s risk of developing CRC 
[24, 26]. 
 
1.4.7.4.2 Physical inactivity and obesity 
 
Persons who are physically inactive have an increased risk of developing CRC likewise does 
obesity. The risk of developing CRC does seem to be greater in men than women [26].  
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1.4.7.4.3 Smoking and heavy alcohol consumption 
 
Smoking has been well documented as a cause of lung cancer however, it has also been linked 
to other cancers such as CRC. Long-term smokers have a higher risk than non-smokers. The 
development of CRC has also been linked to heavy alcohol consumption. This is possibly due 
to lower levels of folic acid in the body of a person who consumes large amounts of alcohol 
regularly [26].  
 
1.4.7.5 Non-modifiable risj factors 
 
1.4.7.5.1 Age 
 
CRC affects both young and old however, elderly people, particularly from the age of 60, are 
at an increased risk of developing the disease [24]. It has been reported by the American 
Cancer Society that 9 out of 10 people diagnosed with CRC are over the age of 50 [26].  
 
1.4.7.5.2 Inflammatory bowel disease 
 
 When the colon is inflamed for a long period of time, such as with ulcerative colitis or 
Crohn’s disease (but not irritable bowel syndrome (IBS)); the likelihood of developing 
dysplasia increases. Dysplasia is when the cells lining the colon or rectum have an abnormal 
appearance, but are not cancerous however they can result in neoplastic development [26, 28]. 
The development of dysplasia is thought to contribute to a patient’s risk of developing CRC at 
some stage [21].  
 
1.4.7.5.3 Type 2 diabetes mellitus (T2DM) 
 
Both CRC and T2DM have common risk factors such as excessive weight therefore people 
who have T2DM are at a risk for developing CRC. These patients, once diagnosed, have a 
worse prognosis than patients without diabetes. There is also growing evidence to support a 
strong association between metabolic syndrome and an increased risk of developing CRC [26, 
29].  
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1.4.7.5.4 Personal history of polyps or colorectal cancer 
 
Patients with a history of polyps have an increased risk of developing CRC and more so if the 
polyps are abundant and large in size. A previous incidence of CRC poses a risk, even if the 
cancer was successfully removed via surgery. The risk is furthermore increased if the first 
incidence cancer was at a young age [21, 26].  
 
1.4.7.5.5 Family history 
 
CRC can occur in people who do not have a family history of the disease however, if a person 
has a family history their risk is increased. This increased risk is even greater if the relatives 
are first-degree relatives and if the relative was diagnosed at an early age. These cancers, 
which are said to “run in a family”, are due to inherited genes, shared environmental factors 
or the combination of each [24, 26]. Certain racial and ethnic groups also have a 
predisposition to CRC such as African Americans and Ashkenazi Jews. Not all the reasons for 
this is understood, however, it is most likely due to inherited genetic mutations [25, 26].  
 
1.4.7.5.6 Inherited syndromes  
  
Inherited gene mutations can often result in the development of disease and about 5-10% of 
people diagnosed with CRC have inherited gene mutations. These defects often lead to people 
developing CRC at an earlier age than statistics show. Two such inherited syndromes include 
familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer 
(HNPCRC). FAP is caused by mutations in the APC gene (tumour suppressor gene) (5q22.2) 
however, only 1% of all CRCs are due to FAP. FAP patients tend to develop many polyps in 
the colon and rectum at an early age and the cancer develops from one or more of these 
polyps by the time these people are in their early twenties [21, 26].   
 
HNPCC, also known as Lynch syndrome, is caused by inherited mutations in many DNA 
repair genes HNPCC is the most common hereditary form of CRC but contributes 2-4% of all 
diagnosed cases. People who have this syndrome have a lifetime risk of 80% and patients 
generally develop CRC at a much younger age than non-hereditary cases however, these 
patients are not as young as the patients with FAP [21, 25, 26].  
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1.4.7.5.7 Acquired gene mutations 
 
Inherited genetic mutations only account for a small percentage of all CRC cases thus due to 
the genetic nature of cancer most cases are due to acquired gene mutations. It is not known 
what causes these acquired mutations but the above mentioned risk factors may play a role 
[26]. Most CRC cases are adenocarcinomas and as such many somatic mutations have been 
found. These mutations are more recently used as predictive markers to ensure patient 
responses to certain therapies as well as targets for drug development. These acquired 
mutations occur in genes such as RAS family  (KRAS, NRAS) and BRAF [30]. The RAS/RAF 
pathway (Figure 1.5) is essential for eukaryotic cell survival. This pathway ensures that cells 
grow, proliferate and undergo programmed cell death (apoptosis) [7] as discussed under 
sections 1.4.2 and 1.4.3. These genetic mutations affect the cellular pathways seen in Figure 
1.5. 
 
Figure 1.5 Schematic of the MAPK and PI3K pathways – Following activation, the cell 
will proliferate but genetic mutations occur these pathways result in uncontrolled cell 
proliferation [31]. 
 
1.4.7.6 Symptoms of colorectal cancer 
 
Although most CRCs remain undetected for some time as no symptoms are present in the 
patient, there can be an onset of symptoms such as abdominal pain. The symptoms that occur 
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are linked to the primary site of the tumor. As the tumor grows, the symptoms become more 
apparent. The abdominal pain and tenderness some patients experience can be due to an 
invasive tumor, which penetrates the muscularis propria and invades the adjacent tissue. 
However, an acute abdominal pain may actually result from perforation of the colon [21, 24, 
26].  
 
Any obstruction of the colonic lumen can result in abdominal distension, pain, nausea and 
vomiting. Diarrhea and constipation are associated with the development and spread of CRC 
due to the change in bowel movements. Some patients are reported to have bloody stools. The 
reason for this is possibly linked to trauma experienced by the fecal stream, this can lead to 
iron deficiency anemia. Weight loss without reason may also be experienced by patients [21, 
26].  
 
1.4.7.7 Incidence of colorectal cancer 
 
CRC is the third most commonly diagnosed cancer in men globally with 746 000 cases 
reported in the GLOBOCAN 2012 statistics while in women 614 000 cases were reported in 
the same year however is the second most common cancer in women [11]. In the 2008 
GLOBOCAN statistics 60% of all cases reported occurred in LMICs however, a decline to 
55% was seen in 2012. This indicates that lifestyle risks are associated with developing CRC 
moreover it shows that as the LMICs become more developed, diseases such as CRC increase 
(Figure 1.6) [11, 13]. GLOBOCAN statistics for mortality show more CRC patients have died 
as a result of the disease in the most recent statistics as opposed to 2008. This includes the 
HICs however, LMICs display a much larger increase in their mortality statistics than the 
HICs (Figure 1.7).  
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Figure 1.6 Comparative graph of the incidence of colorectal cancer cases for certain 
GLOBOCAN regions for 2008 and 2012 [11, 13] – dark grey (2008) and light grey (2012) 
 
 
Figure 1.7 Comparative graph for GLOBOCAN colorectal cancer mortality statistics 
for certain regions for 2008 and 2012 [11, 13] - dark grey (2008) and light grey (2012) 
 
The latest GLOBOCAN statistics indicate that Africa has one of the lowest incidence and 
mortality rates for CRC however, research shows that Southern Africa, particularly South 
Africa, has a high incidence rate (Table 1.2) [11, 13]. Although the data indicates a high 
incidence, the GLOBOCAN data is extrapolated from another population and the 
transferability could be questioned for the South African population [13]. Notwithstanding 
this, colorectal cancer has moved into the top three cancers for both sexes in the country. This 
change is largely due to a decrease in the incidence and mortality rates of esophageal cancer. 
Mortality rates have also shown a decrease from 2008 to 2012 for the South African 
population.  
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The most recent cancer statistics published in South Africa (NCR statistics) for 2012 report 
the number of confirmed colorectal cancer cases as 3396 and when compared to 
GLOBOCAN for the same time, a great difference is seen (Table 1.2) [32]. This could be that 
the South African NCR published data only reports cancer cases which are diagnosed by  
biopsy and tissue examination and does not account for alternative clinical diagnostic 
methods in accordance with the NCR regulations [13, 33, 34]. The limitation of the 
regulations is that the onus for reporting is placed on the pathologists as opposed to the 
oncologists. In addition to this, private diagnostic laboratories were not required to report 
confirmed cancer cases until 2011.  
 
Table 1.2 Differences between GLOBOCAN and NCR statistics for South Africa for 
2008 and 2011/2 [11, 13, 32, 33, 35]. 
Data source Incidence of colorectal cancer cases 
GLOBOCAN 2008 5050 
NCR 2008  2297 
NCR 2011 2913 
GLOBOCAN 2012 4697 
NCR 2012 3396 
   
Taking into consideration that the Sub-Saharan region consists of 48 countries and 24 711 
cases were recorded, the significance of the high incident rate in South Africa is noted even 
more [13]. It means that over 20% of all cases for Sub-Saharan Africa are diagnosed in South 
Africa. When comparing South Africa to the USA, the USA still has a higher incidence of 
10,7%, regardless of their population size, compared to 6,8% for South Africa [13].  
 
1.4.8 Conventional treatment of Colorectal Cancer 
 
Treatment depends on a number of factors such as the stage of the cancer as well as the 
preference by both the attending physician and the patient. The age of the patient however 
should not play a role in the choice of treatment [36, 37]. Although evidence suggests the 
benefit of chemotherapy for geriatric patients, these patients are found to be undertreated 
which contributes to the poor outcome geriatric patient’s experience [38, 39]. Although 
literature states that age shouldn’t influence the choice of treatment, the likelihood for older 
patients to receive the same chemotherapeutic regimens is lower and is often due to the 
patient choosing quality of life over possible adverse events [38].  
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Apart from patient preference, research conducted in 2010 revealed that oncologists are less 
likely to prescribe intensive chemotherapy regimens despite the benefits for older patients 
[40]. Older patients are often not prescribed chemotherapy due to factors such as performance 
status or ECOG status and not due to a lack of efficacy or safety [41]. Ideally a 
Comprehensive Geriatric Assessment should take place in order to assess the best treatment 
plan for the older patient. Additionally studies have shown that even with an increase in age, 
the survival benefit of adjuvant chemotherapy such as fluorouracil does not decrease [36]. In 
another study conducted, it was found that elderly patients are able to tolerate adjuvant and 
palliative chemotherapy similarly to younger patients suggesting that age shouldn’t be a factor 
when considering treatment options [37]. Clinical trial data is few for this group of patients 
but a pooled analysis of  fluorouracil versus observation did show a similar benefit for older 
and younger patients with similar rates of grade 3 and 4 toxicities [42, 43].  
There are three common conventional treatment regimens available to patients diagnosed 
namely surgery, radiation therapy and chemotherapy which includes biological therapies [21, 
26].  
 
1.4.8.1 Surgery 
 
Surgery is used for early stages of cancer however later stages of CRC can be treated with 
surgery by removing not only cancerous cells but the part of the colon which is cancerous [21, 
24, 26]. The type of surgical procedure undertaken will depend on the location of the cancer 
in the colon or rectum, the size of the cancerous tumor and whether or not metastasis has 
occurred. 
 
A local resection will be done to remove early stage tumors but also to send the samples 
obtained to pathology in order to establish the stage of the cancer. With any surgical 
procedure, nearby healthy tissue will also be removed in order to ensure that no cancerous 
cells remain behind. If the cancer is not entirely removed, it is likely to continue growing and 
possibly undergo metastasis [21].  
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1.4.8.2 Radiation  
 
Radiation therapy involves using high-energy x-rays or other radiation in order to kill the 
cancer cells or to prevent their growth by damaging the cell’s DNA. There are two different 
types of radiation therapy used depending on the various factors such as stage and type of 
cancer (Table 1.3) [24, 44].  
 
Table 1.3 Factors that influence the type of radiation therapy cancer patients receive 
[44] 
1.  The type of cancer. 
2.   The size of the cancer. 
3.   The location of the cancer in the body. 
4.   The vicinity to normal tissues that is sensitive to radiation. 
5.   The distance the radiation has to travel within the body. 
6.   The general health and medical history of the cancer patient. 
7.   Whether the patient will receive other types of cancer treatment. 
8.   Additional factors, such age and comorbidities. 
 
Radiation will either be via external beam or internally via radioactive materials being placed 
inside the body near the cancer cells (brachytherapy). Alternatively systemic radiation could 
be used whereby patients either ingest or receive the radioactive material intravenously, 
radioactive iodine or a monoclonal antibody with a bound radioactive substance [44]. CRC 
particularly doesn’t require radiation however once the cancer spreads to the liver, radiation 
will be used or if the patient experience severe pain [24]. 
1.4.8.3 Chemotherapy 
 
Chemotherapy involves the administration of medication to target and destroy cancerous 
cells. Chemotherapy works to stop or slow down the growth rate of the cancer cells, which are 
rapidly dividing cells however the treatment also affects healthy cells negatively. The damage 
incurred by healthy cells determines the side effects of the treatment. Depending on the stage 
of the CRC, chemotherapy will be administered to cure, prolong life, control or ease the 
symptoms of the cancer. Adjuvant chemotherapy will be administered to reduce the 
likelihood of the cancer returning but if the cancer is not cured by the chemotherapy, it will 
either be slowed down preventing metastasis or administered to shrink the tumors to alleviate 
any pain or pressure caused by them. The latter is commonly referred to as palliative 
chemotherapy [21].  
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Chemotherapy is also used in conjunction with radiation or biological therapy in order to 
improve the prognosis of the cancer [24]. Combinational chemotherapy is often more 
effective [24, 26]. Many chemotherapeutic medicines also have a narrow therapeutic index 
indicating that the therapeutic doses used are very close to toxic levels. This means the side 
effects of the treatment will be worse and will occur in the majority of patients. Many of the 
common side effects are as a result of the chemotherapy affecting normal fast dividing cell 
groups such as those found in the blood, hair, mouth, skin and nails [26, 45]. 
 
1.4.8.3.1 Adverse drug reactions of Chemotherapy 
 
Chemotherapy decreases the level of the blood components namely erythrocytes, leukocytes 
and thrombocytes resulting in less oxygen been carried from the lungs to the rest of the body 
resulting in patients feeling tired and short of breath. Hair loss is common for patients due to 
the cells of the hair follicles, which are responsible for growth and maintenance, being 
affected by the treatment. The hair loss can also affect the scalp, face and any other parts of 
the body containing hair. A sore throat and mouth are also likely due to the cells lining the 
inside of the mouth and throat dividing rapidly and thus are susceptible to harm by the 
chemotherapy. Diarrhea, constipation, nausea and vomiting are common adverse drug 
reactions but are easily treated. Allergic reactions or hypersensitivity reactions can also occur 
in which case patients will need to undergo prophylactic treatment before receiving any 
further chemotherapy if severe. There are also adverse drug reactions specific to certain of the 
chemotherapeutic medicines. These include hand-foot-skin (HFS) syndrome with 5-
fluorouracil or capecitabine, neuropathy with oxaliplatin treatment and irinotecan can cause 
severe diarrhoea [26, 45, 46]. 
 
1.4.8.3.2 Conventional Chemotherapy for CRC 
 
Conventional CRC chemotherapy is summarised in Table 1.4 below.   
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Table 1.4 Summary of conventional CRC chemotherapy medicines  
Medicine Indications Chemical Structure Pharmacological Mechanism of 
Action 
Properties of the medicine Clinical Trial Data 
5-
Fluorouracil 
(5-FU) 
Early and 
Advanced 
CRC  
Pyrimidine antagonist of 
thymidylate synthase (TS). 
 
Figure 1.8 Chemical 
Structure of 5-
Fluorouracil [47] 
 multiple enzymatic reactions 
allow for activation  
 metabolite, 5’fluoro-2’-
deoxyuridine-5’-monophosphate 
(5FdUMP) will covalently bond 
to an enzyme thymidylate 
synthetase.  
 incorporation of the active form 
of 5-FU, cell death occurs due to 
both DNA and RNA processes 
being inhibited [46] 
 
 immunosuppressant [45]  
 used in combination with folinic 
acid - formyl derivative of 
tetrahydrofolic acid, the active 
metabolite of folic acid and is 
prescribed to aid augmentation 
of the neoplastic effects when 
prescribed with 5-FU [45]. 
 multiple dosing regimens: de 
Gramont regimen (5FULV2), 
MAYO regimen [48]. 
 combination with oxaliplatin 
and irinotecan demonstrated 
an improvement in survival [49, 
50].  
 
 
 GERCOR (2004) the 
sequence of FOLFIRI 
followed FOLFOX or the 
reverse has similar overall 
survival (OS) rates, 
progression free survival 
(PFS) and reaction rates 
(RR).  
 the two regimens differ 
only in the dosing of the 
irinotecan and 
oxaliplatin  [51].  
 
Capecitabine
(XELODA®; 
Hoffmann-La 
Roche, Inc., 
Basel, 
Switzerland)  
Early and 
Advanced 
CRC 
Oral prodrug of 5-FU  
 
Figure 1.9 Chemical 
Structure of 
Capecitabine [52] 
 undergoes enzymatic activation 
by thymidylate phosphatase  to 
form 5-FU  
 can be used in place of  5-FU  
 adverse events: hand-foot 
syndrome (Figure 1.10), 
diarrhea, neutropenia [53].  
 with irinotecan  seems to be 
more adverse effects [54, 55]. 
 
Figure 1.10 Capecitabine induced 
hand-foot-skin syndrome 
(http://jamanetwork.com/data/Journals/DE
RM/22502/dob110011f1.png)  
 
 studies have revealed the 
compatibility of 
capecitabine with 
irinotecan and 
oxaliplatin [54, 55]. 
 non-inferior to 5FU plus 
folinic acid 
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Trifluridine/
Tipiracil 
[TAS-102] 
(LONSURF®; 
Taiho 
Pharmaceutical
s, Tokyo, Japan 
& Servier 
Laboratories, 
Paris, France) 
Refractory 
Advanced 
CRC 
TAS-102 is made up of 
trifluridine (thymidine-
based nucleic acid 
analogue) and tipiracil 
hydrochloride (thymidine 
phosphorylase inhibitor) 
[56].  
 
 
Figure 1.11 Chemical 
Structure of TAS-102 
[57] 
 
 trifluridine is the cytotoxic 
component, tipiracil prevents the 
degradation of trifluridine by 
thymidine phosphorylase thus 
ensuring more active drug is 
present in the blood stream [56]. 
 neutropenia and leukopenia are 
common adverse drug events 
[56]. 
 RECOURSE (2015)  
TAS-102 compared to 
placebo had a significant 
improval in overall 
survival (OS) [56]. 
Oxaliplatin  Early and 
Advanced 
CRC – until 
disease 
progression 
3
rd
 generation platinum co-
ordination compound. 
 
Figure 1.12  Chemical 
Structure of Oxaliplatin 
[47] 
 
 bind specifically to the guanine 
and cytosine residues of the 
DNA, resulting in cross-linkage 
of the DNA.  
 thus inhibit the DNA synthesis 
and function by inducing 
apoptosis.  
 also binds to cytoplasmic and 
nuclear proteins which will also 
form cross-links [45].  
 synergistic with 5-FU   
suppresses TS. 
 dose-limiting factor is peripheral 
neuropathy [26, 46, 58]. 
 MOSAIC (2004) and 
NASBP-C06 (2011) trials 
 adding oxaliplatin to 
5-FU, significantly 
increases the 3-year 
cancer free survival rate 
of early-staged colon 
cancer patients [16, 59].  
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Irinotecan Advanced 
CRC – 
upfront, 
reoccurrence 
or disease 
progression 
but has no 
benefit in 
early CRC.  
3
rd
 generation derivative of 
camptothecin 
 
Figure 1.13 Chemical 
structure of Irinotecan 
[47] 
 inhibits the topoisomerase 1 
enzyme  prevents the re-
ligation of the DNA strands, 
resulting in double DNA strand 
breakages and cell death. 
 S-phase specific [46].  
 a prodrug that undergoes 
conversion in the liver to a more 
potent metabolite, SN-38 [46]. 
 limiting factor for the 
metabolite’s action  inefficient 
enzyme conversion by human 
liver carboxylesterase [60]. 
 Adverse drug reactions: severe 
diarrhea prescribe loperamide 
as soon as this starts so as to 
avoid dehydration; cholinergic 
syndrome  treated with 
atropine [45, 46, 58]. 
 CALGB 89803 and 
PETACC3 trials  
adding irinotecan to 5-
FU, has no significant 
benefit to patients [61, 
62].  
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1.4.8.3.3 Biological therapies 
 
Biological therapies involve the use of monoclonal antibodies or other agents in cancer 
treatment. These agents can be used alone or in combination with chemotherapeutic agents 
such as those mentioned above. The development of these newer agents has brought about 
new methods to the management of advanced CRC colorectal cancer. Combining these agents 
with the conventional chemotherapeutic agents and resection where possible has been found 
to increase the overall survival of patients from a few months to as much as 30 months [63]. 
There are a number of both FDA and MCC (Medicines Control Council) approved agents and 
which target specific cellular receptors or growth factors. These are thought to increase the 
capacity for metastasis [64]. 
 
 
Figure 1.14 The EGF and VEGF pathways – Both the EGF and VEGF pathways are 
activated by the growth factor binding to its receptor initiating a signal transduction pathway. 
EGF leads to the activation of the RAS/RAF/MEK/ERK, PI3K/AKT/mTOR or JAK/STAT 
pathways resulting in tumour cellular growth and cell survival. VEGF results in the MAPK 
cascade activation and then the PKB/PLC-δ pathways in endothelial cells, which leads to 
angiogenesis [65]. 
 
Figure 1.14 shows the respective pathways that are activated by either the EGF or VEGF 
growth moreover it can be seen that if either one is over-expressed, the cells will experience a 
remarkable increase in proliferation, growth and survival thus increasing the risk of tumor 
formation and spread. Approximately 70% of colorectal cancers have an increased expression 
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of EGFR contributing to advanced disease stage along with poor prognosis. Due to increased 
angiogenesis and vascular permeability as a result of increased VEGF expression, there is a 
greater ability for metastasis to occur. [64]. Table 1.5 summarises all the approved biological  
therapies for CRC. 
 26 
Table 1.5 Summary of the biological agents available for CRC 
Medicine Indications Chemical Structure Pharmacological Mechanism 
of Action 
Properties of the medicine Clinical Trial Data 
*Bevacizumab 
(Avastin ®; 
Hoffmann-La 
Roche, Inc., 
Basel, 
Switzerland and 
Genentech, South 
San Francisco, 
CA) 
Advanced 
CRC 
Humanised 
Recombinant 
Monoclonal Antibody 
(MoAB) 
 VEGF inhibitor  block 
endothelial cell 
proliferation (Figure 
1.14) 
 results in decreased 
angiogenesis [65]. 
 Binds circulating VEGF in 
the blood, reducing the 
ability of VEGF to bind to 
its endothelial receptor 
(VEGFR) [64, 66].   
 Used in combination with 
chemotherapy  leads to the 
induction of apoptosis.  
 combination will stabilise the 
tumor vasculature increasing the 
delivery of the chemotherapeutic 
agent to the tumor thus it is 
standard practice to administer 
bevacizumab in combination with 
a chemotherapeutic agent [64, 
66]. 
 Hurwitz et al. (2004) [67]  
clinically meaningful and statistically 
significant result for OS, PFS and 
duration of response 
 Saltz et al. (2008) [68]  only PFS 
was statistically significant 
 Giantonio et al. (2007) [69]  
clinically meaningful and statistically 
significant result for OS, PFS and 
duration of response 
 AVEX (elderly patients) [70]  only 
PFS was statistically significant  
Aflibercept 
(ZALTRAP®; 
Sanofi, Paris, 
France and 
Regeneron 
Pharmaceuticals, 
Tarrytown, NY) 
Relapsed 
Advanced 
CRC 
Recombinant fusion 
protein made up of the 
VEGFR-1 and -2 with 
human IgG1 
 Binds to VEGF-1, VEGF-2 
and Placental Growth 
Factor [71].  
 free aflibercept had to be in 
excess of bound aflibercept 
in order for 
pharmacological action to 
be optimal [72]. 
  Early phase clinical trials  
aflibercept as a single agent and 
combinational treatments 
 a phase 2 trial established a suitable 
dose in combination with FOLFIRI 
which allowed for disease control 
[72].  
 VELOUR (2012) study was able to 
prove an improved benefit when 
aflibercept is used in combination 
with FOLFIRI in patients failing 
FOLFOX.  
 Furthermore all efficacy endpoints for 
the study were in favour of aflibercept 
when compared to placebo [73]. 
Ramucirumab 
(CYRAMZA®; 
Eli Lilly  
Indianapolis, IN) 
Relapsed 
Advanced 
CRC 
Fully Human IgG1 
Monoclonal Antibody 
(MoAB) 
 Selectively blocks 
VEGFR-2 
 Acts directly on the 
receptor resulting in a 
decreased angiogenesis 
[74]. 
 
 found to cause hemorrhages in 
patients and as such contains a 
black box warning for this adverse 
drug reaction [74]. 
 RAISE (2015)  used in 
combination with FOLFIRI, 
significant median overall survival 
was increased by 1,6 months [74-76].    
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*Cetuximab 
(ERBITUX®; 
Merck Serono, 
Darmstadt, 
Germany and Eli 
Lilly, 
Indianapolis, IN) 
Advanced 
CRC; 
Irinotecan-
Refractory 
Advanced 
CRC  
Chimeric 
human/mouse IgG1 
EGFR Monoclonal 
Antibody (MoAB)  
 EGFR inhibitor  bind to 
EGFR extracellularly 
preventing the ligand from 
binding and downstream 
activation [65]. 
 inhibits tumour cell growth  
and survival (Figure 
1.14) 
 RAS wildtype tumor (patients 
where RAS is not mutated) are the 
only patients that gain benefit from 
EGFR inhibitors [77]. 
 Anaphylactic reactions are 
common during infusion 
particularly with cetuximab [66]. 
 
Figure 1.15 Anti-EGFR therapy induced 
skin rash 
(https://3c1703fe8d.site.internapcdn.net/newm
an/gfx/news/hires/2016/1-prophylactic.jpg)  
 Used in combination with 
FOLFOX and FOLFIRI. 
 The cetuximab combination also 
proved to be more effective than 
cetuximab monotherapy for 
irinotecan-refractory patients 
moreover, the use or nonuse of 
oxaliplatin previously had no effect on 
the efficacy of cetuximab thus patients 
who have been previously treated with 
oxaliplatin or FOLFOX can 
potentially benefit from cetuximab 
[78].  
 CRYSTAL (2009) advanced CRC 
is treated initially with FOLFIRI and 
cetuximab as opposed to FOLFIRI 
alone, disease progression decreases 
and response rate increases [77]. 
Panitumumab 
(Vectibix®; 
Amgen, 
Thousand Oaks, 
CA) 
Advanced 
CRC 
Fully human IgG2 
Monoclonal Antibody 
(MoAB) 
 Apart from the RAS benefits as 
with cetuximab, panitumumab 
does not mediate antibody-
dependent cell-mediated 
cytotoxicity or complement-
mediated cytolysis [79]. 
 Used in combination with 
FOLFOX and FOLFIRI. 
 Panitumumab monotherapy is well 
tolerated and effective  compared to 
best supportive care alone there is no 
overall survival benefit but is 
comparable to other studies in 
response rates, duration of response 
and progression free survival [80].  
 PRIME (2013)  compared 
panitumumab - FOLFOX4 to 
FOLFOX4, significant improvement 
for PFS and ORR [81, 82].  
 randomised phase 3 study   
combination with FOLFIRI increased 
the median OS and PFS by 2 months 
as well as reduced the risk of 
progression or death in patients 
progressing on FOLFOX [83]. 
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*Regorafenib 
(STIVARGA®; 
Bayer HealthCare 
Pharmaceuticals 
Inc., Leverkusen, 
Germany) 
Advanced 
CRC 
following 
chemotherap
y and other 
biological 
therapy 
failure  
Oral tyrosine kinase 
inhibitor 
 Targets multiple kinase 
molecules in the 
angiogenic and tumour 
growth promoting 
pathways. 
 Undergoes enterohepatic 
circulation, highly plasma bound 
and a CYP enzyme inducer. 
 Interaction with medicines that are 
UCT substrates such as 
irinotecan. 
 Possible adverse drug reaction: 
Hand-foot syndrome [64, 84]. 
 CORRECT (2013)   improvement 
in overall survival, PFS and disease 
control rate 
 Regorafenib stabalises the disease 
rather than decrease the tumour size 
[85].  
 
 
Note: Medicines with a * next to the name are unavailable to South African patients [86]
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1.4.8.3.4 Colorectal cancer medicine combinations 
 
Combinations of the medicines mentioned above are often used in an effort to make them 
more effective. Table 1.6 shows the most common combinations and regimens that are 
available for the treatment of advanced colorectal treatment. Early CRC chemotherapy 
treatment consist of capecitabine, 5FU-folinic acid, FOLFOX and CAPOX regimens only. 
There is no place for irinotecan or biological therapies in adjuvant therapy of CRC [26].  
 
Table 1.6 Chemotherapy combinations prescribed for advanced colorectal cancer 
treatment according to the American Cancer Society [26]  Note: 1. Medicines in bold are 
unavailable to South African patients [86]; 2. XELIRI (Capecitabine + irinotecan) is not recommended by the 
American Cancer Society however is used in practice).  
 
Combination Medications included 
FOLFOX FOLFOX: 5-FU+Folinic acid+oxaliplatin 
FOLFIRI FOLFIRI: 5-FU+Folinic acid+irinotecan 
CAPOX CAPOX: Capecitabine+oxaliplatin 
FOLFOXFIRI FOLFOXIRI: 5-FU+Folinic acid+oxaliplatin+irinotecan 
FOLFOX+biological  Biological therapies include 
FOLFIRI+biological  
Bevacizumab or Aflibercept or Ramucirumab or 
Cetuximab or Panitumumab 
CAPOX+biological  
FOLFOXFIRI+ biological  
5-FU+Folinic acid with/without biological  
Capecitabine with/without biological  
Irinotecan with/without biological  
Cetuximab monotherapy  
Panitumumab monotherapy  
Regorafenib monotherapy  
Trifluridine + tipiracil   
 
1.4.8.3.4.1 CRC treatment and liver resection 
 
Research has shown that patients treated with oxaliplatin as opposed to irinotecan for liver 
metastases in the first line, perform better when undergoing liver resection surgery. Although 
the mechanisms for this remain unclear, it has been found that patients on a FOLFOX 
regimen can develop  sinusoidal dilatation known as a “blue liver”. This blue liver can lead to 
an increased amount of bleeding when liver resection is done. Patients treated with FOLFIRI 
on the other hand can develop chemotherapy-associated steatohepatitis  (CASH) known as a 
“yellow liver” [87].  
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Patient selection for liver resection does seem to vary however, patients who have more than 
50% or 6 segments which are diseased, any extra-liver disease or who are unfit are unable to 
undergo any resection and will be deemed unsuitable for conversion therapy [88]. The choice 
of neoadjuvant chemotherapy does seem to impact the outcome of patients who are eligible 
for liver resection. Likewise the PRIME study showed that the resection rate was higher with 
the addition of panitumumab for patients that were able to undergo resection [81, 82].  
 
1.4.8.3.4.2 Acquired mutations and CRC treatment 
 
1.4.8.3.4.2.1 RAS mutations  
 
Cetuximab and panitumumab (EGFR inhibitors) have led to the discovery that the RAS 
(KRAS and NRAS) (section 1.4.3) status is important for anti-EGFR treatment to be 
effective. Initial and updated analysis of both the CRYSTAL and OPUS trials have shown 
that the KRAS mutation status can be used as a predictive marker for a clinical outcome with 
anti-EGFR monoclonal antibodies [89, 90]. Karapetis and colleagues (2008) [91] showed that 
KRAS mutation status is associated with overall survival for advanced CRC colorectal cancer 
patients who are treated with cetuximab. Wild-type KRAS tumours had nearly double the 
median OS and PFS when compared to the best supportive care group. There was also no 
significant survival benefit for patients with mutated KRAS [91]. The CRYSTAL trial 
showed that KRAS mutational status is important for patient’s response to cetuximab [77]. 
Likewise the PRIME study showed that a wild-type KRAS is important for clinical benefit as 
the final analysis shows a significant improvement for PFS and ORR. When panitumumab 
was compared to cetuximab, patients treated with panitumumab had worse outcomes [81, 82, 
92]. Another study compared the addition of panitumumab to chemotherapy and 
bevacizumab. The addition of panitumumab decreased patients PFS and increased the number 
of toxicities. This indicates that adding multiple biological therapies is not always in the best 
interest of the patient [93].  
 
1.4.8.3.4.2.2 BRAF mutations 
 
Unlike RAS mutations which are predictive for patient’s response to treatment, BRAF tumour 
mutations are prognostic [89, 90]. BRAF mutations have been found to play no role in a 
patient’s response to anti-EGFR therapy (cetuximab or panitumumab). Thus doesn’t appear to 
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have a predictive role in treatment [94, 95]. The prognostic role has however been well 
studied whereby patients with BRAF mutations have a poorer prognosis. This was clearly 
illustrated in a study whereby BRAF mutations had a significant effect on the patient’s overall 
survival [96].  
  
1.4.8.3.4.3 Left-sided vs Right-sided CRC and treatment  
 
New analysis of the FIRE-3 and CALGB/SWOG 80405 trials have found that RAS wildtype 
patients response to treatment may be based on whether the CRC is of left-sided or right-sided 
origin [97, 98]. Initially the data from the CALGB/SWOG 80405 trial indicated no difference 
in either PFS or OS between the two treatment arms. However, recent preliminary analysis 
shows that patients with left-sided CRC have longer survival and better outcomes, regardless 
of which treatment arm they were randomised to. Patients with left-sided CRC that received 
cetuximab in their treatment regimen had a greater median overall survival (36 mnths vs. 16.7 
mnths) and those that received bevacizumab also displayed a greater median overall survival 
(31.4 mnths vs. 24.2 mnths) when compared to right-sided CRC [97]. 
 
The authors also found that patients with right-sided CRC do not benefit from cetuximab (or 
other EGFR-inhibitors) but rather benefit from bevacizumab. Post-hoc analysis of the FIRE-3 
trial has shown that the side of origin is prognostic for OS or PFS and that right-sided CRC 
has worse outcomes. This new data does suggest that RAS wildtype CRC patients treatment 
should be stratified based on the side of origin of the colorectal region [98].  
 
1.4.9 Drug Utilisation Review as a means to determine the resource utilisation in 
theory and clinical practice 
 
Drug utilisation research is “the marketing, distribution, prescription, and use of medicines in 
society, with special emphasis on the resulting medical, social and economic consequences.” 
[99] Drug utilisation reviews (DURs) are structured in order to review the prescribing of the 
practitioner, the dispensing by the pharmacist and the use of the medicines by the patients 
[100]. DURs are therefore used to assess if the prescribed medicine therapies are rational in 
the real-world setting. These reviews can be prospective (before the patient receives the 
medicines), concurrent (while the patient is being treated and taking the medicines) or 
retrospective (after the patient has received the medicines) [100]. Data sources for DURs 
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include but are not limited to drug regulation agency data, distribution (supplier) data, 
practice or community setting data. All these data sources will be reviewed and will illustrate 
different facets of drug utilisation. Subsequent to this economic analysis can take place and 
economic outcomes analysis, i.e. cost-effectiveness or cost-benefit amongst others, can be 
performed [99]. 
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1.5 Literature Review  
 
The literature review  covers topics including a brief introduction pertaining to medical costs 
and cancer, healthcare expenditure as a proportion of GDP, the incidence and expenditure of 
cancer, secondary costs associated with cancer, assessing the value of these treatments and 
how costs can be controlled. The literature review will then cover colorectal cancer costs in 
particular in relation to the concept of clinical pathways and the current treatments available. 
Finally the literature review will cover the South African healthcare system in more depth in 
terms of the financing and expenditure.  
 
The literature search strategy involved searching for published research using databases such 
as PubMed and Google Scholar using key words such as colorectal cancer, cancer incidence, 
chemotherapy, cancer treatment, treatment/clinical/care pathways, healthcare expenditure, 
resource utilisation, costs, secondary costs, public healthcare and private healthcare. 
 
1.5.1 Introduction  
 
Medical costs worldwide have been increasing for a number of years in developed countries, 
largely due to an aging population but also due to the technological advances within 
medicine. The problem posed by such a situation is the burden placed on the healthcare 
system. This in turn can have dire economic impacts such as the recession experienced by 
Japan and the impact this had on their social health insurance system [101]. Cancer, due to its 
high incidence imposes substantial financial burdens on both the patient and society. This is 
largely due to the prevention and management of the disease [102].  
 
However, LMICs seem to have weaker healthcare systems that lack adequate infrastructure in 
order to deal with diseases such as cancer [103]. Much research has been done around the 
issue of health inequalities which has shown that it is often related to the economic system 
and therefore health outcomes are impacted [104].   
 
According to the WHO technical report (No. 804) more than 50% of cancer patients live in 
these low-middle income countries. These patients account for less than 10% of all cancer 
control and care expense. Thus it is no surprise that only 5% of cytotoxic medicines are 
consumed by LMICs [105]. Igene (2008) also noted that developing countries have larger 
corruption issues and although the budgets assign finances to programs, it is not always spent 
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on these programs or where it is spent it yields substandard results due to mismanagement. 
The result is a lack of resources. This could present as unavailable treatment or unaffordable 
treatment to the majority of patients but also the use of outdated technology [104].  
 
1.5.2 Healthcare expenditure as a proportion of the Gross Domestic Product 
 
Levels of national income – which is measured by the gross domestic product or GDP – can 
be the same among many countries however health expenditure is not the same. The United 
States in comparison to the EU and other countries spends approximately 16% GDP on 
healthcare. The EU and other countries have much lower expenditure i.e. <12% but this 
doesn’t mean that the US has better health outcomes for patients. Thus GDP isn’t a good 
indicator that more spend has a better outcome. Also Luengo-Fernandez and colleagues 
(2013) [102] found that although some countries within the EU have the same levels of 
national income, which is not unusual, health expenditure and in particular cancer expenditure 
can vary. Therefore expenditure is expected to vary thoughout developed and developing 
countries and therefore is difficult to compare.  [102, 106]. 
 
1.5.3 The incidence of cancer and implications for expenditure on treatment  
 
Cancer data shows that global incidence patterns for cancer are changing. While most 
developed countries such as the United States show cancer incidence rates decreasing, 
developing countries show increases [2]. This change in incidence has been attributed to 
increasing westernisation of such countries as cancers such as breast or colon are ever 
increasing. The adoption of unhealthy lifestyles, which influence factors such as reproductive, 
dietary, metabolic and hormonal determinants increase the risk of such cancers in these less 
developed countries [1, 2]. Assuming constant social and economic development, global 
cancer incidence is projected to be 22.2 million by 2030 as opposed to the estimated 12.7 
million in 2008 [1].  As cancer incidence rates increase so too do the costs of cancer 
treatment. The costs involved in such treatment include chemotherapy medicines, supportive 
care medicines and the administration of these but to name a few.  
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1.5.4 The cost of chemotherapy  
 
The high cost of chemotherapy also appears to be a global issue however, less-developed 
countries with lower-median incomes show that the costs largely fall on the patient [3]. In 
addition to this, there are also differences within the access and provision to services and 
treatment within countries. One such country is South Africa. About 15% of South Africa’s 
population belong to private voluntary medical insurance which allows a greater access to 
better healthcare [107].  
 
These increasing problems with oncology costs are attributed to chemotherapeutic medicines 
circulating in a non-competitive market. In other words, the introduction of newer 
chemotherapeutic medication does not result in lower-costs for older medicines, as most 
cancer patients will be treated with all the available medicines at some point. This is largely 
due to the limited efficacy of these medicines together with the fact that newer version 
medications are add-on’s to older versions and do not provide alternative treatment. This 
therefore sustains the current non-competitive pricing [3]. 
 
The costs associated with having such a disease have been assessed in many developed 
countries across Europe and the Americas [102, 108]. In the United States, it has been 
estimated that cancer care spending exceeds $125 billion annually and is projected to further 
increase in the near future according to a projection study published by Mariotto and 
colleagues [109] in 2011. A recent population-based cost analysis study looked at the 
economic burden of cancer across the European Union (EU) and found that the total cost was 
more than €126 billion in 2009. Interestingly the countries with the highest populations - 
Germany, France, Italy and the United Kingdom – accounted for majority of these costs. 
When comparing the contributing factors to cancer care costs, the medicine expenditure for 
2009 was in excess of €13,5 billion. This is 27% of the total costs incurred for the disease 
[102]. Importantly, this analysis only included chemotherapeutics and hormone therapies, 
immunosuppressants, antiemetics and opioids were excluded, thus the total medicine 
expenditure should in fact be much greater as these additional medications are dispensed 
however could not be included due to insufficient information. These differences are 
attributed to medicine acquisition costs, medicine consumption and the differences in the type 
of medicines been consumed [102].  
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Other factors that influence the cost could be the price setting, reimbursement mechanisms as 
well as clinical practice variation [102]. Hassett and Elkin [106] describe reasons as to why 
there are increases in the per-unit medicine costs as indicated in Table 1.7. These together 
with the increasing costs of existing medication and increased use of chemotherapeutics all 
contribute to the increased spending for the treatment of cancer [106]. 
 
Table 1.7 Reasons for increasing per-unit medicine costs [106] 
Increase in per-unit medicine costs are a result of:  
1. Increased drug development costs 
2. Newer agents are more targeted and are not suitable for all patients 
3. Regulatory approval is not based on cost effectiveness or affordability 
4. Laws and policies in certain countries limit the negotiation of lower medicine costs 
5. Willingness to pay for the newer therapies by private and public funders 
 
1.5.4.1 Secondary costs associated with chemotherapy 
 
Importantly the costs associated with such a disease are not only restricted to the 
chemotherapy but patients also experience substantial costs due to supportive care medicines 
and adverse drug reactions. Montero and colleagues (2012) [110] found that in the 
chemotherapeutic subgroup of patients with advanced breast cancer, the highest pharmacy 
costs were incurred. These costs included antiemetic’s, analgesics as well as anticoagulants 
and antidepressants among others. The cost amounted to $725 per patient per month (PPPM) 
[110]. Out-of-pocket costs are also likely to be incurred by cancer patients however these 
have rarely been studied in the literature.  
 
1.5.4.2 Assessing the value of treatments and controlling cancer costs 
 
Assessing the value of medical treatments is important as some treatments may not be worth 
the financial implications such as the use of ixabepilone in combination with capecitabine for 
taxane- and anthracycline- resistant advanced CRC breast cancer. The addition of ixabepilone 
costs an additional $4000 per cycle of chemotherapy while providing just over 1 month 
progression-free survival (PFS). The incremental cost-effectiveness ratio (ICER) is the 
preferred method for assessing such treatments. The cost utility analysis (CUA) is measured 
in quality-adjusted life-years or QALYs which allows for comparisons between treatments 
within disease areas. The cost-effectiveness threshold or gold standard for QALYs in the USA 
ranges from $50 000-$100 000 and is estimated to be equivalent to the cost/QALY renal 
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dialysis for end-stage renal disease patients [106]. The cost differences include medicine 
acquisition costs as well as administrative costs, costs related to monitoring the effect and 
treating of the adverse drug related costs [111]. However, CEAs do not give information as to 
how much is too much to spend on healthcare treatments (i.e. affordability) or what patients 
would be willing to pay for a medical intervention [106]. 
 
Therefore in order to control expenditure, a number of strategies can be employed such as 
restricting specific treatment coverage to formularies determined by principles of cost, 
efficacy and cost-effectiveness as well as limiting access to certain plan types within the 
medical scheme (i.e. only high-income plans or plan with differing financial limits on 
expenditure). This also limits the overuse of certain high cost medications, especially where 
cost-effectiveness is uncertain or not proven. Other ways include reducing the reimbursement 
rates for specific medications or introduction of capitated agreements with service providers. 
[106]. 
 
1.5.5 Colorectal cancer costs 
 
Resource utilisation studies for colorectal cancer are far fewer than cancers such as breast. It 
could possibly be attributed to a lower incidence rate for colorectal cancer. Costs associated 
with colorectal cancer are substantial particularly when newer medicines and biologicals are 
included in the treatment regimens as seen in literature.  
 
Adjuvant chemotherapy with FOLFOX was found to cost € 3 743 per cycle as opposed to € 6 
085 per cycle when bevacizumab is added to FOLFOX for advanced CRC [112]. Other 
research has calculated per patient costs to average $97 400 for CRC treatment. These costs 
include chemotherapy and biological in addition to other medicines that may be required as 
well as the outpatient and inpatient costs [113]. Costs in South Africa may be very different 
depending on a number of factors. However, it is noted that bevacizumab substantially 
increases the total cost which is also seen in South Africa. What is similar between the two 
studies is that as disease progression occurs and patients advance from 1
st
 line therapy 
onwards costs increased considerably. Recent publications studying the clinical outcomes of 
patients with advanced CRC colorectal cancer show that both first-line treatment regimens of 
FOLFOX and FOLFIRI - these two regimens are similar in response rate, progression-free 
survival and time to progression as well as overall survival but do have different toxicity 
profiles - are compatible with Bevacizumab [114, 115].  
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However, Bevacizumab is an antiangiogenic monoclonal antibody and once included in the 
treatment plan increases the costs substantially. Randomised trials have also shown that in the 
absence of a biologic agent, such as Bevacizumab, the 1
st
 line treatment regimens appear to be 
non-inferior and the sequence of the first line agent exposure is less important than receiving 
all three agents, namely oxaliplatin, 5-FU and irinotecan [114]. Despite this, the availability 
of these biological agents seems to place pressure on both clinicians and patients to use 
biologics regardless of the cost implications or benefit patients may receive. A biologic such 
as bevacizumab has been publically funded in Ontario, Canada since 2008 however recently 
was one of 21 cancer medicines cut from the reformed UK cancer drug fund at the end of 
2015. In addition to bevacizumab for colorectal cancer, anti-EGFR monoclonal antibodies, 
cetuximab and panitumumab were also removed during the new reformation of the UK’s 
cancer drug fund [115-117]. These biologics however have never been made available to 
public sector patients in South Africa.  
 
1.5.5.1 Cost-effectiveness of biological treatment 
 
A study done by Ewara and colleagues (2014) [115] looked at the cost-effectiveness of 
bevacizumab plus FOLFIRI as opposed to cetuximab or panitumumab plus FOLFIRI. The 
bevacizumab treatment arm dominated despite the other two biologics having showed 
improved patient outcomes compared to patients using FOLFIRI or FOLFOX alone, however 
when compared to the current practice (FOLFIRI + bevacizumab) these other biologics may 
not be cost-effective options in Ontario. Comparing FOLFIRI+bevacizumab to 
FOLFIRI+cetuximab resulted in an incremental loss of 0.008 QALYS per person at an 
incremental cost of $3 159 whereby FOLFIRI+panitumumab resulted in an incremental loss 
of 0.033 QALYS per person at an incremental cost of $23 359 thus FOLFIRI+bevacizumab 
was favoured.   
 
In addition, both 1
st
 line treatment regimens (FOLFIRI and FOLFOX) are compatible with 
bevacizumab with respect to effectiveness and treatment patterns however, the use of the 
FOLFOX regimen with bevacizumab is more costly due to the cost of oxaliplatin in 
comparison to FOLFIRI+bevacizumab. This could be the reason for the approval of FOLFIRI 
plus Bevacizumab in the public sector in Ontario [114, 115].  
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Studies such as these have led to the development of “clinical pathways” which are used in 
order to reduce the rising costs of treatment.  
 
1.5.6 Clinical/care pathways  
 
A clinical or care pathway was first defined in 2007, by Vanhaecht and colleagues (2007) 
[118] as: “A care pathway is a complex intervention for the mutual decision-making and 
organisation of care processes for a well-defined group of patients during a well-defined 
period.” [118]. The aim of the pathway is not only to improve patient outcomes but also to 
enhance the use of the available resources [111]. Oncology, particularly in the United States, 
have made use of pathways as they are multi-disciplinary and have been found to reduce costs 
and improve care. Moreover, companies and health plans in the US have been involved with 
the development and implementation of clinical pathways for a while now however, some 
view this as counterproductive to the age of personalised medicine [119, 120]. While others 
believe that it has and will continue to ensure that beneficial medicines based on the correct 
pathway will be prescribed to patients thus reducing resource wastage while improving 
patient outcomes [121].  
 
In order for the clinical pathways to benefit patients, many health schemes and companies 
have had to employ reimbursement schemes for oncologists to use the pathways but 
nonetheless research has shown the benefit [119, 122]. Pathway programs such as those 
reported by Feinberg and colleagues (2013) [123] showed that more than $ 8 million of 
savings were acquired from the Cardinal Health program. Savings were obtained from 
medicine and non-medicine expenses [123]. Other studies looking at colorectal cancer and 
non-small cell lung cancer have shown that when pathway programs are compared to patients 
who are not on treatment pathways, the costs are lower while survival rates are similar [124, 
125].  
 
Based on the definition of a clinical pathway, South Africa does not have well-defined 
pathways for oncology however looking at both sectors there are guidelines (Standard 
Treatment Guidelines - STGs, Independent Clinical Oncology Netwotk - ICON and South 
African Oncology Consortium - SAOC protocols) and formularies  (Essential Medicine Lists 
- EMLs and private medical insurance formularies) which do allow oncologists and other 
medical professionals to make clinical decisions based on what is available [126-129]. 
Although these resources are evidence-based as stated by the relevant bodies, the healthcare 
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professionals may select any medicine or regimen that is listed. This can result in wastage of 
resources and increase the costs of treatment which the patient will need to cover should their 
medical insurance funds run short. In the public sector it means that the cost to state is higher 
when patients receive unnecessary treatments but moreover resource utilisation becomes an 
issue. The PMBs and STGs are, in effect, clinical pathways. 
 
1.5.7 The South African healthcare system  
 
At present, South Africa’s healthcare system is divided into two sectors. Each sector, namely 
public and private, has a range of healthcare provisions. These range from basic primary 
healthcare to highly specialised health services such as oncology treatment. While these two 
sectors offer similar services and data published has shown similar expenditure, there is a 
difference in both funding and the population that makes use of these services [4, 130]. The 
larger proportion of the population (85%) makes use of public healthcare whereby a smaller 
percentage of the population (15%) subscribe to medical insurance and have access to private 
healthcare services [4, 131].  
 
1.5.7.1 The public healthcare sector 
 
1.5.7.1.1 Medicine selection in the public healthcare sector 
 
Since 1996, the National Drug Policy (NDP) has aimed to provide equal access to 
medications for all South Africans by establishing the Essential Drugs Programme (EDP). 
This EDP is overseen by the National Department of Health and comprises Essential 
Medicines Lists (EMLs) and Standard Treatment Guidelines (STGs) [132]. The National 
Essential Medicines List Committee (NEMLC) has four subcommittees, namely primary care, 
adult, paediatric and tertiary/quaternary EMLCs. 
 
The World Health Organisation [133] [133] has promoted a set of EML guidelines to 
encourage equal access for all patients to certain medicines on a sustainable basis. This is 
because healthcare is a basic human right in most constitutions [134]. The WHO also define 
essential medicines as medicines, which satisfy the healthcare needs of a population, therefore 
EMLs can differ from one country to the next. The WHO provides a ‘model’ which allows for 
the selection of essential medicines in order to improve the health of the relevant population. 
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The models considers aspects relating to the rational for the medicine use, regulation and 
quality in addition to the procurement and supply of the necessary medicines [135]. Essential 
medicines are not only meant to be available in adequate quantities in the healthcare sector 
but also in the suitable dosage forms and at a price that both individuals and the community 
can afford. Therefore the medicines are selected based on the efficacy and safety of the 
medicine, disease prevalence and comparative cost [132]. With regard to comparative cost, 
the WHO guidelines also state that generic substitution may take place in order to provide 
affordable medicines to the public thus it is not uncommon to find many low-cost generics on 
the South African EMLs [134]. The process of EML selection in South Africa is evidence-
based and includes pharmacoeconomic considerations (Figure 1.16). There is constant review 
of the EML be it at primary healthcare, paediatric, adult hospital level or tertiary/quaternary 
level healthcare. As of February 2014, a total of 1 279 medicines can be found on the EML 
which covers primary, paediatric, adult hospital level and tertiary/quaternary healthcare [135].  
 
 
Figure 1.16 The process of selection of the EML and STGs in the South African Public 
Healthcare Sector [135]
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1.5.7.1.2 Availability of the essential medicines 
 
According to the United Nations MDG report (2008), most LMICs have lower medicine 
availability in the public sector and these regions also appear to have considerable availability 
differences between the public and private sectors [136]. Poor availability therefore becomes 
an obstacle to accessing affordable medicines. Access to essential medicines by all citizens is 
possible in a country such as South Africa however availability of these medicines has, in 
recent years, become more of a problem. This led the National Department of Health to 
appoint a task team in 2015 to advise as to why the non-availability of medicines is occurring 
and what can be done by it.  The task team discovered that the supply issues surrounding 
many of the essential medicines is due to ordering and supply issues between the medicine 
depots and relevant facilities. Furthermore intercontinental transport system delays, 
manufacturer difficulties and supply accounts that are in arrears contribute to the lack of 
availability of the necessary medicines [137].  
 
Most notably it was recognised that the non-availability of essential medicines is a global 
issue and not unique to South Africa but communications need to be strengthened and 
directed to include healthcare professionals and patients with regard to how long the shortage 
is expected, what alternative therapies are available and any additional information that 
maybe required. Locally it was suggested that monitoring tools should be implemented to 
keep track of the stock levels at all types of facilities. These include tools such as the mobile 
stock visibility technology adopted for clinics. In addition to monitoring, a forecasting tool 
should also be developed to avoid the current erratic ordering and poor quantification [137]. 
 
1.5.7.1.3 Medicine procurement in the public sector 
 
Medicine procurement is influenced by the STGs and EMLs and the tender procurement 
process influences the pricing of the medicine in the public sector. This process is government 
regulated and in recent years has been taken over by the National Department of Health 
however is still in line with National Treasury procedures [138]. The aim for medicine 
procurement, according to the NDP, is to maintain the healthcare system in such a way so that 
medical supplies are obtained at the best possible price [139]. In order for this procurement 
process to occur, a competitive bidding process was implemented and has provided the 
necessary reform in the sector. The process for awarding tenders, as stated in the NDP, is 
transparent and conducted according to the Tender Board recommendations however, 
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negotiations with preferred bidders does take place. This ensures that additional savings are 
also acquired by the Department of Health. Thus the medicine acquired is more cost-effective 
within the public sector [138, 139]. 
 
1.5.7.2 The private healthcare sector 
 
The private medical sector in South Africa is aimed at middle- and higher-income earners 
who “voluntarily” join medical schemes in order to substitute cover. While the scheme will 
pay for services and medications, co-payments are frequent and covered by the beneficiaries. 
All schemes are non-profit organisations while their administrators are profitable [4]. South 
Africa has around 97-registered medical schemes with approximately 15% of the population 
covered, however the expenditure is very similar to the public sector [131, 140]. 
 
The private healthcare sector also attracts most of the country’s healthcare professionals 
resulting in unequal distribution of resources [141]. A survey conducted by the Human 
Sciences Research Council (HSRC) in 2005 found that public sector facilities and majority of 
private facilities have a copy of the National STGs even though it is not officially applicable 
to this sector [142]. This is understandable as the National Department of Health, has 
encouraged the private sector to make use of the STGs and EMLs, wherever applicable [132]. 
What remains unclear is whether or not the training of these professionals or the Department’s 
encouragement influences the use of the STGs and EMLs and if these private sector patients 
pay more for the same treatment when these guidelines are used.  
 
1.5.7.2.1 Regulation of the private healthcare sector 
 
The Council for Medical Schemes (CMS) is a statutory body established by the Medical 
Schemes Act (131 of 1998) which regulates medical schemes. It has sought to provide 
regulatory supervision of the private healthcare financing offered by these schemes [140]. The 
council regulates the industry in a fair and transparent manner by a number of means (Table 
1.8) [143]. 
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Table 1.8 The mission statements of the Council for Medical Schemes [143] 
Protecting the public and informing them about their rights, obligations, and other matters in respect of 
medical schemes. 
Ensuring that complaints raised by members of the public are handled appropriately and speedily. 
Ensuring that all entities conducting the business of medical schemes, and other regulated entities, 
comply with the Medical Schemes Act. 
Ensuring the improved management and governance of medical schemes. 
Advising the Minister of Health of appropriate regulatory and policy interventions that will assist in 
attaining national health policy objectives. 
 
1.5.7.2.2 Medicine selection in the private sector 
 
Funding for medicine in the private sector is largely based on the medical scheme formularies 
and medical scheme benefit designs. In 2004 the South African government implemented a 
single exit price on medicines to ensure transparency in the sector. It is set out to discourage 
perverse practices such as bonusing and discounting. Practices such as this often led to the use 
of “high-cost” medicine inappropriately. This law also ensures that only a dispensing fee is 
added to the SEP and no other additional levies or discounts can be applied [144]. Thus the 
selection of medicines for medicine formularies is largely based on price and will often 
include the lowest cost generics. High cost medicines however are evaluated according to 
their cost-effectiveness together with their clinical efficacy and effectiveness [138]. 
Prescribed minimum benefits (PMB) ensure that all medical scheme beneficiaries have access 
to a minimum package of care, which are comparable to public healthcare treatment. 
According to the Medical Schemes Act (131 of 1998), this coverage includes the diagnosis, 
medical management and medications listed on the chronic disease list (CDL). Treatment 
algorithms for each CDL condition have also been set up by the CMS. The PMB formulary 
allows patients to access medications regardless of the remaining funds on the medical 
scheme or whether or not a medical savings account exists. The PMB formulary is used in 
conjunction with the medical scheme formulary as the PMB formulary will most often only 
specify a class of medicine to be used thereby lacking the specificity of the particular 
medication to prescribe [138].  
 
Under the PMB, medical schemes can use certain measures (Table 1.9) to help manage their 
benefits and control their costs but at the same time a PMB level of care must be maintained 
for all patients [138]. 
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Table 1.9 Measures that enable medical schemes to manage benefits and control costs 
under PMB [138] 
Designating service providers for PMB services. 
Employing a formulary and associated management tools such as a pre-authorisation (i.e. patients must 
fulfill certain requirements as laid down by the medical scheme prior to authorisation for funding being 
issued) and protocols. 
Establishing risk-sharing arrangements with different types of providers. 
Contracting with specified hospitals or hospital groups to provide services. 
 
1.5.7.3 Healthcare financing in South Africa 
 
The current healthcare system is financed by the general population and follows a progressive 
financing mechanism. This means that all South Africans contribute to healthcare financing in 
some way. The proportion to which different sectors of the population contribute to this 
system is based on the household income. The norm is that the higher the household income, 
the greater the contribution made to the healthcare system [145].   
 
Research done in this area has displayed that the richest 20% of the population spend 18% of 
their resources on healthcare in comparison to the 5% spend by the poorest 20% (Figure 1.17) 
[4]. The healthcare financing in South Africa is funded through the general taxation revenue, 
of which around 12% was allocated to healthcare by the South African National Treasury for 
2007. Private medical scheme contributions and out-of-pocket (OOP) payments also fund the 
sector. The OOP payments are however regressive but the overall financing remains 
progressive. This research also captured medical scheme contributions as the major driver for 
this progressive financing mechanism (Figure 1.17) [4]. 
 
 
Figure 1.17 The total healthcare financing distribution for South Africa [4] – Quintile 1 
represents the poorest while quintile 5 represents the richest.  
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The same research also found that the benefits received from using the healthcare system in 
South Africa favoured the population that contributed more towards the financing. The poor 
therefore receive less benefit but require the healthcare benefits the most (Figure 1.18) [4]. 
The majority of the population (around 55 million people) most likely found in the first two 
quintiles, depend on the public sector for healthcare. This also places pressure on service 
delivery and facilities thereby contributing to the lower benefits received (Figure 1.18) [131]. 
 
 
Figure 1.18 The benefit distribution received based on the contributions toward 
healthcare financing in South Africa [4]  – Patients that receive the highest benefits, 
irrespective of sector, favour those who contribute the most (quintile 5).  
 
1.5.7.4 Healthcare expenditure between the sectors in South Africa 
 
The public healthcare sector utilises approximately 11% of the national budget each year 
however in research conducted it was found that the healthcare sector of the budget has been 
declining from 2000/2001 to 2007/2008 and is far below the 15% as set out by the Abuja 
declaration [145, 146]. These taxation revenue funds are allocated to the 9 provinces but the 
way in which resources are distributed to the provinces and service delivery carried out by the 
provinces varies [145]. 
 
Total expenditure on healthcare for 2011/2012 was R258.4-billion ( 8.6% of GDP), but the 
expenditure is split equally between the National Department of Health and the private sector 
however; the private sector only services approximately 16% of the population [4, 130]. The 
percentage of GDP has increased since 2005 whereby it was only 7.7% and had decreased 
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from a level around 8% in the late 1990s/early 2000s [147]. Therefore government spending 
is only around 3.5% of GDP and 2007 expenditure figures indicate that approximately 41% of 
all healthcare expenditure comes from the government. The remaining 59% is consequently 
private funding [148].  
 
This means that the per capita spending is far greater in the private sector and in fact has 
remained this way since 1996. The gap per capita spending between the public and private 
sectors however has increased over the subsequent years. For example the per capita spending 
in 1996 was triple in the private sector than the public sector and by 2004 that gap had 
increased to more than seven times [4]. The total healthcare expenditure per capita has once 
again decreased between 2011 and 2014 from $ 686.94 to $ 570.21 as reported by the World 
Bank. Interestingly the out-of-pocket expenses have decreased from 7% to 6.5% over the 
same period. The reason for this appears to be unclear but does relate to an increased 
expenditure on public healthcare (48% vs. 48.24%) [149-151]. This raises concerns as to 
whether or not medical schemes and their beneficiaries receive value for money and whether 
or not these two healthcare sectors provide equitable treatments for the same medical 
conditions.  
 
From the literature review it can be seen that the colorectal cancer cost evaluation literature 
for low-middle income countries and in particular South Africa is not comprehensive and 
many studies available from LMICs are outcome costing studies. This makes it difficult to 
quantify the actual costs associated with colorectal cancer in LMICs or South Africa. In 
addition for the outcome analysis and costing models, such as decision analysis, to be used, 
comprehensive cost evaluation needs to take place [152].  
 
Therefore, this research aims to calculate how much the actual (observed) cost of colorectal 
cancer is in South Africa, in comparison to reported figures but also to calculate and compare 
the costs for each healthcare sector in South Africa for colorectal cancer treatment. 
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2. CHATPTER TWO – METHODOLOGY  
 
2.1 Assumptions 
 
2.1.1 Patient classification for advanced CRC disease 
 
2.1.1.1 Public healthcare sector 
 
Patients were only classified as advanced CRC if they were initially diagnosed with 
metastasis or the disease progressed to an advanced CRC state at some point as noted in the 
patient records. If no indication of metastasis occurred, patients were classified as early CRC 
from the records. These classifications were based on the staging system mentioned in section 
1.4.7.1. Certain instances, treatment plans revealed that metastasis might well have occurred 
however, this can’t be confirmed but is noted in the analysis and results.  
 
2.1.1.2 Private healthcare sector 
 
Similarly to the public sector and using the staging system in section 1.4.7.1, advanced CRC 
disease was noted if patients were initially diagnosed with metastasis or the disease 
progressed to an advanced CRC state at some point. However, the treatment pathways were 
used to finalise the advanced CRC status due to the discrepancy between data sets A1 (initial 
claims data received from the medical scheme) and A3 (demographical data for all memebers 
included in dataset A1). Based on the treatment pathways patients were reclassified as 
advanced CRC if biological agent was used in their 1
st
 or 2
nd
 line treatment or more than two 
lines of therapy followed by a biological agent. 
 
2.1.2 Dosages  
 
Information such as dosages are not recorded in claims data thereby the data for the number 
of vials or tablets and their strength are used to calculate the final dosages. The claims data for 
these medicines claimed were assumed to be the dosages prescribed for and used by the 
patients.   
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2.1.3 Treatment lines for private sector patient cohort 
 
A change in treatment line was considered to have occurred when a change in treatment 
occurred between oxaliplatin and irinotecan or if a biological agent was included or changed 
to another biological agent. Patients were considered to have remained on the same treatment 
line if an agent was dropped for a certain number of cycles, if 5-FU was changed to 
capecitabine or vice versa and lastly if an oxaliplatin/irinotecan-containing regimen was 
changed to 5-FU/capecitabine monotherapy.  
 
2.2 Overview of Methodology 
 
 
Figure 2.1 Overview of  the methodology used in the study including all the constituents 
of each section 
 
 
 
 
 
 
 
3. Private Healthcare Sector 
Cost calculations Drug utilization review (DUR) 
2. Public Healthcare Sector 
Cost calculations including time and motion study 
for administrative costs  Drug utilization review (DUR) 
1. Treatment Pathways  
Literature search, pathway development and 
comparison to international standards 
Theoretical costing of pathways including costing model 
development for public and private healthcare systems 
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2.3 Treatment pathways 
 
2.3.1 Literature search  
 
2.3.1.1 Treatment reviews and clinical trial identification 
 
In order to construct the clinical pathways that encompassed all current available medicines 
globally, a literature search for treatment reviews was conducted on PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) and SCOPUS (http://0-www.scopus.com.innopac.wits.ac.za). The 
search terms were broad search terms and included what is known as personalised medicine. 
Personalised medicine referred to all the newer biological treatments available to patients 
globally. The search terms included “colorectal cancer”, “treatment review”, “personalised 
treatment”. Not only did these articles gave a basis of which medicines where currently 
available but also at what stage of treatment they should be used for i.e. early or late.  
 
Articles with titles containing the search terms were selected and the exclusion criteria was 
applied. Articles were included if all approved colorectal cancer chemotherapry treatment was 
discussed. Articles were excluded if specific treatments were considered or subsequent 
analysis of specific regimens were conducted. Articles that were also excluded were those that 
considered cost analysis and model development (as the developed pathways were to reflect 
the flow of treatment and were not based on cost or cost outcomes analysis), genetics, 
monotherapy/specific regimen reviews, clinical effectiveness/efficacy (clinical trials were 
used subsequent to identifying the medicines), diagnostic factors/predictor. In addition to this 
any articles that included interventions other than chemotherapy or studied only various 
routes of administration, or were published before the year 2000 were excluded.  
 
From the CRC chemotherapy identified in the included papers (based on selection criteria 
discussed above), the relevant clinical trials and references were identified. Clinical trials 
were excluded if they were exclusively done in only one population and not globally, 
published before 2000, for the treatment of liver resection, observational studies, pooled 
analysis or meta-analysis conducted prior to 2000, published guidelines or recommendations 
(these were used in the comparisons), alternate formulations of the same chemotherapy 
medicines were compared or if it was simply a review of chemotherapy treatment. Clinical 
trials based on treatment targeted specifically to the patient’s BRAF status were also 
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excluded, as current treatment is not available based on this unlike the RAS status. Clinical 
trials that discussed treatment other than chemotherapy (radiation or surgery) were excluded 
as this study looked at chemotherapy.  
 
The published clinical trials were included if the studies were Phase 3 randomised controlled 
trials, included only one monoclonal antibody or similar targeted therapy as treatment, only 
included chemotherapy (monotherapy or a regimen) and was a completed published article.  
 
These results of this published literature, was verified using UpToDate
®
 (http://0-
www.uptodate.com.innopac.wits.ac.za/contents/search). If the relevant literature was included in 
UpToDate
® 
and cited in literature, the results were used to guide the development of the 
treatment pathways.  
 
2.3.1.2 Clinical trials that were identified  
 
The relevant published clinical trials were retrieved, using the exact publication title as cited 
in the reviews, through PubMed (http://www.ncbi.nlm.nih.gov/pubmed) or SCOPUS (http://0-
www.scopus.com.innopac.wits.ac.za). The results of these clinical trials were then used to construct 
the pathways, as these are the evidence-base (i.e. published clinical outcomes) which has 
contributed to the use of these medicines in clinical practice.  
 
2.3.2 Treatment pathway development  
 
The clinical treatment pathways were then developed, with the help of a medical oncologist, 
based on clinical trial data. The medicines included in the treatment pathways for colorectal 
cancer were compared to the available medicines in both healthcare sectors of South Africa, 
so as to ensure the pathways would be relevant to the South African setting. Medicines for the 
public healthcare sector were found in the standard treatment guidelines (STG) and essential 
medicines lists (EML) where the private healthcare sector uses the South African Medicine 
Price Registry (2014) and South African Oncology Consortium (SAOC) and Independent 
Clinical Oncology Network (ICON) guidelines [127, 153-155]. Medicines approved on 
Section 21 of Act 101 of 1965 were also included (Figure 2.2).  
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The pathways were validated against the key clinical trial data for the relevant treatment 
regimens. The pathways were also compared against international guidelines such as 
American Cancer Society (ACS – United States of America), National Comprehensive 
Cancer Network (NCCN – United States of America) and National Cancer Institute (NCI – 
United States of America) as well as National Institute for Health and Care Excellence (NICE 
– United Kingdom) and European Society for Medical Oncology (ESMO – Switzerland based 
for Europe) [25, 26, 156-162].  
 
 
Figure 2.2 The sources consulted and used in the construction of the treatment pathways 
for South Africa 
 
2.3.3 Cost analysis of the treatment pathways  
 
The study was conducted between 2014 and 2016 in order to calculate the costs based on the 
developed treatment pathways for both the public and private healthcare sectors for 2014. The 
dataset for the costs obtained were for the year 2014.  
 
2.3.3.1 Cost data source 
 
2.3.3.1.1 Public Healthcare sector 
 
All medicine costs, including chemotherapy and supportive care, for the public healthcare 
sector were obtained from the essential medicines list tariff document for February 2014 
[154]. Administrative costs were obtained via a time and motion study performed at the 
oncology unit of CMJAH – unit 495 (section 2.3.4.4.1). 
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2.3.3.1.2 Private healthcare sector 
 
In the private sector, all medicine costs were obtained from the single exit price (SEP) tariff 
document for August 2014. It was found on the South African Medicine Price (SEP) Registry 
website [153]. Administrative costs for this sector were based on the 2015 National Reference 
Price List for Health Services (NRPL-HS) tariff guidelines for medical schemes. The NRPL-
HS is published by the Council for Medical Schemes in order to reimburse service providers 
[163]. There were two sets of codes depending on whether or not facilities are accredited or 
not. Non-accredited costs were excluded in this study so as to try and simplify the already 
complex costs that will be charged by approved service providers. The non-accredited costs 
pertain to service providers who are not approved i.e. private.  
 
2.3.4 Costing model development 
 
The costing model for both healthcare sectors was developed in Microsoft Excel for Mac 
2011 and was based on the treatment pathways that were developed. Each pathway comprised 
6 spreadsheets. The spreadsheets reflected different components required to calculate the total 
costs involved in chemotherapy treatment. Figure 2.3 shows an example of the various 
components required by the model. The number of columns will however, vary depending on 
how many origins/stages are included as well as the regimens used in treatment of each.  
 
 
Figure 2.3 Total costs included for each regimen in order for the total costs of each 
pathway to be calculated 
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Colour coding in the first column is the same for the corresponding cost spreadsheet. From 
Figure 2.3 it can be seen that the treatment costs per cycle is calculated first in order to 
calculate the total treatment cost for the selected number of cycles. The total cost for the 
treatment pathway is a summation of the individual treatment regimens, this is however, more 
relevant for advanced CRC as seen in the results. 
2.3.4.1 Chemotherapy medicine costs  
 
The total chemotherapy medicine costs were calculated based on the number of cycles, the 
number of administrations per cycle (as a few oral medicines require multiple dosing), as well 
as the dose per administration (Figure 2.4). The dose per administration was calculated based 
on doses used in literature and prescribed by the relevant manufacturers (Table 2.1). The 
average human body surface area of 1,73 m
2
 and ideal body weight of 70kg was used to 
calculated the total dosages [164-166]. A retrospective drug utilisation review was conducted 
(section 2.4) in order to determine how many vials/ tablets are actually prescribed in clinical 
practice in order to make dispensing and administration easier. This was incorporated into the 
costing model to more accurately reflect current clinical practice. 
 
 
Figure 2.4 Chemotherapy medicine cost spreadsheet for the costing model 
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Table 2.1 Prescribed treatment regimen
♯ 
doses  
5-FU/LV (LV5FU2) 
every 2 weeks 
o LV *400mg/m2 over 2hrs 
o 5-FU bolus 400mg/m2 + IV 2400mg/m2 over 
48hrs (D1 & 2) 
FOLFIRI [51] 
every 2 weeks 
 
o LV *400mg/m2 over 2hrs 
o Irinotecan 180mg/m2 over 2hrs 
o 5-FU bolus 400mg/m2 + IV 2400mg/m2 over 
48hrs (D1 & 2) 
FOLFOX-6 [51] 
every 2 weeks 
 
o LV *400mg/m2 over 2hrs 
o Oxaliplatin 85mg/m2 over 2hrs 
o 5-FU bolus 400mg/m2 + IV 2400mg/m2 over 
48hrs (D1 & 2) 
Capecitabine  
every 3 weeks  
o Capecitabine 650-1250mg/m2 twice daily 
(D1 – 14) 
o Rest one week 
CAPOX 
every 3 weeks  
o Oxaliplatin 130mg/m2 over 2hrs 
o Capecitabine 650-1250mg/m2 twice daily 
(D1 – 14) 
o Rest one week 
PANITUMUMAB [80-83, 167] 
every 2 weeks 
o 6mg/kg over 60 – 90min  
 
CETUXIMAB [77, 78, 91] o 400mg/m2 over 2hrs (loading dose) 
o 250mg/m2 over 1hr weekly or 500mg/m2 
over 1 hour every 2 weeks 
BEVACIZUMAB  [67, 68, 70] o 1st line: 5mg/kg over 90/60/30min (2 weeks) 
OR 7,5mg/kg (3 weeks) 
o 2nd line: 10mg/kg over 90/60/30min (2 
weeks) OR 15mg/kg (3 weeks) 
RAMUCIRUMAB [76] 
every 2 weeks 
o 8mg/kg over 60-90 minutes 
AFLIBERCEPT [73] 
every 2 weeks 
o 4mg/kg over 1hr 
 
REGORAFENIB [85] 
Every 4 weeks 
o 160mg once daily for 3 weeks (flat dose) 
o Rest 1 week 
Trifluridine/tipiracil [56] 
Every 4 weeks 
 
o 35mg/m2 for 5 days, 2 days rest (total 10 
days) i.e.. days 1-5 and 8-12 
o Rest 14 days 
BSC in combination with 
‘the provision of the 
necessary services for those living with or affected 
by cancer to meet their informational, emotional, 
spiritual, social, or physical needs during their 
diagnostic, treatment, or follow-up phases 
encompassing issues of health promotion and 
prevention, survivorship, palliation, and 
bereavement.’ [168] 
o CHEMO: including Dexamethasone 16 – 
20mg + 5HT3 receptor blocker antiemetic + 
atropine ½ amp (irinotecan only) 
 
o CETUXIMAB/PANITUMUMAB: 
including Cyclizine 12.5mg iv and  
Doxycycline/Minocycline 100mg/day 
o BEVACIZUMAB including cyclizine 
12.5mg iv 
 
* Not only symptomatic relief 
Doses for patients without renal/hepatic impairments or sub-populations (elderly); * LV is a racemic mixture
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2.3.4.2 Administration costs  
 
The administration costs for the public sector were based on baseline costs from [169] and 
CMJAH special dispensary book for 2015. All costs were adjusted for CPI to reflect 2014 
costs (http://www.inflation.eu/inflation-rates/south-africa/historic-inflation/cpi-inflation-south-africa.aspx). 
The administration costs and admixture costs were calculated according to Figure 2.5. 
 
Figure 2.5 Administration cost spreadsheet for the costing model
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The administration costs for the public sector only comprised of the admixtures such as 5% 
dextrose and normal saline as well as ports, pumps, syringes, swabs etc.  
 
2.3.4.3 Supportive care medicines costs  
 
Supportive care medicines were based on relevant evidence found on UpToDate
®
 (http://0-
www.uptodate.com.innopac.wits.ac.za/contents/search) for use in cancer chemotherapy. For the public 
sector however, the information found on UpToDate
®
 was then refined to reflect what is 
available on the EML. The supportive care medicines corresponded to the emetogenic 
potential of the regimen as this would influence prescriptions. The model included all the 
medicines that could be prescribed even for low emetogenic regimens (Figure 2.6). 
 
Furthermore the retrospective drug utilisation review conducted helped to improve the model 
so as to better reflect medicines that were actually used in clinical practice. Figure 2.6 
indicates that the model was developed to include a range of supportive care medicine costs 
as doses of particular medicines vary, the number of medicines within a class vary as well as 
the use of a mixture of generic and originators. This variation not only applies to the private 
sector but does play a role in public healthcare. This therefore influenced the notion of the 
“basket” approach for supportive care medicines. The “basket” approach allows classes of 
medicines to be grouped together regardless of the number of medicines within the class and 
then assigned to each regimen. This means that for every regimen there is a “basket” and the 
costs range from lowest to highest for that basket. The ranges of costs per basket were due to 
the number of possibilities of medicine combinations possible. This “basket” approach was 
however, much more simplified for the public sector as in some instances there is only one 
medicine available, usually a generic, in the class of medicines but there is a range of doses 
prescribed. The average “basket” cost for the supportive care medicines was used in order to 
calculate the final costs for each regimen. For the private sector however, it was the average 
of the lowest cost SEP “basket”, as this is more comparable to the public sector.   
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Figure 2.6 Supportive care medicine costs spreadsheet for the costing model 
 
2.3.4.4 Administrative costs  
 
The administrative costs included all the costs associated with patients receiving 
chemotherapy. For the public sector this cost is unknown and therefore a Time and Motion 
study was performed and included all the tasks associated with the administrative component 
to a patient receiving chemotherapy. These included tasks performed by the administrative 
clerks, nurses, pharmacists and physicians  (section 2.3.4.4.1). The costs obtained from the 
Time and Motion study were compared to the NRPL-HS costs used in the private sector.  
 
Administrative resources and utilisation are consistent within a sector no matter which 
chemotherapy medicines are prescribed or how much of the chemotherapy medicine is 
 59 
prescribed. The only difference within a sector is whether or not the regimen consists only of 
oral medication or intravenous medication. For oral regimens, the administrative costs are 
fewer as the patient does not have to wait in the facility/clinic in order for an intravenous 
script to be prepared and dispensed nor wait for a drip to be administered.  
 
2.3.4.4.1 Time and Motion Study 
 
A Time and Motion (T&M) study was conducted in the Adult Medical Oncology Unit (Unit 
495) at the CMJAH for the process of patients receiving chemotherapy. The workflow 
diagram was constructed based on similar studies [170, 171]. Each step in the workflow 
diagram was a step that needed to be timed in the study using the relevant data collection 
sheet (Appendix A). The workflow diagram was updated following observations and timing 
in the outpatient clinic. The study was done in triplicate (i.e. on 3 separate days) and each step 
consisted of 9 readings per round/day. This resulted in a total of 27 readings per step. Figure 
2.7 shows the methodology employed in order to obtain the final time per step and associated 
cost.  
 
 
Figure 2.7 Methodology used in order to obtain final times (minutes: seconds), which 
were equated, to cost (Rands) 
Initial times for each step 
(minutes: seconds, split 
seconds) 
Rounded off times  
(minutes: seconds)  
Calculate the average time 
per step  
(summation of each time/27) 
Average time was equated 
to cost (Rands) 
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The administrative cost (Rands) was calculated using the administrative clerk, nursing 
pharmacy, and physician salaries per annum for the respective Gauteng Department of Health 
employee based on the  vacancy website (https://www.govpage.co.za/gauteng-health-vacancies.html) 
[172]. Due to the number of tiers employed by the Government for the respective positions, 
an average salary per annum was calculated. The reason for this is that any one of the 
employees, regardless of the tier they are on, can interact with a patient. Following similar 
costing studies performed elsewhere, an average 2080 hours per annum was used in order to 
calculate the costs (https://www.opm.gov/policy-data-oversight/pay-leave/pay-administration/fact-
sheets/computing-hourly-rates-of-pay-using-the-2087-hour-divisor/). This allowed the average cost per 
hour to be obtained and the average cost per minute. The average times could then be equated 
to an average cost (standard deviation). If a final time was less than 30 seconds, it was 
rounded down to that minute reading and if greater than 30 seconds, rounded up to the next 
minute reading. All calculations were performed using Microsoft Excel for Mac 2011.    
 
2.3.4.4.2 NRPL-HS  
 
The private sector administrative costs were based on the NRPL-HS prices for 2015, as 2014 
costs were unattainable. The administrative costs comprised of a global fee and a facility fee. 
The global fee pertained to the method of administration of the chemotherapy (oral or I.V) 
and the facility fee was based on the type of facility whereby patients receive their treatment 
(Table 2.2).   
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Table 2.2 NRPL-HS tariffs for the selected medical scheme for 2015 
NRPL Code Description Medical 
Scheme Rate 
5790 Non Infusional Chemotherapy: Global Fee for the management 
of and for related services delivered in the treatment of cancer 
with oral chemotherapy (per cycle), intramuscular, subcutaneous, 
intrathecal or bolus chemotherapy or oncology specific drug 
administration per treatment day - for exclusive use by doctors 
with appropriate oncology training (consultations to be charged 
separately) 
R473.00 
5791 Non Infusional Chemotherapy Facility Fee: A facility where 
oncology medicines are procured or scripted for oral 
chemotherapy, intramuscular, subcutaneous, intrathecal or bolus 
chemotherapy or oncology specific drug administration per 
treatment day. This fee is chargeable by doctors with appropriate 
oncology training who owns or rents the facility, and by others 
e.g. hospitals or clinics that provide the services as per the 
appropriate billing structure 
R269.70 
5792 Non Infusional Chemotherapy Facility Fee: A facility where 
oncology medicines are purchased, stored and dispensed during 
oral chemotherapy (per cycle), intramuscular, subcutaneous, 
intrathecal or bolus chemotherapy or oncology specific drug 
administration per treatment day. This fee is chargeable by 
doctors with appropriate oncology training who owns or rents the 
facility, and by others e.g. hospitals or clinics that provide the 
services as per the appropriate billing structure 
R337.10 
5793 Infusional Chemotherapy: Global fee for the management of and 
for services delivered during infusional chemotherapy per 
treatment day - for exclusive use by doctors with appropriate 
oncology training using recognised chemotherapy 
facilities(consultations to be charged separately) 
R1404.90 
5794 Infusional Chemotherapy Facility Fee: A facility where oncology 
medicines are procured, stored, admixed and administered, and in 
which appropriately-trained medical, nursing and support staff 
are in attendance. This fee is chargeable by doctors with 
appropriate oncology training who owns or rents the facility, and 
by others e.g. hospitals or clinics that provide the services as per 
the appropriate billing structure 
R991.40 
5795 Infusional Chemotherapy Facility Fee: A facility where oncology 
medicines are purchased, stored, dispensed, admixed and 
administered and in which appropriately-trained medical, nursing 
and support staff are in attendance. This fee is chargeable by 
doctors with appropriate oncology training who owns or rents the 
facility, and by others e.g. hospitals or clinics that provide the 
services as per the appropriate billing structure 
R1239.30 
 
The administrative costs were then calculated according to the model in Figure 2.8.  
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Figure 2.8 Administrative cost spreadsheet for the costing model  
 
2.3.5 Cost comparisons  
 
The theoretical chemotherapy and supportive care medicine costs were calculated using the 
relevant medicine lists and databases described in section 2.3.3.1.1 and section 2.3.3.1.2 
respectively. Administrative fees for the public sector were calculated from the Time and 
Motion study (section 2.3.4.4.1) and the private sector fees came from the NRPL-HS (section 
2.3.4.4.2).   
 
In addition the theoretical number of cycles for each regimen was found in literature and 
treatment guidelines such as the NCCN. Theoretical dosages were calculated based on the 
BSA (m
2
) or BM (kg) of the average cancer patient [165, 166]. The observed costs however, 
were calculated based on the data collection from the DUR for both sectors (2.4).  
 
The costing model was then applied in order to calculate the theoretical (based on literature) 
and observed (based on the retrospective DURs) costs for the treatment of CRC. For each 
stage of CRC, the theoretical and observed costs for each sector was compared and 
furthermore the two healthcare sectors were compared to each other, where appropriate.  
 
Similarities and differences were recorded and reasons as why these occurred were 
formulated.  
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2.4 Retrospective Drug Utilisation Review (DUR) 
 
2.4.1 Public healthcare sector 
 
2.4.1.1 Patient identification from “new case” books 
 
The “new case” books from the CMJAH adult oncology clinic – unit 495 for the period 2012 
– 2014 were used to identify patients who were newly diagnosed with colorectal cancer. 
Patient information was obtained, which could then be used to extract the relevant patient 
files from the clinic. Patients diagnosed with the following diagnosis were initially identified 
so as to cover all possible patients that could have colorectal cancer. The diagnosis included:  
 Malignant tumour cell 
 Colon 
 Rectal/rectum 
 Stomach/gastric 
 Adenocarcinoma 
 Anal/anus 
 Sigmoid 
 Bowel/small bowel 
 Caecal/caecum 
 Abd mass 
 
Patients that had no diagnosis were also recorded so as to confirm what the diagnosis was. 
These patients would then be included/excluded depending on the final diagnosis found in the 
patient file. Any patients removed from the books were excluded and the final diagnosis was 
based on the diagnosis found on the patient file. Patients with missing information, which 
would exclude patients from the sample, were also noted. All patient names were only known 
to the researcher and remained coded for the entire period. Patient files were used to extract 
data as there is no electronic capturing system in place at the CMJAH for this information 
 
2.4.1.2 Data capture from patient files 
 
Following patient identification, the identified patient files were used to obtain basic 
information such as diagnosis confirmation, treatment history and current treatment as well as 
any relevant pathology (Appendix B). Doses and cycle lengths were also recorded. All 
information that was recorded in patient files was accepted to be correct and was recorded as 
final. All patient data was completely anonymised and coded. Only the researcher had access 
to the coding.  
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2.4.1.3 Data analysis from patient files 
 
2.4.1.3.1 Treatment pathways for patient cohort 
 
Data was first divided into early CRC and advanced CRC disease. This was determined from 
pathology results and dates of diagnosis of firstly the colorectal cancer and then the 
metastasis. Patients were placed into the advanced CRC group if initial diagnoses were 
advanced CRC or metastasis occurred during the observation period. If the patient file had no 
indication of metastasis then patients were classified as early CRC. Furthermore the results 
were stratified according to origin within the colorectal region so as to see any differences 
within treatment or lines of therapy. The treatment that each patient received was used to 
construct treatment timelines for each patient and treatments were colour coded based on the 
line of therapy. This was used to identify the most common treatment regimens and the 
number of treatment lines. Important events or notes found in the files were also included as 
in some instances these provided explanations for changes in treatment or for patients to be 
placed on Best Supportive Care (BSC). Certain medicines prescribed were also noted as these 
indicated if an adverse drug reaction [173] was present or had developed.  
 
2.4.1.3.2 Demographical analysis for patient cohort 
 
Following the advanced CRC classification of the patients, the average, median and range 
ages were calculated together with gender for each sub-group. Other calculations included the 
number of patients on each treatment line and the number of patients per site of origin of the 
CRC.  
 
2.4.1.3.3 Cost analysis for patient cohort 
 
2.4.1.3.3.1 Average costs for patient cohort 
 
Following the entire treatment regimen and treatment line identification, the number of cycles 
and doses for each patient was determined. The average number of cycles and doses were 
then calculated for the patient cohort. These values were used in the costing model so that the 
costs for the patient cohort could be determined. The Time and Motion study, conducted in 
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section 2.3.4.4.1, was used for the administrative costs and the supportive care medicine costs 
were calculated in the same manner as the theoretical costs however, the type of medicines 
included were found in some patient files but also had to be confirmed by the pharmacy and 
medical staff at the clinic. The administration costs were calculated and used for both the 
theoretical and observed costs. The costs obtained for the patient cohort was compared to the 
theoretical costs. The differences and similarities were studied and possible reasons for this 
are discussed in later sections.   
 
2.4.2 Private healthcare sector 
 
2.4.2.1 Data capture from data sets 
 
A data request was sent to a private medical scheme for all newly diagnosed CRC patients 
between the 2012 and 2014. Two anonymised claims data sets (A1 and A2) was obtained, the 
first consisting of all the medical claims and the second all non-medical claims (Table 2.3). 
 
Table 2.3 Medical and Non-medical data set contents for the claims data 
Medical data set contents (A1) Non-medical data set contents (A2) 
Anonymised Patient identifier Anonymised  Patient identifier 
Advanced CRC status Service date 
ATC code Advanced CRC status 
NAPPI code Quantity 
Product name Amount paid 
Strength MOB enrollment date 
Dosage form Number of months since enrollment 
Quantity Procedure ID 
Amount paid Procedure code description 
MOB enrollment date High level description 
Number of months on scheme before enrollment Practice number 
Days from enrollment Practice type description 
Service date  
ATC description 
Chemotherapy 
Date of first surgery  
Days since surgical procedure 
MOB enrollment year 
 
The patient identifiers from each data set was coded and only known to the researchers for the 
entire duration of the research. The medical data set included patients enrolled prior to 2012 
and after 2014 therefore patients were excluded based on the enrollment year. Furthermore 
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additional data was required and obtained to complete demographical information (data set 
A3). This included age and gender of the patients enrolled between 2012 and 2014. Patients 
with incomplete demographical information were excluded. This gave rise to a modified data 
set of A1, which was called A4. Patients were classified as advanced CRC if initially the 
diagnosis was advanced CRC or metastasis occurred and classified as early CRC if the patient 
had no indication of metastasis.  If the patient’s metastasis status was unknown, this was 
confirmed with the additional data obtained from the medical scheme (data set A3). The 
advanced CRC status of patients was confirmed from data set A3 but the treatment pathways 
for each patient finalised the advanced CRC status (section 2.4.2.2.1). 
 
The patients that were included from the above ordering (data set A4) under went further 
ordering from data set A2. Patients that had received chemotherapy but were found to have 
had no claims in the non-medical data set A2 were excluded and this resulted in a further 
modification of data set A4 and A2, which was subsequently called A5 and A6. This data set 
was used to map treatment pathways for each patient. Following this, patients who received 
chemotherapy medicines not indicated for CRC were excluded (section 2.4.2.2.1). This was 
the final data set for the project and referred to A7 (Figure 2.9). The final non-medical 
database (A6) contained all the administrative costs including the global fees, facility fees and 
consultations. The codes used to extract information from data set A2 and the new high-level 
description allocated to each code can be seen in Table 2.4. The exact patient numbers can be 
found in section 3.2.2.1 of the results.  
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Figure 2.9 Flow diagram indicating process of elimination of patients in order to obtain 
final patient cohort  
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Table 2.4 Procedure codes used for chemotherapy administrative in the private sector 
PROCEDURE 
ID 
PROCEDURE CODE DESCRIPTION 
HIGH LEVEL 
DESCRIPTION 
5790 
RA5790 - Non Infusional Chemotherapy: Global Fee for the management of and for related services delivered in the treatment of cancer with oral 
chemotherapy (per cycle), intramuscular, subcutaneous, intrathecal or bolus chemotherapy or oncology specific drug administration per treatment day -  
Global fee-oral 
5791 
RA5791 - Non Infusional Chemotherapy Facility Fee: oncology medicines procured or scripted for oral chemotherapy, IM, subcutaneous, intrathecal or 
bolus chemotherapy or oncology specific drug administration per treatment day. Chargeable with appropriate oncology training, and others that provide 
the services as per the appropriate billing structure.  
Facility fee-oral 
5792 
RA5792 - Non Infusional Chemotherapy Facility Fee: oncology meds purchased, stored and dispensed during oral chemo (per cycle), IM, subcut, 
intrathecal or bolus chemo or oncology specific drug administration per treatment day. Chargeable with appropriate oncology training, and by others that 
provide the services as per the appropriate billing structure.  
Facility fee-oral 
5793 
RA5793 - Infusional Chemotherapy: Global fee for the management of and for services delivered during infusional chemotherapy per treatment day - for 
exclusive use by doctors with appropriate oncology training using recognised chemotherapy facilities(consultations to be charged separately) 
Global fee 
5794 
RA5794 - Infusional Chemotherapy Facility Fee: oncology meds procured, stored, admixed and administered, where appropriately trained 
medical/nursing and support staff are in attendance. Chargeable by doctors with appropriate oncology training, and by others that provide the services as 
per the appropriate billing structure. 
Facility fee 
5795 
RA5795 - Infusional Chemotherapy Facility Fee: oncology medicines purchased, stored, dispensed, admixed and administered where appropriately 
trained medical/nursing and support staff are in attendance. Chargeable by doctors with appropriate oncology training, and by others that provide the 
services as per the appropriate billing structure.  
Facility fee 
109 
RA0109 - Hospital follow-up visit to patient in ward or nursing facility - Refer to general rule G(a) for post-operative care) (may only be charged once 
per day) (not to be used with items 0111, 0145, 0146, 0147 or ICU items 1204-1214) 
Consultations 
129 
RA0129 - Prolonged face-to-face attendance to a patient:  ADD to either item 0192, item 0175 or item 0169 as appropriate, for each 15-minute period 
only if service extends 10 minutes or more into the next 15-minute period following on the first 60 minutes 
Consultations 
190 
RA0190 - New and established patient: Consultation/visit of new or established patient of an average duration and/or complexity. Includes counselling 
with the patient and/or family and co-ordination with other health care providers or liaison with third parties on behalf of the patient (for hospital 
consultation/visit - refer to item 0173-0175 or item 0109) - not appropriate for pre-anaesthetic assessment followed by the appropriate anaesthetics - refer 
to new anaesthetic structure 
Consultations 
191 
RA0191 - New and established patient: Consultation/visit of new or established patient of a moderately above average duration and/or complexity. 
Includes counselling with the patient and/or family and co-ordination with other health care providers or liaison with third parties on behalf of the patient 
(for hospital consultation/visit - refer to item 0173-0175 or item 0109) - not appropriate for preanaesthetic assessment followed by the appropriate 
anaesthetics - refer to new anaesthetic structure 
Consultations 
192 
RA0192 - New and established patient: Consultation/visit of new or established patient of long duration and/or high complexity. Includes counselling 
with the patient and/or family and co-ordination with other health care providers or liaison with third parties on behalf of the patient (for hospital 
consultation/visit - refer to item 0173-0175 or item 0109) - not appropriate for pre-anaesthetic assessment followed by the appropriate anaesthetics - refer 
to new anaesthetic structure 
Consultations 
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Therefore similarly to the public sector, the data included in the final data sets for the cohort 
included demographical information, treatment and non-medical information (Table 2.5). 
 
Table 2.5 Final information included in the medical and non-medical data sets for the 
patients enrolled between 2012 and 2014 
Medical data set contents (A7) Non-medical data set contents (A6) 
Patient cohort code Patient cohort code 
Gender Service date 
Age Advanced CRC status 
Advanced CRC status  Quantity 
ATC code Amount paid 
NAPPI code MOB enrollment date 
Product name Number of months since enrollment 
Strength Procedure ID 
Dosage form Procedure code description 
Quantity High level description 
Amount paid Practice number 
MOB enrollment date Practice type description 
Service date  
ATC description 
MOB enrollment year 
 
2.4.2.2 Data analysis from data sets 
 
2.4.2.2.1 Treatment pathways per patient based on medical data set 
 
Data set A7 was restructured to include an ATC classification column. This allowed each 
claim to be classified as administration medicines, chemotherapy, diagnostic/radiation 
medicines, pain management, secondary supportive medicine and supportive medicine. The 
medicines under each category can be seen in Appendix C. 
 
An automatic two-dimensional pivot table was constructed in Excel for Mac (2011). All fields 
within the data set were selected for the pivot table and the pivot table was built so as to 
summarise each patient’s treatment in order to establish the treatment pathways per patient 
(Appendix D). The treatment regimens and subsequent pathways were developed based on 
the service dates of the claims. Chemotherapy medicines claimed over a window period of 3 
months were grouped together due to the difficulties patients may experience during 
chemotherapy treatment and the difficulties of claim processing. Therefore a break in claims 
didn’t result in an automatic treatment line change. Patients that were early CRC were 
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changed to advanced CRC if a biological medicine was used in their 1
st
 or 2
nd
 line treatment 
or more than two lines of therapy followed by a biological medicine. 
 
Within treatment pathway development, treatment lines were colour coded and it was 
assumed that a change in treatment line occurred when a change occurred between oxaliplatin 
and irinotecan or a biological medicine was included or changed to another biological 
medicine. Patients remained on the same treatment line if a medicine was dropped for a 
certain number of cycles, if 5-FU was changed to capecitabine or vice versa and lastly if an 
oxaliplatin/irinotecan-containing regimen was changed to 5-FU/capecitabine monotherapy.  
 
2.4.2.2.2 Demographical analysis for medical data set 
 
Following the final classification of advanced CRC status based on the treatments patients 
received, a new Excel workbook was opened in which the patient cohort code, age, gender, 
advanced CRC status and date of surgery was copied from data set A7. The duplicates were 
removed. This meant that every line represented a patient. The date of surgery column was 
changed to whether or not the patient underwent surgery. Using pivot tables, the number of 
patients that were early CRC and advanced CRC was calculated. For each sub-group the 
average, median and range of the age was calculated in addition to the number of patients that 
underwent surgery.  
 
2.4.2.2.3 Cost analysis for medical data set 
 
A two-dimensional pivot table was constructed from data set A7 in order to establish the 
observed claimed costs per patient for all the medical claims from enrollment to the end 2015. 
All fields were selected within the data set and were filtered by the advanced CRC status 
(Appendix D).  
 
2.4.2.2.3.1 Cost adjustment  
 
Cost adjustment to 2014 was performed in order to allow for comparisons between the two 
sectors and to the theoretical costs. All costs claimed were adjusted to the last cost claimed in 
2014 for each medicine. Where quantities claimed didn’t match the claimed SEP, the 
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quantities were adjusted to reflect the claimed prices. Medicines where no claims were found 
for 2014 were adjusted by the August 2014 SEP database 
(http://www.mpr.gov.za/PublishedDocuments.aspx). These prices corresponded to the theoretical cost 
calculations. Instances where 2014 prices couldn’t be obtained for medicines due to 
registration after or withdrawal prior to August 2014, calculations were based on the last 
claimed price in 2012, 2013 or the first claimed price in 2015 and the annual increase for the 
SEP database was applied (Table 2.6). Section 21 medicines and the claims classified as 
“ethical nonspecific” were adjusted by the annual average Consumer Price Index (CPI) 
increase (http://www.inflation.eu/inflation-rates/south-africa/historic-inflation/cpi-inflation-south-africa.aspx).   
      
Table 2.6 Annual price SEP increase calculations – The adjustment calculations accounted 
for the adjustment from the year the price was obtained straight up to 2014 hence 2012 is a 
more complex calculation as it accounts for 2012 and 2013 adjustment in one calculation 
where 2013 and 2015 only require adjustment by one year.  
Year  SEP annual 
increase  
Calculation  
2012 5,8% 
Adjustment per Item=((2012 Price+(2012 Price*5,8%))+(2012 
Price+(2012 Price*5,8%)*5,82%)/Quantity claimed 
2013 5,82% Adjustment per Item=(2013 Price+(2013 Price*5,28%))/Quantity claimed 
2015 7,5% Adjustment per Item=(2015 Price-(2015 Price*7,5%))/Quantity claimed 
 
If claims were from more than one of the above-mentioned years then, 2013 or 2015 was used 
and all adjustments were by that year.   
 
2.4.2.2.3.2 Average costs per treatment regimen  
 
Based on the cost adjustment data, the average costs per regimen and the average number of 
cycles was calculated and compared to the public healthcare sector. Using the adjusted data, a 
pivot table was constructed for the early CRC and advanced CRC sub-groups, in order to 
calculate the average costs (Appendix D). The pivot table generated the total cost per ATC 
classification (medicines were grouped based on the role the medicine played within 
treatment i.e. whether it was chemotherapy, supportive medicine etc.) as well as the number 
of times it was claimed. The sum of the number of cycles was calculated from a pivot table 
generated from the treatment lines and for a particular regimen and then filtered by regimen in 
order to calculate the total number of cycles (Appendix D) and the average number of cycles 
(Table 2.7). The average number of cycles was rounded up to a whole number due to the 
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nature of receiving chemotherapy. Subsequently the average cost per regimen was calculated 
however this was not specific to the line of therapy (Table 2.7).   
 
Table 2.7 Calculations used to calculate the average costs per medicine and regimen 
together with the average number of cycles for cohort 
Average cost per cycle=Sum of Total adjusted price for 2014 for regimen 
                                                          Average number of cycles  
Average number of cycles=Sum of the number of cycles per regimen for cohort  
                                                  Number of patients that received that regimen 
 
The average adjusted costs for the administration and supportive medicines were calculated 
from a pivot table generated similarly to Appendix D. These average cost is based on the total 
cost claimed divided by the number of claims. This is similar to the basket approach used in 
the public sector and the basket medicines can be seen in Appendix E. The average costs were 
multiplied by the number of cycles calculated for the regimens and added to the 
chemotherapy regimens.  
 
2.4.2.2.4 Cost analysis of non-medical (administrative) data set 
 
Observed claimed costs per patient for all the administrative costs from enrollment to the end 
2015 were established. All fields were filtered by the advanced CRC status similarly to the 
medical data set (Appendix D).  The biggest difference within the pivot tables is that the non-
medical dataset doesn’t include ATC descriptions but rather high level descriptions, namely 
global fee; global fee-oral; facility fee and facility fee-oral. 
 
2.4.2.2.4.1 Cost adjustment 
 
Cost adjustment was in line with the medical database in that the last claimed cost for 2014 
was used. No other sources of data were required for the global and facility fees.  
 
2.4.2.2.4.2 Average costs per treatment regimen 
 
Based on the cost adjustment data, the average administrative costs per regimen were 
calculated and compared to the public healthcare sector. The administrative costs include the 
 73 
global fee and facility fee. For simplification, the global and facility fees were averaged for an 
oral and I.V regimen. The costs per cycle and the total adjusted costs were calculated based 
on the average number of cycles per regimen calculated in section 2.4.2.2.3.2. Early CRC and 
advanced CRC filters weren’t required as the administrative costs aren’t dependent on this.  
 
2.4.2.2.5 Average costs for patient cohort 
 
The total average costs for the patient cohort was calculated according to Table 2.8.  
 
Table 2.8 Calculations for average costs for patient cohort 
Total cost for regimen per cycle=chemotherapy regimen cost + administration cost + supportive 
medicine cost + administrative cost 
Total cost for x cycles=Total cost for regimen per cycle x average number of cycles for that regimen 
 
These average costs were compared to the theoretical costs for the relevant regimens.  
 
2.4.2.2.5.1 Average chemotherapy dosages for patient cohort 
 
The average chemotherapy dose for each chemotherapy medicine was calculated based on the 
average cost per medicine and the cost per vial or tablets for the medicine with the lowest 
SEP (Figure 2.10).  The lowest SEP price was selected to allow for comparison between the 
public and private healthcare sectors.   
 
 
Figure 2.10 Average dose calculations for the cohort 
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2.4.2.2.5.2 Average number of cycles per regimen for patient cohort 
 
For each chemotherapeutic regimen noted in the sub-groups, the average number of cycles 
was calculated by firstly tallying the total number of cycles for that regimen and the number 
of patients receiving that regimen. The average was therefore total number of cycles divided 
by number of patients. The cycles were rounded off to the nearest whole number if need be.  
 
2.5 Sensitivity Analysis  
 
A one-way sensitivity analysis was carried out to assess the impact that changes of the input 
variables would have on the costs of receiving chemotherapy per regimen in the costing 
model based on the theoretical costs. The input variables included chemotherapy cost, 
administrative costs, supportive care medicine costs, administration costs and the number of 
cycles and were all varied separately to test the sensitivity. This analysis was used so as to 
determine which variables the costing model is most sensitive to. These variables were 
changed by (+/-) 50% and (+/-) 20% (Figure 2.11). Changes greater than R1000 in the total 
cost were noted and it was concluded that these were the variables most likely to affect the 
model.   
 
 
Figure 2.11 Sensitivity analysis table used to test the robustness of the costing model 
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3. CHAPTER THREE - RESULTS  
 
3.1 Treatment pathways 
 
3.1.1 Literature search  
 
The results of the literature search using PubMed can be seen in Figure 3.1.  
 
 
Figure 3.1 Results for the literature search on PubMed 
 
The literature search on SCOPUS produced fewer new results, as three of the four articles 
were already acquired on PubMed. The search using the second search term produced no new 
results at all (Figure 3.2). From both literature searches, seven articles where used to identify 
the relevant medicines and clinical trials. Of the seven, two articles addressed the treatment of 
geriatric patients. The articles used can be found in Appendix F. 
 
 
Figure 3.2 Results for the literature search on SCOPUS 
 
Search terms: "colorectal 
cancer", "treatment 
review" 
Total articles 
retrieved  
N=20 
After exclusion criteria 
was applied  
N=4 
Search terms: "colorectal 
cancer", "personalised 
treament" 
Total articles 
retrieved  
N=12 
After exclusion 
criteria was applied  
N=2 
Search terms: "colorectal 
cancer", "treatment 
review" 
Total articles 
retrieved 
N=31 
After exclusion criteria 
was applied 
N=4 
Search terms: "colorectal 
cancer", "personalised 
treament" 
Total articles 
retrieved 
N=0 
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3.1.1.1 Clinical Trials identified from literature search 
 
The review literature identified the pivotal clinical trials, which provide evidence that a 
treatment is adequate enough to be used in clinical practice. The results of this search through 
the review articles are shown in Table 3.1. 
 
Table 3.1 Relevant clinical trials found from a search of review articles 
Review 
article 
Relevant phase 
3 clinical trial 
authors and 
date 
Treatment 
line 
Regimen 
Number of 
citations in 
review 
articles 
UpToDate® 
(Yes or No) 
Results 
Golfinopoul
os et al., 
2006* [174] 
 
Tol and 
Punt, 2010 
[175] 
 
Edwards et 
al., 2012 
[176]  
 
Heinemann 
et al., 2013 
[177] 
 
Kordatou et 
al., 2014* 
[178] 
 
Bekaii-Saab 
and Wu, 
2014 [179] 
 
Fakih, 2015 
[180] 
 
 
Douillard et al., 
2000 [181] 
First 
FU + LV/ 
FOLFIRI 
2 Yes 
Inc. RR, PFS, OS and 
longer QoL 
Saltz et al., 
2000 [49] 
First 
FU + LV/ 
FOLFIRI 
2 Yes Inc. PFS and OS 
De Gramont et 
al., 2000** [48] 
First 
FU + LV/ 
FOLFOX 
4 Yes 
Inc. PFS and 
maintenance of QoL 
Hurwitz et al., 
2004** [67] 
First 
IFL/ IFL + 
BEV 
6 Yes OS benefit 
Cunningham et 
al., 2004** [78] 
Irinotecan 
refractory 
Irinotecan + 
CET/ CET 
monotherapy 
3 Yes 
Clinical benefit of 
adding CET to 
Irinotecan even in 
irinotecan refractory 
cancer 
Goldberg et al., 
2004 [182] 
First 
IFL/ 
FOLFOX/ 
IROX 
3 Yes 
Inc. PFS, RR and 
median OS 
Tournigand et 
al., 2004 [51] 
First or 
Second 
depending 
on sequence 
FOLFIRI  
FOLFOX6/ 
FOLFOX6  
FOLFIRI 
1 Yes 
Similar OS, RR and 
PFS 
Colucci et al., 
2005 [183] 
First 
FOLFIRI/ 
FOLFOX4 
1 Yes 
No difference in OS, 
ORR or TPP 
Van Cutsem et 
al., 2007 [92] 
Chemo. 
refractory 
BSC alone/ 
BSC + 
PANIT 
3 Yes 
Significant 
improvement in PFS 
Giantonio et al., 
2007 [69] 
Fluoropyrim
idine and 
irinotecan 
resistant 
FOLFOX 
alone/ 
FOLFOX + 
BEV/ BEV 
alone 
4 Yes 
Combination Improves 
survival duration (Inc. 
PFS and ORR) 
Jonker et al., 
2007 [184] 
Chemot. 
refractory 
BSC alone/ 
BSC + CET 
4 Yes 
CET improves OS, PFS 
and QoL measures 
Saltz et al., 
2008 [68] 
First 
FOLFOX or 
CAPOX/ 
FOLFOX or 
CAPOX + 
BEV 
5 Yes 
Improved PFS but no 
OS benefit 
Sobrero et al., 
2008 [185] 
Second 
(following 
fluoropyrim
idine and 
oxaliplatin 
failure) 
Irinotecan 
alone/ 
Irinotecan + 
CET 
3 Yes 
Improved PFS and RR, 
better QOL 
Van Cutsem et 
al., 2008 [80] 
Chemo. 
refractory 
BSC/ BSC + 
PANIT 
 Yes 
Significant 
improvement in PFS 
Karapetis et al., 
2008 [91] 
 
BSC/ BSC + 
CET 
3 Yes 
Wild-type KRAS is 
required for efficacy 
 
Amado et al., 
2008 [167] 
 BSC/ PANIT 3 Yes 
Wild-type KRAS is 
required for efficacy 
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Hurwitz et al., 
2009 [186] 
First 
IFL/ IFL + 
BEV 
1  
Clinical benefit 
regardless of KRAS 
status 
Van Cutsem et 
al., 2009 [187] 
First 
FOLFIRI 
alone/ 
FOLFIRI + 
CET 
4 Yes 
Inc. PFS 
Beneficial for wild-type 
KRAS. OS benefit on 
subsequent analysis 
Bokemeyer et 
al., 2009 [188] 
First 
FOLFOX 
alone/ 
FOLFOX + 
CET 
2 Yes 
Inc. ORR, PFS for wild-
type KRAS 
Kim et al., 2009 
[189] 
Second (5-
FU 
refractory) 
FOLFOX4/ 
Irinotecan 
1 Yes 
OS is not significantly 
different, FOLFOX4 
has higher RR and 
longer TPP when 
started before irinotecan 
Douillard et al., 
2010  
and 2013 [81, 
190] 
First 
FOLFOX4 
alone/ 
FOLFOX4 + 
PANIT 
4 Yes 
Significant 
improvement in PFS for 
wild-type KRAS. 
Subsequent data 
showed improved PFS 
as well as OS benefit in 
RAS WT. 
Peeters et al., 
2010 [83] 
Second 
FOLFIRI 
alone/ 
FOLFIRI + 
PANIT 
4 Yes 
Improved PFS for wild-
type KRAS 
Maughan et al., 
2011 [191] 
First 
FOLFOX or 
CAPOX/ 
FOLFOX or 
CAPOX + 
CET 
3 Yes 
Inc. RR, no benefit in 
PFS or OS for KRAS 
wild-type 
Van Cutsem et 
al., 2011 [90] 
First 
FOLFIRI/ 
FOLFIRI + 
CET 
3 Yes 
Improved survival for 
wild-type KRAS 
Van Cutsem et 
al., 2012 [73] 
Previously 
treated with 
oxaliplatin 
FOLFIRI/ 
FOLFIRI + 
Aflibercept 
2 Yes Inc. survival benefit 
Tveit et al., 
2012 [192] 
First 
Nordic 
FLOX/ 
Nordic FLOX 
+ CET 
3 Yes 
No, CET did not add 
any benefit 
Bennouna et al., 
2013 [193] 
Second 
Standard 
Chemo/ 
Standard 
Chemo + 
BEV 
2 Yes 
Clinical benefit to 
continue BEV passed 
disease progression 
Cunningham et 
al., 2013 [70] 
First line for 
elderly 
patients 
Capecitabine/ 
Capecitabine 
+ BEV 
2  Inc. PFS 
Grothery et al., 
2013 [85] 
Second/ 
Third 
BSC/ BSC + 
Regorafenib 
2 Yes 
Inc. PFS, OS and 
disease control 
Heinemann et 
al., 2014 [194] 
First 
FOLFIRI + 
CET/ 
FOLFIRI + 
BEV 
1 Yes 
OS benefit. FOLFIRI + 
CET are preferred in 
wild-type KRAS. 
Subsequent analysis 
showed further OS 
improvement in RAS 
WT patients. 
* Treatment review for geriatric patients; ** Also referenced from geriatric paper 
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3.1.2 Theoretical developed treatment pathways  
 
Based on the definition of a clinical pathway, South Africa does not have well-defined 
pathways for oncology [126-129] therefore review of the literature and consultations with 
oncologists at the CMJAH confirmed that once the cancer is advanced CRC, the origin of the 
cancer i.e. colon or rectum, is irrelevant thus treatment is the same. Stage 2 colorectal cancer 
was excluded as there is no consensus as to whether or not chemotherapy treatment is 
necessary. Early-staged colorectal cancer is however, treated with adjuvant chemotherapy. 
The main difference between colon and rectum is that early-staged rectum cancer will also be 
treated with radiation. The treatment pathways for early-staged adjuvant CRC can be seen in  
Figure 3.3 and Figure 3.4. 
 
 
Figure 3.3 Treatment pathway for early adjuvant colorectal cancer in the public 
healthcare sector for South Africa –  5FU/LV is 5-fluorouracil and folinic acid, CAPOX – 
capecitabine and oxaliplatin, FOLFOX - 5-fluorouracil, folinic acid and oxaliplatin. RT – 
radiation therapy, Chemotherapy D1-4: days 1 to 4 and D22-25: days 22 to 25. Radiation D1-
25: days 1 to 25, Monday to Friday.  
 
RECTUM COLON 
§ 5FU/LV  
OR 
§ CAPECITABINE 
OR 
§ CAPOX/FOLFOX (high risk) 
§ Surgery à Chemo RT 
OR 
§ Chemo RT à Surgery 
 
Where RT: 5/52 
Chemo: 5FU/LV D1-4 & D22-25 
followed by Radiation D1-25 (M-F) 
PUBLIC SECTOR 
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Figure 3.4 Treatment pathway for early adjuvant colorectal cancer in the private 
healthcare sector for South Africa - 5FU/LV is 5-fluorouracil and folinic acid, CAPOX – 
capecitabine and oxaliplatin, FOLFOX - 5-fluorouracil, folinic acid and oxaliplatin. RT – 
radiation therapy, Chemotherapy D1-4: days 1 to 4 and D22-25: days 22 to 25. Radiation D1-
25: days 1 to 25, Monday to Friday.  
 
Most notably the differences between the early adjuvant CRC treatment pathways that 
5FU/LV and capecitabine are usually reserved for older and frail patients. This is not 
necessarily the case in the public sector as the CAPOX and FOLFOX regimens are reserved 
for high risk patients. Figure 3.5 and Figure 3. show the treatment pathways for advanced 
CRC for each sector respectively.  
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Figure 3.5 Treatment pathway for advanced CRC colorectal cancer in the public healthcare sector for South Africa - 5FU/LV is 5-fluorouracil 
and folinic acid, CAPOX – capecitabine and oxaliplatin, FOLFOX - 5-fluorouracil, folinic acid and oxaliplatin. XELIRI – capecitabine and irinotecan, 
FOLFIRI – 5-fluorouracil,  folinic acid and irinotecan. RAS tests – MT: Mutant type; RAS, WT: Wildtype RAS. 
CONVERSION  RESECTABLE 
MEDICALLY 
UNFIT/
ELDERLY 
(15%) 
IRRESECTABLE 
§ BSC 
OR 
§ CAPECITABINE  
OR 
§ 5FU/LV 
§ FOLFOX 
OXALIPLATIN à 
(blue liver) 
OR 
§ FOLFIRI 
IRINOTECAN à 
(yellow liver) 
      NB! Diarrhea à Atropine 
RAS tests 
à MT (45%) 
à WT (55%) 
 
§ CAPOX 
(FOLFOX)  
 
§ FOLFIRI 
(XELIRI) 
PUBLIC SECTOR 
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Figure 3.6 Treatment pathway for advanced CRC colorectal cancer in the private healthcare sector for South Africa – medicines such as 
Panitumumab, Aflibercept, Ramucirumab and Regorafenib were not commercially available in South Africa at the time of this research, therefore, the 
combinations could only be prescribed under a Section 21 application. Aflibercept was however available on an Expanded Access Programme 
(EAP). Panitumumab has since been approved (2016). 5FU/LV is 5-fluorouracil and folinic acid, CAPOX – capecitabine and oxaliplatin, FOLFOX - 
5-fluorouracil, folinic acid and oxaliplatin. XELIRI – capecitabine and irinotecan, FOLFIRI – 5-fluorouracil, folinic acid and irinotecan, Bev – 
bevacizumab, Pani – panitumumab, CET – cetuximab. Pathway in blue is used in the USA and EU: – Tipiracil + Trifluridine, Aflibercept and 
Ramucirumab are new medicines and not available to South African patients. Ramucirumab can be used in combination with FOLFIRI  in place of  
Aflibercept. 
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Comparing the developed public and private sector pathways indicates a big difference in the 
number of medicines available to patients for advanced CRC disease. The developed private 
sector pathways are comparable to the local South African guidelines however the public 
sector has fewer medicines available to patients [126, 127]. The most notable difference is the 
availability of biological agents to patients in the private sector and not the public sector. 
Although irinotecan is found on the public sector pathways, it has only recently become 
available in the sector with patients who received irinotecan in this sector previously having 
to purchase this medicine themselves.  
 
When comparing the private sectors pathways, the availability of medicines is more 
comparable to international guidelines such as American Cancer Society (ACS – United 
States of America), National Comprehensive Cancer Network (NCCN – United States of 
America) and National Cancer Institute (NCI – United States of America) as well as National 
Institute for Health and Care Excellence (NICE – United Kingdom) and European Society for 
Medical Oncology (ESMO – Switzerland based for Europe) [25, 26, 156-162]. Patients have a 
greater access to newer therapies and early-staged patients do have access to regimens such as 
CAPOX and FOLFOX,  which is independent of their risk unlike in the public sector.  
 
Panitumumab is absent when comparing pathways in the United States of America although it 
has recently been registered in South Africa. Aflibercept was not commercially available to 
all patients, Section 21 applications provided access to patients on an Expanded Access 
Program. 
 
Medicines such as ramucirumab and combinational treatment containing trifluridine and 
tipiracil are newly FDA and EMA approved agents used in advanced CRC although they are 
not yet registered in South Africa. Ramicurumab is used in combination with FOLFIRI as a 
2
nd
 line therapy following failure of treatment with FOLFOX + bevacizumab. Trifluridine and 
tipiracil (TAS-102) is used for third line treatment of advanced CRC similarly to regorafenib. 
Although it is not registered in South Africa, it may be obtained with MCC approval via 
Section 21 of Medicines and Related Substances Act 101 of 1965 via the expanded access 
program in both the public and private healthcare sectors [195]. At this stage the choice 
between the two agents appears to be dependent on patient access (funding) and oncologist 
choice. 
 
 
 84 
3.1.2.1 Supportive care medicines relevant to the treatment regimen 
 
The relevant supportive care medicines which were identified and refined to reflect the 
availability in each sector are shown in Table 3.2.  
 
Table 3.2 Table of supportive care medicines relevant to the regimen for which they are 
indicated (http://0-www.uptodate.com.innopac.wits.ac.za/contents/search).  
Chemotherapy 
medicines 
*Emetogenic 
Potential 
Supportive care 
medicines for Public 
Sector 
Supportive care medicines 
for Private Sector 
5-FU (+ LV) Low  Corticosteriod (CS) + 
Metoclopramide 
 Metoclopramide 
Capecitabine Low   Metoclopramide  Metoclopramide 
Oxaliplatin Moderate 5HT3 antagonist + CS +/- 
Metoclopramide 
5HT3 antagonist + CS +/-
Aprepitant 
Irinotecan Moderate 5HT3 antagonist + CS +/- 
Metoclopramide + 
Atropine 
5HT3 antagonist + CS +/-
Aprepitant + Atropine 
  
Not applicable to patients 
in this sector. 
 
Bevacizumab Minimal Cyclizine 
Aflibercept Low Cyclizine 
Regorafenib Minimal N/A 
Cetuximab Minimal Cyclizine 
Panitumumab Low Cyclizine 
Ramucirumab Low Cyclizine 
TAS-102 (Trifluridine 
+ Tipiracil) 
Low N/A 
* Key: frequency of emesis (%) - Minimal <10, Low 10-30, Moderate (MEC) 30-90, High >90 
 
Medicines with minimal effect do not contribute to emesis thus there is clinically no need to 
prescribe antiemetics. With combination treatment regimens, emesis is treated with the 
medicines from highest tier of frequency. Combination regimens may have a higher emetic 
risk than single medicines but none of the currently available  colorectal cancer regimens have 
a high emetogenic risk [196, 197].   
 
3.1.3 Public healthcare sector observed treatment pathways 
 
3.1.3.1 Observed treatment pathways for early CRC disease 
 
Figure 3.7 reveals that although most patients seek treatment however, ~15% of patients don’t 
receive treatment at all. Capecitabine is used extensively in early CRC treatment regimens 
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regardless of the site of origin of the cancer. There are a low number of patients that change to 
an alternative regimen (approx. 3%). A change in regimen was considered as a change in the 
fluoropyrimidine and/or the addition of a non-standard adjuvant medicine such as mitomycin. 
The number of chemotherapy cycles and dosages for each patient (Table 3.3) was used in 
order to calculate the average number of chemotherapy cycles and dosages for each regimen. 
The averages seen in Table 3.3 were used to calculate the total cost of chemotherapy in the 
costing model (section 2.3.4.1). The observed treatment pathways per patient can be found in 
Appendix G. 
 
 
Figure 3.7 The number of early CRC patients per the number of treatment regimens 
used in the public healthcare sector 
 
Table 3.3 Average number of cycles of chemotherapy treatment for early CRC in the 
public healthcare sector 
Chemotherapy Regimens - colon 5-FU + LV CAPECITABINE  CAPOX 
Averages (Rounded off to nearest 
whole number) 
6 4 6 
Chemotherapy Regimens - rectal 5-FU + LV CAPECITABINE CAPOX 
Averages (Rounded off to nearest 
whole number) 
3 2 5 
 
When compared to the theoretical number of cycles seen in Table 3.14 capecitabine use is less 
than the 8 cycles found in literature but oxaliplatin use is restricted due to suspected 
neuropathy development therefore 6 cycles of CAPOX is more likely to be administered in 
clinical practice. FOLFOX is not used at all in this patient cohort and is largely related to the 
easier administration of CAPOX. Rectal cancer patients received less active treatment than 
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colon cancer patients, this is not unexpected as literature does indicate fewer cycles of 
treatment.  
3.1.3.2 Observed treatment pathways for advanced CRC disease 
 
 
 
Figure 3.8 The number of advanced CRC patients per treatment line in the public 
healthcare sector 
  
The advanced CRC sub-group of patients had more patients receiving treatment in 
comparison to the early CRC sub-group. In addition, a few patients only received best 
supportive care and no active chemotherapy. Similarly to the early CRC sub-group, 
capecitabine was extensively administered in 1
st
 line treatment but more patients did receive 
2
nd
 line treatment. Most of the 2
nd
 line treatments contained irinotecan-containing regimens 
Interestingly 76% of patients between 60 and 70 years received oxaliplatin however, it can’t 
be determined if these patients are high-risk or not. In addition, more patients were placed 
onto maintenance therapy with capecitabine although this doesn’t seem to be standard 
practice for CRC (Figure 3.8). The observed treatment pathways per patient can be found in  
Appendix H. 
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Table 3.4 Average number of cycles of chemotherapy treatment for advanced CRC in 
the public healthcare sector 
Chemotherapy 
Regimens 
5-FU 
+ LV 
CAPE 
(1ST) 
CAPOX 
CAPOX 
(2ND) 
XELIRI 
XELIRI 
(2ND) 
Cape-
Mito 
CAPE 
(2ND) 
Averages (Rounded 
off to nearest whole 
number) 
6 3 6 6 1 4 2 3 
Chemotherapy 
Regimens 
FOLFOX OXALI FOLFIRI FOLFIRI (2ND) CAPE (MAINT) 
Averages (Rounded 
off to nearest whole 
number) 
6 6 7 7 14 
 
Although capecitabine is widely administered, the average number of cycles is lower for the 
patient cohort where capecitabine is combined with oxaliplatin. Oxaliplatin toxicity is a 
problem thus 8 cycles as found in literature is probably higher than used in clinical practice. 
FOLFOX is used for advanced CRC treatment and is used at the prescribed number of cycles.  
 
Table 3.5 Average dosages for each treatment cycle for advanced CRC disease in the 
public healthcare sector 
Chemo. 
Regimen  5-FU + LV 
Cape 
(1
st
 
line) 
CAPOX 
CAPOX (2
nd
 
line) 
XELIRI 
XELIRI (2
nd
 
line) 
Medicine 
composition 
for the 
regimen 
5
-F
U
 
L
V
 
C
ap
e 
C
ap
e 
O
x
al
ip
la
ti
n
 
C
ap
e 
O
x
al
ip
la
ti
n
 
C
ap
e 
Ir
in
o
te
ca
n
 
C
ap
e 
Ir
in
o
te
ca
n
 
Average dose 
(mg) per cycle 
3600 180 43960 42896 208 38164 207 32200 350 42728 370 
 
Chemo. 
Regimen Cape-Mito 
Cape 
(2
nd
 
line) 
FOLFOX Oxal. FOLFIRI FOLFIRI (2
nd
 line) 
Medicine 
composition 
for the 
regimen 
C
ap
e 
M
it
o
 
C
ap
e 
5
-F
U
 
L
V
 
O
x
al
ip
la
ti
n
 
O
x
al
ip
la
ti
n
 
5
-F
U
 
L
V
 
Ir
in
o
te
ca
n
 
5
-F
U
  
L
V
 
Ir
in
o
te
ca
n
 
Average dose 
(mg) per cycle 
37492 11 44800 5440 640 160 260 4700 700 300 4680 680 300 
 
Chemo. 
Regimen 
Cape 
(maint) 
 
Medicine 
composition 
for the 
regimen 
C
ap
e 
 
Average dose 
(mg) per cycle 
37240  
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When used in FOLFOX or FOLFIRI, the doses are however, much higher and closer to the 
theoretical doses. Capecitabine also falls within the prescribed range expect when 
administered with irinotecan. This regimen has a lower capecitabine dose but higher 
irinotecan dose than the theoretical doses based on the average BSA for a cancer patient. The 
maintenance capecitabine dose is nevertheless, expected to be lower than active treatment 
doses. For this group of patients the 2
nd
 line treatment doses are not necessarily higher as seen 
with FOLFIRI and CAPOX. This could be due to patient cohort characteristics and 
tolerability after much 1
st
 line treatment.  
 
3.1.4 Private healthcare sector 
  
3.1.4.1 Observed treatment pathways for early CRC disease 
 
Majority (69%) of early CRC patients received one regimen or didn’t change their regimen 
notably, the number of patients changing their regimens is lower however, a noteworthy 
number of patients only received best supportive care (9%) and 11% didn’t receive any 
treatment (Figure 3.9). A change in regimen was noted if the fluoropyramidine changed or the 
patient switched between irinotecan and oxaliplatin or the addition of a non-standard 
medicine was observed. Maintenance therapy was not often recorded (0,36%) similarly with 
3
rd
 and 4
th
 treatment regimen changes. Of all the early CRC patients that received no 
treatment (93 in total), 78,5% underwent surgery. In addition, 56% of these patients were 
male. The observed treatment pathways per patient can be found in Appendix I. 
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Figure 3.9 The number of early CRC patients per treatment line in the private 
healthcare sector 
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The average number of cycles per regimen was calculated from the treatment pathways 
whereby the same regimen for the group of early CRC patients was summed and an average 
calculated for the number of patients that received that regimen (Table 3.6).  
 
Table 3.6 The average number of cycles per conventional CRC regimen for the early 
CRC group of patients in the private healthcare sector 
Chemotherapy regimens 
Total no. of 
cycles 
No. of patients 
per regimen 
Average no. of 
cycles 
Rounding 
5FU 684 135 5,07 5 
Capecitabine 1376 306 4,50 5 
Oxaliplatin 62 31 2 2 
FOLFOX 1395 186 7,50 8 
CAPOX 1007 201 5,01 5 
Based on the theoretical costing model, the average dosages for the patient cohort were 
calculated. The lowest SEP prices were used and were only calculated for the conventional 
CRC medicines as the theoretical costing model only comprised of these medicines (Table 
3.7). 
 
Table 3.7 The average dose (mg) per conventional CRC chemotherapy medicine for the 
early CRC group in the private healthcare sector– the doses are regardless of monotherapy 
or combined in a regimen 
Chemotherapy  5-FU LV Capecitabine Oxaliplatin 
Average cost per 
claim  
R232,94 R840,92 R3 513,10 R2 862,09 
Medicine 
price/vial 
R15,66 R184,00 R12,40 R974,13 
  R552,00 R41,71 R1 948,26 
No. of vials 
  
15 2 84 1 
  2   1 
Vial size/tab 500mg 100mg, 300mg 150mg, 500mg 50mg, 100mg 
Dose per cycle 
(mg) 
7437 623 42113 194 
 
3.1.4.2 Observed treatment pathways for advanced CRC disease 
 
Majority (65%) of advanced CRC patients received 1
st
 line treatment, the number of patients 
receiving 2
nd
 line treatments are greater than the early CRC group. Fewer patients received 
best supportive care (1,5%) and few patients didn’t receive any treatment (1,3%) (Figure 
3.10). Maintenance therapy was not often recorded (0,7%) similarly with 3
rd
 and 4
th
 line 
treatments however, there was one patient that received 6 lines of therapy. Although a small 
number of advanced CRC patients received no treatment (6 in total), 66,7% or two-thirds 
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underwent surgery for colorectal cancer. In addition, all of these patients were male.  The 
observed treatment pathways per patient can be found in Appendix J. 
 
 
Figure 3.10 The number of advanced CRC patients per treatment line in the private 
healthcare sector 
 
The average number of cycles for the advanced CRC group was calculated (Table 3.8) in 
addition to the average doses per chemotherapy medicine (Table 3.9). 
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Table 3.8 The average number of cycles per conventional CRC regimen for the 
advanced CRC group of patients in the private healthcare sector 
Chemotherapy regimens 
Total no. of 
cycles 
No. of patients 
per regimen 
Average no. 
of cycles 
Rounding 
5-FU 346 74 4,68 5 
Capecitabine 551 133 4,14 4 
Irinotecan 105 33 3,18 3 
Oxaliplatin 60 36 1,67 2 
FOLFOX 1112 170 6,54 7 
FOLFIRI 772 131 5,89 6 
CAPOX 512 118 4,34 4 
XELIRI 180 36 5 
 
FOLFOXIRI 30 4 7,50 8 
Bev 135 47 2,87 3 
5-FU+Bev 70 20 3,5 4 
Capecitabine+Bev 201 42 4,79 5 
Oxaliplatin+Bev 43 16 2,69 3 
Irinotecan+Bev 49 9 5,44 6 
FOLFOX + Bev 737 108 6,82 7 
FOLFIRI+Bev 496 77 6,44 6 
FOLFOXIRI+Bev 1 1 1 
 
CAPOX+Bev 314 64 4,91 5 
XELIRI+Bev 93 16 5,81 6 
Cet 141 30 4,70 5 
5-FU+Cet 20 7 2,86 3 
Capecitabine+Cet 1 1 1 
 
Irinotecan+Cet 105 22 4,77 5 
FOLFOX + Cet 114 24 4,75 5 
FOLFIRI+Cet 356 57 6,25 6 
CAPOX+Cet 12 3 4 
 
XELIRI+Cet 8 2 4 
 
Regorafenib 34 15 2,27 2 
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Table 3.9 The average dose (mg) per conventional CRC chemotherapy medicine for the advanced CRC group in the private healthcare sector 
– the doses are regardless of monotherapy or combined in a regimen and cetuximab includes the loading dose 
Chemo/ 
Biological  
5-FU LV Capecitabine Oxaliplatin Irinotecan Bevacizumab Cetuximab Regorafenib 
Average cost per claim  R272,31 R962,29 R3 470,76 R2 966,24 R2 325,89 R11 683,80 R19 335,34 R50 374,15 
Medicine price/vial 
R15,66 R184,00 R12,40 R974,13 R370,50 R3 682,56 R2 897,69 R628,37 
  R552,00 R41,71 R1 948,26 R934,80 R14 730,25     
No. of vials/tablets 
  
17 2 83 2 2 1 7 80 tablets 
  2   1 4       
Vial size/tab 500mg 
100mg, 
300mg 
150mg, 
500mg 
50mg, 
100mg 
20mg, 
100mg 
100mg, 
400mg 
100mg 
Flat dose 
(4x400mg) 
Dose per cycle (mg) 8694 843 41606 205 324 317 667 3207 
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3.2 Retrospective Drug Utilisation Review – patient cohort demographics 
 
3.2.1 Public healthcare sector 
 
3.2.1.1 Patient identification from “new case” books 
   
Table 3.10 Number of patients identified from "new case" books for 3 year period 
starting in 2012 
Year Number of patients 
identified 
Number of patients with 
missing diagnosis 
Number of patient files 
captured 
2012 151 18 74 
2013 103* 7 62 
2014 89* 37 26 
TOTAL 343 62 162 
* Patients could not be identified for the entire year as “new case” books were missing from the clinic.   
 
Patients that were excluded as the missing diagnosis was not colorectal or diagnosis were in 
fact stomach, small bowel or anal cancer. Anal cancer was only included if the origin was 
adenocarcinoma and not squamous cell or neuroendocrine origin.  
 
3.2.1.2 Patient cohort  
 
The patient cohort consisted of 162 patients of whom 73 were females and 89 males. The 
average age at which the patients presented at the clinic was approximately 57 years (s.d +/-
13) (median 58 years, range 67 years). Although more males presented at the clinic, the 
advanced CRC data indicates a similar number for the genders.  
 
Table 3.11 Colorectal cancer incidences per age group for CMJAH between 2012 and 
2014  
Age group 
Males Females 
Number Percentage Number Percentage 
0 – 49 20 23 24 33 
50 – 79 62 72 45 63 
80
+
 4 5 3 4 
Total *86 100 *72 100 
  *Totals exclude the patients where age couldn’t be determined 
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Table 3.12 Colorectal cancer incidences per colorectal site for CMJAH between 2012 
and 2014 
Tumour location 
[198] 
All Males Females 
Number Percentage Number Percentage Number Percentage 
Right-sided 23 14 14 16 9 12 
Left-sided 61 38 39 44 22 30 
Rectum 50 31 26 29 24 33 
Colon - unspecified 21 13 8 9 13 18 
Synchronous 
tumours 
7 4 2 2 5 7 
Total *162 100 *89 100 *73 100 
*Totals include patients where age couldn’t be determined 
 
Table 3.11 and Table 3.12 illustrate the spread of data between age groups and primary 
tumour location within the colorectal region. Most patients presented at the clinic were over 
50 years of age and more distal colon cancer and rectal cancer were treated for this cohort.  
 
 
 
Figure 3.11 Distribution of colorectal cancer tumour location by age and sex for 
CMJAH patient cohort between 2012 and 2014 for males (A) and females (B) – Dark 
grey (0-49 years), Light grey (50-79 years); Medium grey (80+ years) 
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3.2.1.2.1 Early CRC disease 
 
60 patients were identified with early CRC disease and accounts for slightly more than a third 
(37%) of the total identified patient population. Within the early CRC group, majority (82%) 
had left-sided colorectal cancer (Figure 3.12). This includes rectal cancer patients as the 
rectum is anatomically on the left side of the colon.  
 
 
Figure 3.12 Percentage of CRC cases based on diagnosed site of origin for early CRC 
patients at CMJAH 
 
None of the patients had cancer of the transverse colon however, 8% of the patient cases were 
non-specific to the site of origin. With regard to gender and age, more males were diagnosed 
with early CRC disease (62%) and the highest number of cases occurred between the ages of 
40 and 60 years (Figure 3.13).  
 
 
Figure 3.13 Number of early CRC disease patients for each age group based on the age 
at which patients presented at CMJAH  
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3.2.1.2.2 Advanced CRC disease 
 
Of the 162 patients identified, approximately 64% were diagnosed with advanced CRC 
disease. Similarly to the early CRC patient group, left-sided colorectal cancer was more 
common and nearly 60% had rectal cancer as the primary site of origin (Figure 3.14). 
Colorectal cancer of transverse origin is once again a small percentage but there are also a 
higher number of patients with synchronous tumours, which could include the transverse 
colon. The percentage of patients with a diagnosis of only colon cancer is double when 
compared to the early CRC group therefore there may very well be more cases of right-sided 
and transverse colon origins as well.  
 
 
Figure 3.14 Percentage of CRC cases based on diagnosed site of origin for advanced 
CRC patients at CMJAH 
 
In comparison to the early CRC sub-group, the number of cases based on gender is similar for 
the advanced CRC group, 51% male patients and 49% female patients. From this result it can 
be said that CRC is not gender specific particularly for advanced CRC disease diagnosis. In 
terms of age groups, it is similar to the early CRC sub-group in that the ages most likely to 
present at the clinic was between the ages of 40 and 60 years (Figure 3.15). 
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Figure 3.15 Number of advanced CRC disease patients for each age group based on the 
age at which patients presented at CMJAH 
 
3.2.2 Private healthcare sector 
 
3.2.2.1 Data capture from data sets 
 
 
Figure 3.16 Patient enrollment numbers per year from data set A1 
 
The final number of patients included in data set A7 following the subsequent exclusions was 
1297 (Figure 3.17).  
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Figure 3.17 Total number of patients included in the private healthcare sector cohort 
prior to treatment pathway development  
3.2.2.2 Patient cohort  
 
Table 3.13 Colorectal cancer incidences per age group for a South African medical 
scheme between 2012 and 2014 
Age group 
Male Female 
Number % Number % 
20-59 248 53 218 47 
60-79 435 59 302 41 
80+ 46 49 47 51 
Total 729 56 567 44 
 
The patient cohort comprise of 729 males and 567 females (Table 3.13). The average age, 
both advanced CRC and early CRC, was calculated to be 63 years (s.d +/- 12). The average 
age for the advanced CRC sub-group was lower than for the overall cohort at 61 years (s.d +/- 
12). The median and range of the ages for the total cohort was calculated to be 68 and 64 
years respectively. 84% of the cohort underwent surgery but most of these patients were early 
CRC (Figure 3.18).   
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Figure 3.18 The number of patients that underwent definitive surgery for colorectal 
cancer based on their advanced CRC status for patients enrolled onto the medical 
scheme– the type of definitive surgery was not specified in the anonymised data  
Due to the nature in which the medical scheme dataset is captured, it is unclear the specific 
site of disease within the colorectal region.   
 
3.2.2.2.1 Early CRC disease 
 
Just less than two-thirds of the cohort was diagnosed with early CRC disease (65%) of which 
more males (55%) was diagnosed than females (45%). The average age for the early CRC 
group was calculated to be 64 years (s.d +/- 13) with a range and median of 65 years and 68 
years respectively. The most frequently recorded age group on the database with 32% was 
patients in their 60s. Patients in their 20s and 90s were recorded, albeit less than 1% each 
(Figure 3.19).  
 
 
Figure 3.19 Number of early CRC disease patients for each age group based on the age 
recorded on the South African medical  scheme  
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3.2.2.2.2 Advanced CRC disease 
 
Slightly more than one-third of the cohort was diagnosed with advanced CRC disease or 
where disease progression occurred to an advanced stage (35%). Similarly to the early CRC 
group, more males (58%) were diagnosed than females (42%). The average age for the 
advanced CRC group was calculated to be 61 years (s.d +/- 12) with a range and median of 61 
years and 62 years respectively. These demographics are lower than the early CRC group. 
The most frequently recorded age group on the database with 35% was patients in their 60s. 
Patients in their 20s were recorded, albeit less than 1%. There were no patients older than 90 
years of age (Figure 3.20).  
 
 
Figure 3.20 Number of early CRC disease patients for each age group based on the age 
recorded on the South African medical  scheme 
 
3.3 Treatment costs 
 
Treatment costs were calculated (theoretical costs, public healthcare sector and private 
healthcare sector) using the costing model developed in section 2.3.4. Each component of the 
total cost is presented below.  
 
3.3.1 Total cost for CRC treatment 
 
3.3.1.1 Theoretical treatment pathway costs for the public healthcare sector 
 
3.3.1.1.1 Early CRC disease 
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The total theoretical costs for early CRC adjuvant treatment was calculated based on dosages 
in Table 2.1 and the average body surface area and ideal body weight as noted in Section 
2.3.4.1.  Figure 3.21 shows the cost per cycle of the regimens as determined by the treatment 
pathways in Figure 3.3 whereas Table 3.14 shows the total theoretical cost based on the 
recommended number of cycles found in the essential clinical trial data (Table 3.1), 
international guidelines from the American Cancer Society (ACS – United States of 
America), National Comprehensive Cancer Network (NCCN – United States of America) and 
National Cancer Institute (NCI – United States of America) as well as National Institute for 
Health and Care Excellence (NICE – United Kingdom) and European Society for Medical 
Oncology (ESMO – Switzerland based for Europe) [25, 26, 156-162] and local guidelines 
from the South African Oncology Consortium (SAOC) and the Independent Clinical 
Oncology Network (ICON) [127, 155]. 
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Figure 3.21 Theoretical cost per cycle for early CRC treatment regimens in the public healthcare sector – The cost per treatment regimen 
comprises of the chemotherapy cost, administrative cost (grey stripe), supportive care medicine costs (grey) and administration costs (black).  
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Table 3.14 Total theoretical costs per treatment regimen for early CRC in the public healthcare sector - The number of cycles is based on the 
recommended total number of cycles from literature and the total cost is calculated by multiplying the cost per cycle with the number of cycles.  
  COLON 
  5FU + LV FOLFOX Capecitabine 
(850) 
Capecitabine 
(1050) 
Capecitabine 
(1250) 
CAPOX 
(850) 
CAPOX 
(1050) 
CAPOX 
(1250) 
Total treatment costs per 
cycle 
R7 409,18 R9 555,79 R2 052,21 R2 502,23 R2 949,73 R4 602,59 R5 052,61 R5 500,11 
Number of cycles 6 12 8 8 8 8 8 8 
Treatment costs per x 
cycles 
 R 44 455,09   R 114 669,45   R 16 417,70   R 20 017,86   R 23 597,86   R 36 820,70  R40 420,86 R44 000,86 
Total costs for pathway FOR EARLY CRC TREATMENT IS EITHER/OR I.E. NOT ONE FOLLOWING OTHER 
 
 
 RECTAL 
  
5-FU + LV Capecitabine (850) 
Capecitabine 
(1050) 
Capecitabine 
(1250) 
Total treatment costs 
per cycle 
R7 409,18 R2 052,21 R2 502,23 R2 949,73 
Number of cycles 4 4 4 4 
Treatment costs per 
x cycles 
R29 636,73 R8 208,85 R10 008,93 R11 798,93 
Total costs for 
pathway 
FOR EARLY CRC TREATMENT IS EITHER/OR I.E. NOT ONE 
FOLLOWING OTHER 
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3.3.1.1.2 Advanced CRC disease 
 
From the theoretical costs, 5-FU-containing regimens have greater costs per cycle than 
capecitabine-containing regimens for either stage of CRC (Figure 3.4). This is due to higher 
administration costs for intravenous therapy as opposed to oral therapy despite the cheaper 
chemotherapy cost for 5-FU than capecitabine. For regimens where oxaliplatin is also 
prescribed, FOLFOX and CAPOX, the difference between the same regimen without 
oxaliplatin (5-FU or capecitabine) is greater for capecitabine-containing regimens as 
administration costs are then included (Figure 3.21). The theoretical costs for capecitabine-
containing regimens are dose dependent and treatments range between 850 to 1250 mg. 
Therefore the lowest, highest and mid-point doses were used to calculate the range of 
capecitabine-containing regimens. The trend for the cost per cycles is similar between early 
and advanced CRC. The total cost per treatment regimen differs only by the number of 
theoretical cycles a patient will receive (Table 3.14, Table 3.15). This is the only difference 
between early colon and rectal cancer, advanced CRC is one theoretical cost per regimen. The 
total costs are reflective of the pathways as treatment is based on an either/or situation and not 
 more than one defined line of therapy.
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Figure 3.22 Theoretical cost per cycle for advanced CRC treatment regimens in the public healthcare sector – The cost per treatment regimen 
comprises of the chemotherapy cost, administrative cost (grey stripe), supportive care medicine costs (grey) and administration costs (black). 
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Table 3.15 Total theoretical costs per treatment regimen for advanced CRC in the public healthcare sector - The number of cycles is based on 
the recommended total number of cycles from literature and the total cost is calculated by multiplying the cost per cycle with the number of cycles.  
  Advanced CRC 
  
5-FU + LV FOLFOX CAPOX (850) 
CAPOX 
(1050) 
CAPOX 
(1250) 
Capecitabine 
(850) 
Capecitabine 
(1050) 
Capecitabine 
(1250) 
FOLFOX 
(10 cycles) 
Total 
treatment costs 
per cycle 
R7 409,18 R9 555,79 R4 602,59 R5 052,61 R5 500,11 R2 052,21 R2 502,23 R2 949,73 R9 555,79 
Number of 
cycles 
6 6 8 8 8 8 8 8 10 
Treatment 
costs per x 
cycles 
 R 44 455,09   R 57 334,72   R 36 820,70  R40 420,86 R44 000,86 R16 417,70 R20 017,86 R23 597,86  R 95 557,87  
Total costs 
for pathway 
FOR advanced CRC TREATMENT IS EITHER/OR I.E. NOT ONE FOLLOWING OTHER 
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3.3.1.2 Theoretical treatment pathway costs for private healthcare sector 
  
3.3.1.2.1 Early CRC disease 
 
 
Figure 3.23 Theoretical cost per cycle for early CRC treatment regimens in the private sector – The cost per treatment regimen comprises of the 
chemotherapy cost, administrative cost (grey stripe), supportive care medicine costs (grey) and administration costs (black). The administrative costs are the average for the two 
types of facilities, the administration costs include admixtures calculated from the DUR for this sector.  
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Table 3.16 Total theoretical costs per treatment regimen for early CRC in the private sector - The number of cycles is based on the 
recommended total number of cycles from literature and the total cost is calculated by multiplying the cost per cycle with the number of cycles.  
  COLON 
  5FU + LV FOLFOX Capecitabine 
(850) 
Capecitabine 
(1050) 
Capecitabine 
(1250) 
CAPOX 
(850) 
CAPOX 
(1050) 
CAPOX 
(1250) 
XELIRI 
(850) 
XELIRI 
(1050) 
XELIRI (1250) 
Total treatment costs 
per cycle 
R4 321,15 R7 607,65 R4 463,65 R5 273,05 R6 077,94 R9 608,06 R10 417,46 R11 222,35 R9 890,21 R10 729,25 R11 563,78 
Number of cycles 6 12 8 8 8 8 8 8 8 8 8 
Treatment costs per x 
cycles 
R25 926,89 R91 291,84 R35 709,16 R42 184,36 R48 623,48 R76 864,48 R83 339,68 R89 778,80 R79 121,68 R85 834,00 R92 510,24 
Total costs for 
pathway 
FOR EARLY CRC TREATMENT IS EITHER/OR I.E. NOT ONE FOLLOWING OTHER 
 
 
 RECTAL 
 
5-FU + LV 
Capecitabine 
(850) 
Capecitabine 
(1050) 
Capecitabine 
(1250) 
Total treatment costs 
per cycle 
R4 321,15 R4 463,65 R5 273,05 R6 077,94 
Number of cycles 4 4 4 4 
Treatment costs per 
x cycles 
R17 284,60 R17 854,58 R21 092,18 R24 311,74 
Total costs for 
pathway 
FOR EARLY CRC TREATMENT IS EITHER/OR I.E. NOT 
ONE FOLLOWING OTHER 
 
 110 
3.3.1.2.2 Advanced CRC disease 
  
The theoretical costs in the private sector are higher than the public sector (Table 3.14, Table 
3.15, Table 3.16 and Table 3.17). For both stages of CRC, the chemotherapy costs are the 
largest cost contributor. Biological agents are particularly expensive and increase the cost by 
more than 50% in certain instances. An interesting cost trend occurs in that as disease 
progression occurs, the cost per regimen prescribed increases. This is clearly illustrated in the 
cost of Regorafenib, a 3rd line therapy. Figure 3.23 and Figure 3.24  show that intravenous 
regimens have greater costs in comparison to the equivalent oral regimen, more over 
oxaliplatin and irinotecan-containing regimens are very similar in cost and is most noticeably 
absent in the public healthcare sector. The contribution of the administrative costs to newer 
advanced CRC regimens appears much lower due to the high chemotherapy costs. The 
number of cycles of treatment differs not only between early colon and rectum cancer but also 
between the lines of therapy of the regimens used in advanced CRC (Table 3.16, Table 3.17). 
There are definite pathways for advanced CRC in the private sector thus the cost of treatment 
is expected to be higher.  
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Figure 3.24 Theoretical cost per cycle for advanced CRC treatment regimens the private sector – The cost per treatment regimen comprises of 
the chemotherapy cost, administrative cost (grey stripe), supportive care medicine costs (grey) and administration costs (black). The administrative 
costs are the average for the two types of facilities, the administration costs include admixtures calculated from the DUR for this sector. Bev – 
bevacizumab, Cet – cetuximab. 
R 0.00
R10 000.00
R20 000.00
R30 000.00
R40 000.00
R50 000.00
R60 000.00
C
o
st
 p
er
 c
y
cl
e 
Advanced colorectal cancer chemotherapy regimens 
 112 
Table 3.17 Total theoretical costs per treatment regimen for advanced CRC in the private sector - The number of cycles is based on the 
recommended total number of cycles from literature and the total cost is calculated by multiplying the cost per cycle with the number of cycles.  
 
  
5-FU+LV FOLFIRI FOLFOX Cape. (850) Cape. (1050) Cape. (1250) XELIRI (850) 
XELIRI 
(1050) 
XELIRI 
(1250) 
CAPOX 
(850) 
CAPOX 
(1050) 
Total 
treatment 
costs per 
cycle 
R4 315,12 R8 105,42 R7 493,59 R4 463,65 R5 273,05 R6 077,94 R10 105,83 R10 915,23 R11 720,12 R9 494,00 R10 303,40 
Number of 
cycles 
6 12 12 8 8 8 8 8 8 8 8 
Treatment 
costs per x 
cycles 
R25 890,71 R97 265,08 R89 923,12 R35 709,16 R42 184,36 R48 623,48 R80 846,64 R87 321,84 R93 760,96 R75 952,00 R82 427,20 
 
 CAPOX 
(1250) 
FOLFIRI + 
Cet 
FOLFIRI + 
Bev (6 cycles) 
FOLFIRI + 
Aflibercept 
FOLFOX + 
Bev (10) 
FOLFOX + 
Bev (6)  
FOLFOX + 
Panitumumab 
CAPOX 
(850)+ Bev 
CAPOX 
(1050)+ Bev 
CAPOX 
(1250)+ Bev 
Regorafenib 
Total 
treatment 
costs per 
cycle 
R11 108,29 R54 468,46 R33 883,36 R23 946,35 R22 223,84 R33 271,53 R43 348,44 R24 224,25 R25 033,65 R25 838,54 R53 801,43 
Number of 
cycles 
8 12 6 9 10 6 8 10 10 10 3 
Treatment 
costs per x 
cycles 
R88 866,32 R653 621,56 R203 300,18 R215 517,18 R222 238,43 R199 629,20 R346 787,55 R242 242,49 R250 336,49 R258 385,39 R161 404,29 
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3.3.1.2.2.1 Medically unfit patients 
 
Medically unfit patients, according to the treatment pathways seen in Figure 3., will receive 
one treatment regimen as opposed to several regimens, which follow on. The cost of these can 
be seen in Table 3.17.  Medically unfit patients will receive treatment similar to an early CRC 
patient even though they have advanced CRC disease. 
 
3.3.1.2.2.2 RAS mutant type patients 
  
The total theoretical costs (lowest, highest and average costs) for advanced CRC RAS mutant 
type patients are based on the theoretical pathways patients should follow through treatment 
as disease progression occurs (Figure 3.25 and Figure 3.26). The full range of costs for all 
capecitabine-containing regimen doses can be seen in Appendix M. 
 
3.3.1.2.2.3 RAS wildtype patients 
 
The total theoretical costs (lowest, highest and average costs) for advanced CRC RAS mutant 
type patients are based on the theoretical pathways patients should follow through treatment 
as disease progression occurs (Figure 3.27 and Figure 3.28). The full range of costs for all 
capecitabine-containing regimen doses can be seen in Appendix N.
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Figure 3.25 Total theoretical pathway costs for advanced CRC RAS mutant type patients starting treatment with CAPOX – Bev: Bevacizumab  
CAPOX 
*capecitabine doses range from 850 mg to 1250 mg 
FOLFIRI 
FOLFOX 
+ Bev 
*CAPOX 
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Regorafenib 
L: R 755 958,54 
H: R 781 787,18 
Av: R 768 884,89 
XELIRI 
FOLFOX 
+ Bev 
*CAPOX 
+ Bev 
FOLFIRI 
+ Bev 
FOLFIRI + Aflibercept 
Regorafenib 
L: R 775 962,60 
H: R 817 934,14 
Av: R 796 967,92 
L: R 737 020,29 
H: R 762 848,93 
Av: R 749 946,64 
L: R 772 376,98 
H: R 785 291,30 
Av: R 778 840,91 
L: R 792 381,05 
H: R 821 438,27 
Av: R 806 923,19 
L: R 753 438,73 
H: R 766 353,05 
Av: R 759 901,91 
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Figure 3.26 Total theoretical pathway costs for advanced CRC RAS mutant type patients starting treatment with FOLFOX - Bev: Bevacizumab  
 
FOLFOX 
*capecitabine doses range from 850 mg to 1250 mg 
R 786 348,11 L: R 806 352,17 
H: R 822 495,07 
Av: R 814 431,14 
R 767 409, 86 
FOLFIRI 
FOLFOX 
+ Bev 
*CAPOX 
+ Bev 
FOLFIRI 
+ Bev 
FOLFIRI + Aflibercept 
Regorafenib 
XELIRI 
FOLFOX 
+ Bev 
*CAPOX 
+ Bev 
FOLFIRI 
+ Bev 
FOLFIRI + Aflibercept 
Regorafenib 
L: R 769 929,66 
H: R 782 843,98 
Av: R 776 392,84 
L: R 789 933,73 
H: R 818 990,95 
Av: R 804 475,87 
L: R 750 991,41 
H: R 763 905,73 
Av: R 757 454,59 
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Figure 3.27 Total theoretical pathway costs for advanced CRC RAS wildtype patients starting treatment with CAPOX - Bev: Bevacizumab, Cet: Cetuximab, Pani: 
Panitumumab 
CAPOX 
*capecitabine doses range from 850 mg to 1250 mg 
FOLFIRI 
FOLFIRI + Cet FOLFOX + Pani 
FOLFIRI + Aflibercept 
Regorafenib 
FOLFOX + Bev FOLFIRI + Bev 
XELIRI 
FOLFIRI + Cet FOLFOX + Pani 
FOLFIRI + Aflibercept 
Regorafenib 
FOLFOX + Bev FOLFIRI + Bev 
L: R 1 386 970,87 
H: R 1 412 799,51 
Av: R 1 409 852,49 
L: R 1 083 807,84 
H: R 1 109 636,48 
Av: R 1 106 689,46 
L: R 1 403 389,32 
H: R 1 416 303,64 
Av: R 1 399 897,22 
L: R 1 100 226,28 
H: R 1 113 140,60 
Av: R 1 096 734,19 
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Figure 3.28 Total theoretical pathway costs for advanced CRC RAS wildtype patients starting treatment with FOLFOX - Bev: Bevacizumab, Cet: Cetuximab, Pani: 
Panitumumab
FOLFOX 
*capecitabine doses range from 850 mg to 1250 mg 
FOLFIRI 
FOLFIRI + Cet FOLFOX + Pani 
FOLFIRI + Aflibercept 
Regorafenib 
FOLFOX + Bev FOLFIRI + Bev 
XELIRI 
FOLFIRI + Cet FOLFOX + Pani 
FOLFIRI + Aflibercept 
Regorafenib 
FOLFOX + Bev FOLFIRI + Bev 
L: R 1 400 942,00 
H: R 1 413 856,32 
Av: R 1 407 405,17 
L: R 1 097 778,96 
H: R 1 110 693,28 
Av: R 1 104 242,14 
R 1 417 360,44 R 1 114 197,41 
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3.3.1.3 Observed treatment pathways for the public healthcare sector 
 
3.3.1.3.1 Early CRC disease 
 
3.3.1.3.1.1 Total costs per cycle  
 
The cost per cycle is the same for a regimen provided the dosages are the same for either early 
CRC colon or rectal cancer (Figure 3.29). For this patient cohort, all calculated average 
dosages are the same as the recorded dosages per rectal cancer patient showed little variation 
to colon cancer patients thus it was decided to include the two groups to calculate one average 
dose per regimen which results in the same cost per cycle.  
 
Chemotherapy costs have the largest contribution to the total costs and are expected 
particularly for regimens containing capecitabine however; supportive medicines don’t appear 
to affect cost much. It is an unexpected result as it was thought that greater costs would be 
seen with supportive medicines but upon closer inspection, all these medicines are older 
medicines and prices per tablet are cheaper. The use of irinotecan and mitomycin-C was 
unexpected as these medicines have found to have no role in the adjuvant setting for the 
treatment of early CRC (Figure 3.29). This result is furthermore seen in Figure 3.30 where 
irinotecan and mitomycin-C have no theoretical costs therefore no comparison could be made. 
 
The administrative fees calculated from the time and motion study (section 3.3.1.5.4.1.2) 
indicate a fair contribution for intravenously administrated regimens and is a large portion of 
regimens such as 5-FU + LV as these chemotherapy medicines are older and cheaper.  
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Figure 3.29 Cost per cycle for each chemotherapy regimen for early CRC colorectal 
cancer  in the public healthcare sector- The cost per treatment regimen comprises of the 
comprises of the chemotherapy cost, administrative cost (grey stripe), supportive care 
medicine costs (grey) and administration costs (black). The total costs will not be less than 
this. The 1
st
 and 2
nd
 choices were based on a definite change in the patient’s treatment 
regimen.  
 
The greatest difference was observed in the number of cycles a regimen was administered and 
rectal cancer patients received fewer cycles therefore a lower total cost is expected as seen in 
Figure 3.30. Interestingly, not all the regimens used for colon cancer are used for rectal cancer 
and from this patient cohort; only colon cancer patients appear to be prescribed a 2
nd
 choice 
treatment regimen. Capecitabine maintenance therapy was only administered for rectal 
cancer. Treatment regimens such as 5-FU + LV and capecitabine, given as a first regimen for 
treatment, are double the cost for colon cancer as opposed to rectal cancer. This is due to 
colon cancer patients in this cohort receiving double the number of cycles compared to rectal 
cancer patients. CAPOX prescribed as a first regimen however doesn’t follow this trend and 
is much closer in cost. Reserved for high-risk patients, many patients were treated with 
CAPOX (section 3.2.1.2.1) and could account for the one cycle difference.  
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Figure 3.30 Total cost comparison per regimen for early CRC disease in the public 
healthcare sector – Early CRC colon cancer (black and white stripe) and early CRC rectal 
cancer (grey). The 1
st
 and 2
nd
 choices were based on a definite change in the patient’s 
treatment regimen.
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Table 3.18 Total observed costs per treatment regimen for early CRC in the public healthcare sector - The number of cycles is based on the 
average calculated from the patient cohort and the total cost is calculated by multiplying the cost per cycle with the number of cycles.  
  COLON 
  
5-FU + LV 
Capecitabine (1st 
choice) 
CAPOX (1st 
choice) 
Capecitabine (2nd 
choice) 
CAPOX (2nd 
choice) 
XELIRI (2nd 
choice) 
Capecitabine Mito 
(2nd choice) 
Total treatment 
costs per cycle 
R7 038,25 R2 168,25 R5 375,01 R2 284,20 R6 286,40 R7 192,28 R3 800,71 
Number of cycles 6 4 6 2 2 1 2 
Treatment costs 
per x cycles 
 R 42 229,50   R 8 673,00   R 32 250,06   R 4 568,40   R 12 572,80   R 7 192,28  R7 601,42 
 
  RECTAL 
  
5-FU + LV 
Capecitabine (1st 
choice) 
CAPOX (1st 
choice) 
Capecitabine 
(maint.) 
Total treatment 
costs per cycle 
R7 038,25 R2 168,25 R5 375,01 R2 084,90 
Number of cycles 3 2 5 11 
Treatment costs 
per x cycles 
R21 114,75  R 4 336,50   R 26 875,05   R 22 933,90  
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3.3.1.3.2 Advanced CRC disease  
 
3.3.1.3.2.1 Total cost per cycle 
 
Similarly to early CRC, most of the cost for majority of the regimens can be attributed to 
chemotherapy. In addition supportive medicines have less of an impact on the cost and the 
administrative fees are the same as for early CRC as per the time and motion study (section 
3.3.1.5.4.1.2). Regimens that are the same as early CRC have higher chemotherapy costs per 
cycle and are attributed to an increase in observed chemotherapy dosages. This in turn 
increases the average dosage used in the calculations (Figure 3.31).   
 
 
Figure 3.31 Cost per cycle for each chemotherapy regimen for advanced CRC patient 
group in the public healthcare sector- The cost per treatment regimen comprises of the 
comprises of the chemotherapy cost, administrative cost (grey stripe), supportive care 
medicine costs (grey) and administration costs (black). The costs used for irinotecan and 
mitomycin C are the lowest cost SEP as these were unavailable on the EML at the time. The 
total costs will not be less than this.  
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The total costs for advanced CRC disease per regimen are not always higher than early CRC 
disease as seen with 1
st
 line capecitabine therapy for the advanced CRC sub-group when 
compared to 1
st
 choice capecitabine regimens for early CRC. Other regimens such as 2
nd
 line 
CAPOX are more than double the cost for advanced CRC when compared to patients 
receiving CAPOX as a 2
nd
 choice regimen in early CRC (Table 3.19). Although XELIRI 2
nd
 
line also has a great increase, patients will pay for the irinotecan according to SEP therefore it 
is not unexpected to see an increase as much as 280%.  
 
Table 3.19 Total costs per regimen for the public healthcare sector patient cohort for 
early CRC and advanced CRC disease with percentage change – shaded blocks indicate 
no regimen administered for that disease state. A negative percentage change (blue) indicates 
advanced CRC regimen is cheaper and changes greater than 100% are marked red.   
Regimen 
Early Colon 
Cancer 
Early Rectum 
Cancer 
Advanced 
CRC 
% change - 
colon to 
Advanced 
CRC 
% change - 
rectum to 
Advanced 
CRC 
5-FU + LV R4 403,88 R2 201,94 R4 764,48 8% 116% 
Capecitabine (1st 
line/choice) R8 673,00 R4 336,50 R6 532,98 -25% 51% 
CAPOX (1st 
line/choice) R32 193,54 R26 827,95 R36 353,16 13% 36% 
FOLFOX (1st line)     R26 679,46 
  FOLFIRI (1st line)     R27 512,10 
  XELIRI (1st line)     R5 969,24 
  Capecitabine (2nd 
line/choice) R4 568,40   R6 643,89 45% 
 CAPOX (2nd 
line/choice) R12 553,96   R35 059,56 179% 
 FOLFIRI (2nd line)     R27 512,10 
  XELIRI (2nd 
line/choice) R7 182,86   R27 306,92 280% 
 XELIRI-mito (2nd 
line/choice) R7 582,58   R6 421,42 -15% 
 Oxaliplatin (2nd line)     R28 618,20 
  Capecitabine 
(maintenance)   R22 933,90 R26 134,92 
 
14% 
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Table 3.20 Total observed costs per treatment regimen for advanced CRC in the public healthcare sector - The number of cycles is based on the 
average calculated from the patient cohort and the total cost is calculated by multiplying the cost per cycle with the number of cycles. 
 Advanced CRC 
  
5-FU + LV 
Capecitabine (1st 
line) 
CAPOX (1st 
line) 
XELIRI (1st 
line) 
FOLFOX (1
st
 
line) 
FOLFIRI (1st 
line) 
Total treatment costs 
per cycle 
R7 098,35 R2 177,66 R6 068,28 R5 978,66 R10 587,39 R10 237,78 
Number of cycles 6 3 6 1 6 7 
Treatment costs per 
x cycles 
 R 42 590,10   R 6 532,98   R 36 409,68   R 5 978,66   R 63 524,34   R 71 664,46  
 
 Advanced CRC 
  
Capecitabine (2nd 
line) 
CAPOX (2nd 
line) 
XELIRI (2nd 
line) 
Capecitabine-Mito 
(2nd line) 
FOLFIRI (2nd 
line) 
Oxaliplatin (2nd 
line) 
Capecitabine 
(maint.) 
Total treatment costs 
per cycle 
R2 214,63 R5 852,68 R6 836,15 R3 220,13 R10 237,78 R4 779,12 R1 866,78 
Number of cycles 3 6 4 2 7 6 14 
Treatment costs per 
x cycles 
 R 6 643,89   R 35 116,08   R 27 344,60  R6 440,26 R71 664,46  R 28 674,72   R 26 134,92  
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Table 3.21 Total costs per regimen for the public healthcare sector patient cohort and theoretical costs for early CRC and advanced CRC 
disease with percentage change – shaded blocks indicate no regimen administered for that disease state. A negative percentage change (blue) 
indicates advanced CRC regimen is cheaper and changes greater than 100% are marked red.  
Regimen 
Early Colon 
Cancer 
Cohort 
Early Colon 
Cancer 
Theoretical 
% 
change 
Early Rectum 
Cancer Cohort 
Early Rectum 
Cancer 
Theoretical 
% 
change 
Advanced 
CRC 
Cohort 
Advanced 
CRC 
Theoretical 
% 
change 
5-FU + LV R4 403,88 R6 629,47 51% R2 201,94 R4 419,65 101% R4 764,48 R6 629,47 39% 
Capecitabine (1st 
line/choice)* R8 673,00 R16 417,70 89% R4 336,50   
 
R6 532,98   
 CAPOX (1st line/choice)* R32 193,54 R36 745,34 14% R26 827,95   
 
R36 353,16 R36 745,34 1% 
FOLFOX (1st line/choice)   R38 979,69 
 
    
 
R26 679,46 R19 489,84 -27% 
FOLFIRI (1st line)     
 
    
 
R27 512,10   
 XELIRI (1st line)     
 
    
 
R5 969,24   
 Capecitabine (2nd 
line/choice)* R4 568,40 R16 417,70 259%     
 
R6 643,89   
 CAPOX (2nd line/choice)* R12 553,96 R36 745,34 193%     
 
R35 059,56 R36 745,34 5% 
FOLFOX (2nd line)     
 
    
 
  R32 483,07 
 FOLFIRI (2nd line)     
 
    
 
R27 512,10   
 XELIRI (2nd line/choice) R7 182,86   
 
    
 
R27 306,92   
 XELIRI-mito (2nd 
line/choice) R7 582,58   
 
    
 
R6 421,42   
 Oxaliplatin (2nd line)     
 
    
 
R28 618,20   
 Capecitabine 
(maintenance)*     
 
R22 933,90   
 
R26 134,92   
 *lowest theoretical dose of capecitabine 
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3.3.1.4 Observed treatment pathways for the private healthcare sector 
 
3.3.1.4.1 Early CRC disease 
 
The cost per cycle for the observed regimens (Figure 3.32) indicates that the largest 
component of the cost per cycle is due to the chemotherapy particularly for multiple medicine 
regimens.  
 
Although all the regimens in Figure 3.32 are for early CRC disease, the classification of 
patients by origin (colon or rectum) was not known thus the cost per cycle in the private 
sector differs to the public sector for early staged disease. In addition a number of unproven 
treatments were prescribed. These include 5-azacitadine which is commonly used in the 
treatment of Myelodysplastic Syndromes (MDS) or fludarabine which is mainly indicated for 
treatment of Chronic Lymphocytic Leukaemia (CLL) (all these regimens are highlighted in 
Table 3.22) (Figure 3.32; Table 3.22). This may be due to the presence of a second cancer or 
off-label use. 
 
The lowest contributors to the cost include the supportive medicines. Although the supportive 
medicines only included classes of medicines available in the public sector, there were many 
additional medicines claimed. Most notably was the costs attributed to pain management. The 
regimens with the highest costs are the regimens where unproven colorectal cancer 
chemotherapy was prescribed. The total costs for the early CRC patient group can be seen in 
Table 3.22.  
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Figure 3.32 Cost per cycle of each early CRC regimen observed in the private healthcare sector – Chemotherapy costs; Administration costs 
(black); supportive care medicines (light grey) and administrative costs (dark grey stripe); *unconventional CRC treatment 
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Table 3.22 Total cost per chemotherapy regimen for early CRC patient group – regimens 
highlighted in grey are not conventional CRC treatments 
Chemotherapy regimens Cost per cycle Number of cycles Total cost 
5-FU R4 140,13 5 R20 700,64 
Capecitabine R4 523,06 5 R22 615,31 
Irinotecan R4 989,28 3 R14 967,85 
Oxaliplatin R5 928,36 2 R11 856,72 
FOLFOX R7 002,21 8 R56 017,71 
FOLFIRI R6 063,14 8 R48 505,12 
CAPOX R9 441,45 5 R47 207,27 
XELIRI R8 502,38 5 R42 511,90 
FOLFOXIRI R8 925,23 1 R8 925,23 
Oxaliplatin + Tegafur R8 775,77 7 R61 430,41 
FOLFOX + Capecitabine R10 515,31 1 R10 515,31 
Capecitabine + Mitomycin R7 209,11 2 R14 418,21 
5-FU + Capecitabine R7 653,22 1 R7 653,22 
Azacitidine R35 269,17 4 R141 076,69 
FOLFOX + Fludarabine R21 887,05 1 R21 887,05 
Cisplatin R3 218,31 4 R12 873,25 
 
1.1.1.1.2 Advanced CRC disease 
 
Similarly to the early CRC group of patients, the cost per cycle for the observed advanced 
CRC regimens (Figure 3.33) indicates the large component chemotherapy contributes to the 
cycle cost.  
 
Similarly to the early CRC disease observations, patients were found to receive treatments not 
indicated for CRC. These include tretinion+idarubicin for the treatment of Acute 
Promyelocytic Leukemia (APL), carboplatin+paclitaxel for non-small cell lung cancer and 
ovarian cancer; cisplatin+gemcitabine for relapsed breast cancer and biliary tract cancer to 
name a few. This again indicates that patients either were treated for a secondary cancer or the 
treatment was off-label (Figure 3.33; Table 3.23).  
 
The total costs in Table 3.23 are lower for certain regimens when compared to the early CRC 
group however, there are more regimens observed. The total costs are lower than the early 
CRC group as patients with advanced disease were observed to experience treatment changes 
before the same number of cycles for a specific regimen was reached. This is most likely due 
to disease progression due to lack of response to by the specific regimen thereby requiring a 
change in treatment regimen. Biological medicines such as bevacizumab and cetuximab are 
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also included indicating patients move through multiple regimens quicker and this does 
increase cost.   
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Figure 3.33 Cost per cycle of each advanced CRC regimen observed in the private sector – Chemotherapy costs; Administration costs (black); 
supportive care medicines (light grey) and administrative costs (dark grey stripe) *unconventional CRC treatment 
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3.3.1.4.1.1 Total costs 
 
Table 3.23 Total cost per chemotherapy regimen for advanced CRC patient group – 
regimens highlighted in grey are not conventional CRC treatments 
Chemotherapy regimens Cost per cycle Number of cycles Total cost 
5-FU R4 278,53 5 R21 392,64 
Capecitabine R4 464,41 4 R17 857,64 
Irinotecan R5 375,09 3 R16 125,26 
Oxaliplatin R6 010,16 2 R12 020,33 
FOLFOX R7 244,77 7 R50 713,38 
FOLFIRI R6 609,69 6 R39 658,15 
CAPOX R9 480,93 4 R37 923,71 
XELIRI R8 845,85 5 R44 229,24 
FOLFOXIRI R9 575,93 8 R76 607,46 
Bev R14 727,73 3 R44 183,18 
5-FU+Bev R15 962,33 4 R63 849,32 
Capecitabine+Bev R18 198,49 5 R90 992,44 
Oxaliplatin+Bev R17 693,97 3 R53 081,90 
Irinotecan+Bev R17 058,89 5 R85 294,44 
FOLFOX + Bev R18 928,57 7 R132 500,01 
FOLFIRI+Bev R18 293,49 6 R109 760,97 
FOLFOXIRI+Bev R21 259,74 1 R21 259,74 
CAPOX+Bev R21 164,73 5 R105 823,65 
XELIRI+Bev R20 529,65 6 R123 177,91 
Cet R22 379,26 5 R111 896,30 
5-FU+Cet R23 613,87 3 R70 841,60 
Capecitabine+Cet R25 850,02 1 R25 850,02 
Irinotecan+Cet R24 710,42 5 R123 552,12 
FOLFOX + Cet R26 580,11 5 R132 900,54 
FOLFIRI+Cet R25 945,03 6 R155 670,18 
CAPOX+Cet R28 816,26 4 R115 265,06 
XELIRI+Cet R28 181,19 4 R112 724,75 
Irinotecan+Tegafur,combo 
(incl. Folinic acid) 
R9 084,37 2 R18 168,73 
Tegafur,combo (incl.  Folinic 
acid) 
R6 753,20 1 R6 753,20 
Capecitabine+Mitomycin R7 217,26 3 R21 651,77 
Mitomycin R3 746,49 2 R7 492,99 
Regorafenib R51 367,81 2 R102 735,63 
Carboplatin+Paclitaxel R5 818,07 4 R23 272,29 
Cisplatin+Docetaxel R10 214,65 4 R40 858,62 
Cisplatin+Gemcitabine R4 942,29 1 R4 942,29 
Tretinoin R5 163,77 6 R30 982,62 
Tretinoin+Idarubicin R10 823,98 2 R21 647,97 
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Table 3.24 Total costs per regimen for the private sector patient cohort for early CRC and advanced CRC disease with percentage change – 
shaded blocks indicate no regimen administered for that disease state. A negative percentage change (blue) indicates advanced CRC regimen is 
cheaper and changes greater than 100% are marked red. The percentage change is an indication that the cost differences, between regimens prescribed 
for either early or advanced CRC, is a result of the difference in dose or the number of cycles received.    
Regimen Early CRC Advanced CRC % change Regimen Early CRC Advanced CRC % change 
5-FU R20 700,64 R21 392,64 3,34% FOLFIRI+Bev   R109 760,97   
Capecitabine R22 615,31 R17 857,64 -21,04% FOLFOXIRI+Bev   R21 259,74   
Azacitidine R141 076,69     CAPOX+Bev   R105 823,65   
Irinotecan R14 967,85 R16 125,26 7,73% XELIRI+Bev   R123 177,91   
Oxaliplatin R11 856,72 R12 020,33 1,38% Cet   R111 896,30   
FOLFOX R56 017,71 R50 713,38 -9,47% 5-FU+Cet   R70 841,60   
FOLFIRI R48 505,12 R39 658,15 -18,24% Capecitabine+Cet   R25 850,02   
CAPOX R47 207,27 R37 923,71 -19,67% Irinotecan+Cet   R123 552,12   
XELIRI R42 511,90 R44 229,24 4,04% FOLFOX + Cet   R132 900,54   
FOLFOXIRI R8 925,23 R76 607,46 758,33% FOLFIRI+Cet   R155 670,18   
Oxaliplatin + Tegafur R61 430,41     CAPOX+Cet   R115 265,06   
FOLFOX + Fludarabine R21 887,05     XELIRI+Cet   R112 724,75   
FOLFOX + Capecitabine R10 515,31     Carboplatin+Paclitaxel   R23 272,29   
Capecitabine + Mitomycin R14 418,21 R21 651,77 50,17% Cisplatin+Docetaxel   R40 858,62   
Cisplatin R12 873,25     Cisplatin+Gemcitabine   R4 942,29   
5-FU + Capecitabine R7 653,22     Irinotecan+Tegafur,   R18 168,73   
Bev   R44 183,18   Tegafur,combo    R6 753,20   
5-FU+Bev   R63 849,32   Tretinoin   R30 982,62   
Capecitabine+Bev   R90 992,44   Tretinoin+Idarubicin   R21 647,97   
Oxaliplatin+Bev   R53 081,90   Mitomycin   R7 492,99   
Irinotecan+Bev   R85 294,44   Regorafenib   R102 735,63   
FOLFOX + Bev   R132 500,01   
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Table 3.25 Total costs per regimen for the private sector patient cohort and theoretical costs for early CRC and advanced CRC disease with 
percentage change – shaded blocks indicate no regimen administered for that disease state. A negative percentage change (blue) indicates cohort 
regimen is cheaper and changes greater than 100% are marked red. The percentage change is an indication that the cost differences, between regimens 
prescribed in the cohort and the theoretical calculations, is a result of the dose or the number of cycles received. This is also an indication that patients 
often receive less treatment than the literature states due to individual response to treatment.    
Regimen 
Early CRC 
Cohort 
Early CRC 
Theoretical
1 % change 
Advanced 
CRC Cohort 
Advanced 
Theoretical
1
 
% change 
5-FU R20 700,64 R25 242,54 21,94% R21 392,64 R25 242,54 18,00% 
Capecitabine* R22 615,31 R35 709,18 57,90% R17 857,64 R35 709,16 99,97% 
Azacitidine R141 076,69           
Irinotecan R14 967,85     R16 125,26     
Oxaliplatin R11 856,72     R12 020,33     
FOLFOX R56 017,71 R89 923,10 60,53% R50 713,38 R89 923,10 77,32% 
FOLFIRI R48 505,12 
  
R39 658,15 R97 265,06 145,26% 
CAPOX* R47 207,27 R75 952,00 60,89% R37 923,71 R75 952,00 100,28% 
XELIRI* R42 511,90 R80 846,64 90,17% R44 229,24 R80 846,64 82,79% 
FOLFOXIRI R8 925,23     R76 607,46     
Oxaliplatin + Tegafur R61 430,41           
FOLFOX + Fludarabine R21 887,05           
FOLFOX + Capecitabine R10 515,31           
Capecitabine + Mitomycin R14 418,21     R21 651,77     
Cisplatin R12 873,25           
5-FU + Capecitabine R7 653,22           
Bev       R44 183,18     
5-FU+Bev       R63 849,32     
Capecitabine+Bev       R90 992,44     
Oxaliplatin+Bev       R53 081,90     
Irinotecan+Bev       R85 294,44     
FOLFOX + Bev       R132 500,01 R222 238,43 67,73% 
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FOLFIRI+Bev       R109 760,97 R203 300,18 85,22% 
FOLFOXIRI+Bev       R21 259,74     
CAPOX+Bev*       R105 823,65 R242 242,49 128,91% 
XELIRI+Bev       R123 177,91     
Cet       R111 896,30     
5-FU+Cet       R70 841,60     
Capecitabine+Cet       R25 850,02     
Irinotecan+Cet       R123 552,12     
FOLFOX + Cet       R132 900,54     
FOLFIRI+Cet       R155 670,18 R653 621,56 319,88% 
CAPOX+Cet       R115 265,06     
XELIRI+Cet       R112 724,75     
Carboplatin+Paclitaxel       R23 272,29     
Cisplatin+Docetaxel       R40 858,62     
Cisplatin+Gemcitabine       R4 942,29     
Irinotecan+Tegafur       R18 168,73     
Tegafur,combo       R6 753,20     
Tretinoin       R30 982,62     
Tretinoin+Idarubicin       R21 647,97     
Mitomycin       R7 492,99     
Regorafenib       R102 735,63 R161 404,29 57,11% 
1 average cost for both types of facilities 
* Lowest theoretical dose of capecitabine 
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3.3.1.5 Cost components used in cost calculations 
 
3.3.1.5.1 Chemotherapy costs 
  
Table 3.26 indicates the costs (Rands) that were used in the calculations for the theoretical 
and observed costs for each healthcare sector. In the costing model the lowest cost SEP 
(private sector) was compared to the EML (public sector) cost. Using the model for the 
chemotherapy costs (section 2.3.4.1), the total costs for the chemotherapy medicine per cycle 
can be seen in Appendix O.  
Table 3.26 Chemotherapy costs per pack size for the public sector (EML, Feb 2014) and 
the private sector (SEP, Aug 2014) - Ramucirumab and trifluridine/tipiracil are unavailable in South 
Africa, *only originators available and therefore one price for both sectors. 
Chemotherapy (vial 
size/pack size) 
Cost for the 
Public Sector 
Cost for the Private Sector 
Lowest  Highest  Average  
5-FU (10ml) R15,05 R15,66 R28,30 R21,98 
*Bevacizumab  
(4ml) 
(16ml) 
N/A 
 
R3 682,56 
R14 730,25 
*Capecitabine 
(150mg 60 tabs) 
(500mg 120 tabs) 
 
R413,54 
R2 782,42 
 
R743,93 
R5 005,51 
*Cetuximab (20ml) N/A 2 897,69 
Irinotecan  
(20mg/ml) 
(100mg/5ml) 
N/A 
 
R370,50 
R934,80 
 
R370,50 
R2 563,58 
 
R370,50 
R1 194,13 
Folinic acid  
(30ml) 
(10ml) 
(50mg/vial) 
 
R180,00 
N/A 
R30,00 
 
R552,00 
R184,00 
N/A 
Oxaliplatin  
(10ml) 
(20ml) 
 
R702,68 
R1 405,34 
 
R974,13 
R1 948,26 
 
R1 794,62 
R3 589,22 
 
R1 418,11 
R3 228,19 
*Panitumumab (5ml) N/A R7 170,97 
*Regorafenib (40mg 
28 tabs)  
N/A 
R52 782,91 
*Aflibercept 
(100mg) 
(200mg)  
N/A 
 
R5 280,31 
R10 560,62 
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3.3.1.5.2 Supportive care medicine costs 
 
Table 3.27 indicates the supportive care medicine costs that were used in the calculations for 
each sector. In the costing model the average lowest cost SEP (private sector) was compared 
to the average EML (public sector) cost due to the number of combination possibilities. Using 
the model for the supportive care medicine costs (section 2.3.4.3), the average costs for 
supportive care medicines for both sectors can be seen in Table 3.28. The private sector costs 
are based on the lowest SEP costs in order for comparisons to be made. The supportive care 
medicine costs per cycle are the same no matter the stage of the cancer and are represented by 
regimen (Table 3.28).    
 
Table 3.27 Theoretical supportive care medicine costs per pack size for the public sector 
(EML, Feb 2014) and the private sector (SEP, Aug 2014) - the observed costs were 
obtained from the respective patient cohorts.   
Supportive care medicine 
(vial size/*pack size) 
Cost for the Public 
Sector 
Cost for the Private Sector 
Lowest Highest Average 
Ondansetron  
(4mg vial)  
(8mg vial) 
(4mg 5 tabs) 
(4mg 10 tabs) 
(4mg 15 tabs) 
(4mg 30 tabs) 
(8mg 5 tabs) 
(8mg 10 tabs) 
(8mg 15 tabs) 
(8mg 30 tabs) 
 
R4,45 
R7,15 
N/A 
R15,38 
N/A 
N/A 
N/A 
R16,90 
N/A 
N/A 
 
R51,30 
R102,60 
R96,19 
R144,72 
R451,30 
R192,39 
R192,33 
R289,47 
R709,74 
R384,66 
 
R247,08 
R494,16 
R150,43 
R182,02 
R665,66 
R192,39 
R192,33 
R364,03 
R1 050,65 
R384,66 
 
R178,24 
R321,97 
R123,31 
R159,97 
R558,48 
R192,39 
R192,33 
R319,94 
R880,19 
R384,66 
Granisetron  
(1mg vial) 
(3mg vial)  
(1mg 10 tabs)  
(2mg 5 tabs) 
 
N/A 
R63,28 
N/A 
N/A 
 
R151,62 
R545,63 
R178,84 
R291,01 
 
R425,53 
R854,78 
R779,24 
R799,75 
 
R225,26 
R635,31 
R389,03 
R456,59 
Palonosetron (50mcg/ml) N/A R465,14 
Dexamethasone (4mg vial) R4,01 R76,00 R441,38 R173,59 
Prednisone  
(5mg 100 tabs) 
(5mg 40 tabs) 
(5mg 500 tabs) 
(5mg 5000 tabs) 
 
R10,51 
R4,00 
R41,53 
R410,11 
 
N/A 
Metoclopramide 
(10mg/2ml vial)  
(10mg 20 tabs)  
(10mg 100 tabs)  
(10mg 500 tabs) 
(10mg 1000 tabs)  
 
N/A 
N/A 
R6,63 
R19,45 
N/A 
 
R25,35 
R3,34 
R16,71 
R44,97 
R131,81 
 
R92,94 
R42,47 
R212,28 
R143,48 
R131,81 
 
R54,94 
R16,80 
R114,50 
R74,62 
R131,81 
Prochlorperazine 
(12,5mg/ml vial) 
(5mg 25 tabs) 
(5mg 250 tabs) 
(5mg 500 tabs) 
 
N/A 
 
R129,32 
R70,68 
R169,53 
R82,46 
 
R129,32 
R70,68 
R617,88 
R82,46 
 
R129,32 
R70,68 
R393,71 
R82,46 
Aprepitant (COMBO PACK) N/A R714,71 
* Pack sizes were used to calculate the cost per tablet and subsequently lowest, highest and average cost per tab. 
These costs were then used in the costing model; 
1
 Not currently used 
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Table 3.28 Average theoretical supportive medicine costs per cycle for each sector – the 
observed costs were obtained from the respective patient cohorts 
Public sector average supportive medicine costs 
Regimen Average cost  
5-FU + LV or Capecitabine R25,21 
FOLFOX or CAPOX R60,59 
Private sector average lowest SEP supportive medicine costs 
Regimen Average cost  
5-FU + LV or Capecitabine or Regorafenib R242,23 
FOLFOX or CAPOX*  R606,34 
FOLFIRI or XELIRI* R965,66 
* Same cost if a biologic is included in the regimen 
 
The average supportive medicine costs per cycle are more costly in the private sector than the 
public sector for the same regimens. This is largely due to the medicine procurement in the 
public sector, as explained in section 1.5.7.1.3 and the medicine selection in the private sector 
as explained in section 0.  
 
3.3.1.5.3 Administration costs 
 
The administration costs used for the theoretical and observed pathways were based on the 
drug utilisation data obtained from each healthcare sector. The administration costs or the 
public healthcare sector included administration items such as ports, syringes and needles etc. 
and the admixtures and flush for intravenous administration (Table 3.29). The private sector 
costs differed in that it only included admixture and flush costs as the data only accounted for 
medicine costs. The costs for syringes and needles, swabs and cotton wool as well as dressing 
are included in the facility fees that patients will be charged for.  The average costs per cycle 
for administration can be seen in Table 3.30.  
 
Table 3.29 Total administration cost in the public healthcare sector 
Total administration cost 
  5FU+LV Capecitabine FOLFOX CAPOX FOLFIRI XELIRI 
Administration 
component 
R6 251,75 NA R 6 251,75 R 6,21 R 6 251,75 R 6,21 
Admixtures + 
Flush 
R52,52 R55,73 R3,21 R55,73 R3,21 
Total cost per 
cycle 
R6 304,27 R 6 307,48 R 9,42 R 6 307,48 R 9,42 
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Table 3.30 Total administration cost per cycle for the private healthcare sector 
Total administration cost per cycle 
Early CRC disease regimens R 114,06 
Advanced CRC disease regimens  R108,03 
 
3.3.1.5.4 Administrative costs 
 
3.3.1.5.4.1 Time and Motion Study for the public healthcare sector 
 
3.3.1.5.4.1.1 Work flow diagram for CMJAH 
 
Following clinical observations, the final workflow diagram was drawn up and includes 8 
steps (includes laboratory processes) performed by 4 different professionals (Figure 3.34). 
The workflow diagram shows the processes the clinic has in place in which a patient will 
follow in order to receive their chemotherapy. Patients, who are on oral chemotherapy 
regimens, will not follow the last two steps in the procedure.  
 
 
Figure 3.34 Workflow diagram for CMJAH Oncology Clinic – Orange: Oncology Nurse, 
Green: Administrative clerk, Blue: NHLS Nurse, Purple: Oncologist, Turquoise: Pharmacist. 
The laboratory work is excluded (this entails the analysis of the blood obtained from 
phlebotomy), as this does not form part of the duty of the oncology clinic.  
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3.3.1.5.4.1.2 Calculated costs 
 
Table 3.31 shows the overall average time (minutes) and costs (Rands). The initial readings 
and salary calculations can be found in Appendix P. 
 
Table 3.31 Average time (minutes) with the associated costs (Rands) - Orange: Oncology 
Nurse, Green: Administrative clerk, Blue: NHLS Nurse, Purple: Oncologist, Turquoise: 
Pharmacist. The *laboratory work is excluded as this does not form part of the duty of the 
oncology clinic however the blood results take on average 2:15:00. This average time was 
provided by the oncology nurses and physicians at the clinic.   
Task Overall Ave. Std. Dev. Final Ave. Cost (Rands) Total Costs 
Check-in 00:01:38 00:00:38 00:02:00 R5, 27 
R111, 64 (Oral 
script) 
Pink file  00:01:08 00:00:14 00:01:00 R1, 16 
Phlebotomy 00:04:01 00:01:07 00:04:00 R10, 54 
*Lab 02:15:00 N/A 02:15:00 N/A 
Physician visit 00:09:43 00:06:48 00:10:00 R80, 09 
R509, 20 (IV 
script) 
Pharmacy  
oral 
00:02:54 00:01:21 00:03:00 R14, 59 
Pharmacy  
mixing 
00:10:24 00:01:21 00:10:00 R48, 62 
Drip admin. + 
File update 
00:03:26 00:00:53 00:03:00 R7, 90 
Administration 
+ Monitoring 
02:15:00 N/A 02:15:00 R355, 63 
 
Due to the number of different chemotherapy regimens administered and monitored at the 
same time within the clinic and taking into consideration the ethical approval obtained for the 
study, it was difficult to obtain the exact time for colorectal cancer patients. Thus a midpoint 
was taken for the period in which chemotherapy is usually administered and monitored for 
various cancers and this information was provided by the oncology nurses at the clinic.  
 
3.3.1.5.4.2 The NRPL-HS Costs for the private healthcare sector 
 
For accredited facilities, the administrative costs are comprised of a global fee and a facility 
fee. The global fee refers to whether the chemotherapy is administered orally or 
intravenously whereas the facility fee refers to the facility setting where the medicines are 
administered. These fees are industry based and not medical scheme specific,
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Table 2.2 shows the full tariff guideline for the medical scheme industry used in this research. 
The total administrative costs are calculated by adding the global fee to the relevant facility 
fee. There are two costs per type of chemotherapy due to a variation in facility fees as 
calculated from the full NRPL-HS tariff guideline (Table 3.32).   
 
Table 3.32 Administrative costs for the private sector based on the NRPL-HS tariff 
guidelines for the selected medical scheme  
Oral chemotherapy 
NRPL 5790 + NRPL 5791 
(Oral facility type A) 
R 742,70 
NRPL 5790 + NRPL 5792 
(Oral facility type B) 
R 810,10 
Intravenous chemotherapy 
NRPL 5793 + NRPL 5794 
(IV facility type A) 
R 2 396,30 
NRPL 5793 + NRPL 5795 
(IV facility type B) 
R 2 644,20 
 
3.4 Sensitivity analysis 
 
The sensitivity analysis indicated that chemotherapy costs and the number of cycles of 
treatment greatly affect the total cost of treatment for both sectors and each stage of CRC. An 
example of how the chemotherapy cost impacts the total cost of treatment can be seen in 
Figure 3.35 for the public healthcare sector and Figure 3.36 for the private healthcare sector. 
The chemotherapy costs are related to dosages thus the dosages prescribed will impact costs. 
The administrative costs had less of an impact on the model when the sensitivity analysis was 
performed however, had the effect was greater in the private sector than the public sector 
(Figure 3.37). Supportive care medicine costs did not appear to have a large effect except 
where additional medication, such as, atropine was used in regimens containing irinotecan. 
This once again pertains to the private sector however, where patients are prescribed the 
medication in the public sector, it will most likely show an effect. Using the percentage 
variations of +/- 50 % and +/- 20% while varying each cost component individually, the total 
cost variations ranged from less than R 1 000, when using 20%, to well over R 10 000, when 
using 50%. The sensitivity analysis tables can be found in Appendix Q. 
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Figure 3.35 The impact the cost of chemotherapy has on the total cost of CRC treatment 
for two treatment regimens (FOLFOX – black and CAPOX - grey) used in the public 
healthcare sector  
 
 
Figure 3.36 The impact the cost of chemotherapy has on the total cost of advanced CRC 
treatment for four treatment regimens (FOLFOX – light grey, FOLFIRI – black,  CAPOX 
– dark grey and XELIRI – dotted grey) used in the private healthcare sector 
 
 
Figure 3.37 The impact the cost of administrative tasks has on the total cost of advanced 
CRC treatment for four treatment regimens (FOLFOX – light grey, FOLFIRI – black,  
CAPOX – dark grey and XELIRI – dotted grey) used in the private healthcare sector 
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4. CHAPTER FOUR – DISCUSSION  
 
4.3 Treatment pathways 
 
4.3.1 Developed treatment pathways  
 
This research illustrates the limited chemotherapeutic options available to patients within 
South Africa’s public healthcare sector patients while private healthcare sector patients have 
access to most therapies available globally, provided the local medicine regulatory authority, 
the South African Medicines Control Council (MCC) [93] has approved them. Certain 
unregistered medicines may be obtained following MCC approval under section 21 of 
Medicines and Related Substances Act 101 of 1965  (Figure 3.3, Figure 3.4, Figure 3.5, 
Figure 3.6). Various differences for each sector will be discussed under the relevant section 
headings. 
 
4.3.2 Observed treatment pathways  
 
4.3.2.1 The public healthcare sector 
 
From Figure 3.3, early CRC disease treatment is dictated by the origin of the disease within 
the colorectal region. These patients are treated with either one of the regimens found in  
Figure 3.3 however they may be changed from one regimen to another at some point. 
Capecitabine can be used in place of 5-FU+LV as 1
st
 line treatment due to proven non-
inferiority to 5-FU+LV.  Van Cutsem et al. (2001)  showed that the overall response rate 
(18,9% vs. 15,0%), median time to disease progression (5.2 vs. 4.7 months), median time to 
treatment failure (4.2 vs. 4.0 months) as well as median overall survival (13.2 vs. 12.1 
months) was non-inferior for patients treated with capecitabine compared to 5FU/LV [53]. 
Once metastasis occurs, choice of treatment is no longer based on the origin of CRC. This 
means that patients are able to start on a regimen containing oxaliplatin with either 5-FU+LV 
or capecitabine and then move onto a 2
nd
 line therapy or Best Supportive Care as required.  
 
Comparing the developed public sector pathways in this study to international guidelines, 
backbone therapies such as irinotecan were absent at the time. In addition, biological agents 
 143 
such as bevacizumab and cetuximab are also unavailable in the public sector. While these 
agents have become standard therapy in many parts of the world, public sector patients are 
unlikely to receive any biological therapy however a small number were able to receive 
irinotecan (section 3.1.3.1 and 3.1.3.2) [25, 26, 128, 129, 158-162]. Although most of the 
guidelines used for comparison are international, South Africa’s private sector guidelines do 
include medicines such as irinotecan, bevacizumab and cetuximab [126, 127]. This result, 
albeit, unexpected does indicate that patients do have limited access to such therapies 
however; is not standard therapy and majority of patients reliant on public healthcare will not 
receive this treatment should they require it. Irinotecan is however, under review for inclusion 
on the EML.  
 
The use of mitomycin-C use was infrequent and unexpected. Although little research has been 
conducted, Dimou and colleagues (2010) [199] did show that there may be benefit to some 
patients even though it was the previous standard of care (prior to oxaliplatin and irinotecan) 
[199]. In this instance, it is assumed to be prescribed on a compassionate basis for patients 
who couldn’t acquire irinotecan for that cycle. Similarly, capecitabine monotherapy was 
prescribed for maintenance therapy in a few instances, although not standard practice due to a 
lack of evidence for use in CRC, a fixed low-dose has previously been described for 
maintenance therapy [200]. This fixed low-dose appeared to be safe and well tolerated with 
only 13% of the study population discontinuing the regimen. This study, albeit limited, did 
show a median duration of 45 weeks of therapy [201]. From the current retrospective drug 
utilisation review, it cannot be concluded the benefit of maintenance therapy as only 5% of 
the total cohort were thought to receive maintenance therapy but could prove to be 
advantageous, as majority of these patients didn’t require further treatment. These findings 
aren’t conclusive but should be studied further. 
 
The retrospective drug utilisation review did also indicate a preference for capecitabine over 
5-FU + LV as 1
st
 line therapy even though the two regimens have been proven to be 
equivalent [53]. It can’t be concluded that this was due to patient’s preferences, decided by 
the oncologist or decided by the patient’s calculated ECOG score. This is an area of study that 
should be conducted particularly for decision makers and pathway developers. Previous 
studies on patient preference have been conducted elsewhere and are conflicting as a trial 
conducted by Borner and colleagues (2002) [202] concluded that patients preferred oral 
therapy provided efficacy isn’t compromised [202]. A more recent trial, using the same cross 
over methodology, concluded that patients preferred a regimen with less toxicity as opposed 
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to ease of administration thus more patients preferred the I.V. Nordic 5-FU + LV regimen 
[203].  
 
In addition to the frequently administered capecitabine, the treatment pathways clearly 
indicate CAPOX for early CRC high-risk patients however; the retrospective drug utilisation 
review revealed a high use of CAPOX as a 1
st
 choice regimen for early CRC (Figure 3.7). 
Risk factors such as age and co-morbidities play an important role, not only in chemotherapy 
choice but also if chemotherapy should be administered [204, 205]. Upon analysis, 76% of 
elderly patients (>70yrs) diagnosed with advanced CRC disease received oxaliplatin in their 
treatment. Although not prescribed in accordance with the clinical pathways, treatment is 
patient dependent and could indicate healthy elderly patients; however in a recent study where 
more than half of patients over 75yrs received oxaliplatin, cost of treatment increased with no 
survival benefit [206]. Unfortunately the patient records at the oncology clinic do not include 
co-morbidities or factors that could indicate high-risk. Therefore it couldn’t be determined if 
all patients that received CAPOX as a 1
st
 choice regimen were high-risk. It is unclear from the 
patient records whether or not risk-assessments are performed but chemotherapy treatment is 
variable and this patient cohort might be at a higher-risk than another cohort. It could also be 
a more aggressive plan of treatment so as to ensure that disease progression is delayed for as 
long as possible but also to try achieve disease remission with the hope of reducing long term 
consumption of already limited resources. For this patient cohort, 25% of patients treated with 
CAPOX initially were changed to an alternative regimen nevertheless it can’t be presumed 
that disease progression occurred as neuropathy development is common with oxaliplatin 
treatment [48].  
 
The high number of patients initially treated with oxaliplatin could also indicate the 
substantial suspected incidence of peripheral neuropathy, which resulted in dose alterations. 
This is concerning as full dose intensity is favoured for a desired response [207]. It is 
recommended that in severe cases treatment may need to be stopped or delayed and dose 
reductions can also relieve symptoms. International recommendations indicate duloxetine as 
effective treatment for peripheral neuropathy [208, 209], gabapentin and pregabalin may also 
be favoured [210] however, these are unavailable in the public sector and therefore 
amitriptyline is most likely to be prescribed.  
 
In comparison to the theoretical pathways, some patients do switch to an alternative regimen. 
2 of the early staged CRC patients were observed to have a definite change in treatment 
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regimen, such as the addition of oxaliplatin (Figure 3.7). This is not standard practice when 
comparing to local and international guidelines [25, 26, 126, 127, 156-162], it could possibly 
be an indication of metastasis but oxaliplatin-intolerance cannot be ruled out (Figure 3.7, 
Figure 3.8).   
 
4.3.2.2 The private healthcare sector 
 
Although treatment for early CRC is site specific, the data received for the private sector 
didn’t account for this thus it is unclear as to which of the early CRC patients were affected 
by colon cancer and which by rectal cancer. The early CRC per patient results (Appendix I) 
shows that while a few patients may receive 1
st
 choice regimens with a limited number of 
cycles; it can’t be assumed that these patients are rectal cancer patients. These patients may 
well decide to discontinue treatment or oncologists may decide to withdrawal treatment and 
from the data this is unknown. Many factors found in the literature are seen to play a role in 
the discontinuation or withdrawal of treatment [211]. Clarke and colleagues (2015) [211] 
conducted a systematic review on literature in the USA and found that decisions around 
withdrawal occur over a period of time and include clinical factors (disease progression) and 
non-clinical factors (oncologists views or feelings) [211]. A study conducted with leukaemia 
patients indicated older patients are more likely to discontinue chemotherapy for various 
reasons including increased disease-related symptom severity, lower tolerance of adverse 
effects and financial difficulties [212]. Apart from these studies, the literature appears to be 
limited and has a focus on older patients [213] however this issue of discontinuation should be 
followed up and factors affecting the South African population should be studied.  
 
The observed treatment pathways in the private sector did also reveal the use of 
unproven/unconventional CRC chemotherapy (Figure 3.32; Figure 3.33). The reason for the 
use of unproven/unconventional chemotherapy cannot be ascertained from the database 
however it is suspected to be either an off-label use, where prescribers feel that it may be 
appropriate for the patient, or may indicate the presence of a secondary cancer that was not 
captured. Apart from the clinical inappropriateness of these medicines, the cost contributions 
to the patient’s total cost of treatment are unnecessary. For example the use of 
carboplatin+paclitaxel in this patient cohort increased total cost by approximately R 23 000. 
This would be one area whereby cost could be reduced and improve resource utilisation. This 
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is not as much of an issue in the public sector as resources are constrained and access 
controlled by EMLs which indirectly prohibits off-label use (Figure 3.29; Figure 3.31).    
 
Similarly the decision for no treatment or BSC only is unknown due to the nature of the data. 
The reasons for these treatment decisions would be beneficial to know particularly for the 
early CRC group of patients as early CRC disease has a better prognosis and treatment is 
favoured. A recent study by Sankaranarayanan and colleagues (2010) [173] clearly indicated 
that early detection is key to survival but so is the healthcare service resources and 
development [173]. Survival rates are high for colorectal cancer in comparison to other cancer 
and treatment should favour an increased survival however there is conflicting literature that 
this is the case [26]. Research has indicated that chemotherapy might only increase survival 
by 2% but this research is outdated [214]. Thus for the private sector patient cohort, this may 
indicate that the advanced CRC status of patients on the database may be incorrectly captured. 
The regimen change trend within a line of treatment seen in the public sector, particularly for 
the 1
st
 line treatments, is similar for this sector however in the private sector, 2
nd
 line 
treatments are easily attainable thus less change occurs between 1
st
 line therapies. There are 
more 2
nd
 line therapies present in the recorded pathways for the private sector indicating more 
regimen changes within the 2
nd
 line of treatment. Likewise with this sector once metastasis 
occurs the treatment is not based on the origin. This is clear from the high number of cycles 
patients receive in 1
st
 line treatments as well as the apparent quick change from 1
st
 to 2
nd
 
treatment lines.  
 
Comparing the developed treatment pathways to international guidelines indicates that many 
of the treatments available elsewhere globally are available to private sector patients in South 
Africa. Standard therapy including irinotecan, bevacizumab and cetuximab is thus available to 
these patients unlike patients reliant on public healthcare [25, 26, 126-129, 158-162]. This 
does give some indication that chemotherapy treatment for CRC in South Africa does follow 
international trends but there was an absence of medicines such as aflibercept and 
panitumumab as these are yet to be approved by the MCC and are not yet available on Section 
21. Regorafenib was prescribed for a few patients as it is available on Section 21 and will 
most likely be prescribed more frequently once MCC approval is obtained although 
availability will also be dependent on funding for reimbursement. These newer therapies are 
costly and are more likely to be limited to the number of patients that will ultimately receive 
them. This is highlighted in section 4.4.3.5.  
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Maintenance therapy only became apparent following the retrospective drug utilisation review 
of the public sector as it isn’t the standard of practice for a cancer such as colorectal. This 
trend of maintenance therapy is also seen in the private sector. Similarly to the public sector, 
capecitabine was used in maintenance therapy, as was 5-FU. Monotherapy with either one of 
these fluoropyrimidines has been found to be effective [201, 215, 216]. Although research is 
limited for colorectal cancer maintenance therapy recently more studies have been published. 
Many of these studies include biological agents for the use in maintenance therapy such as 
bevacizumab. The CONcePT trial indicates an increased time to treatment failure (4.2 months 
vs. 5.7 months) and the STOP and GO trial showed significant increases in progression free 
survival (8.3 months vs. 11 months) and overall survival (20.2 months vs 23.8 months) [217, 
218]. The benefits of maintenance therapy, whether it is conventional treatment such as 
capecitabine or biological therapies such as bevacizumab, seem to be becoming more 
apparent in colorectal cancer and as such should be included into the developed treatment 
pathways. The use of mitomycin-C was infrequent in the private sector nevertheless was 
unexpected due to the greater number of medicines available to this sector of patients than in 
the public sector. Even though some patients may benefit from mitomycin-C it is the previous 
standard of care [199]. Most notably mitomycin-C was only prescribed as last line therapy for 
the respective patients. This may well be an indication that no other medicines were 
appropriate at the time and it was decided to try mitomycin-C. In addition to the use of 
mitomycin-C, tegafur was also used albeit very infrequent.  
 
Recent literature has looked at the benefit of monotherapy with tegafur/uracil as well as in 
combination with irinotecan particularly for advanced colorectal cancer [202, 219, 220]. 
Tegafur/uracil or UFT is an oral prodrug of 5-flurouracil combined with a DPD inhibitor 
which has been found to benefit mCRC patients. There are studies that have looked at patient 
preference and pharmacoeconomic comparisons of oral UFT versus intravenous 5-flurouracil 
[202, 221]. However from the private sector drug utilisation, capecitabine is the medicine of 
choice when oral therapies are prescribed. Although UFT could be studied further in order 
determine its possible place in therapy as it is no longer available.  
 
Comparing the first treatments received, capecitabine-containing regimens are favoured for 
early CRC patients whereas the advanced CRC treatment pathways indicate a higher use of 5-
FU+LV-containing regimens even though the two regimens have proven non-inferiority for 
any stage of CRC [53]. Based on the high use of capecitabine in the public sector, it is not 
unexpected to see a high use of capecitabine in the private sector. It is unexpected to see a 
 148 
greater use of 5-FU+LV for advanced CRC disease in the private sector but majority of 
regimens contain intravenous medicines other than 5-Fluorouracil thus it may be preference to 
receive treatment all at once. Many patients diagnosed with advanced CRC disease in this 
sector have access to newer biological agents that can only be administered intravenously and 
this may be a factor for the preference for 5-FU+LV over capecitabine when used in 
combination with conventional regimens. Studies have indicated patient preference for 
capecitabine as capecitabine is less toxic and administration is easier thus this does raise an 
important issue in the private sector as to what the drivers are for choice of treatment [202, 
203]. In this study, the choice of chemotherapy regimen in the public sector appear to be 
driven by cost as 5-FU+LV regimens would cost more. The choice of chemotherapy regimen 
for advanced CRC disease in particular for this sector isn’t as clear thus more studies are 
required with regard to this area of patients receiving chemotherapy.  
 
In addition to the preference for capecitabine in early CRC disease for the private sector, the 
treatment pathways mapped for the patient cohort show an extensive use of regimens such as 
CAPOX (FOLFOX) and XELIRI (FOLFIRI). Regimens such as these are usually reserved for 
high-risk (e.g. 70 years) early CRC patients and there appears to be better adherence to this in 
the private sector as less than half the patients over 70 years received a chemotherapy regimen 
containing oxaliplatin or irinotecan first up. It is likely that patients that did receive one of 
these cytostatic agents most likely had disease progression following the initial 1
st
 choice 
regimen. Interestingly all the patients that received these medicines were much younger in the 
over 70yr age group. This does indicate that age and co-morbidities play a role in 
chemotherapy choice and if chemotherapy should even be administered [204, 205].  
 
The preferred use of oxaliplatin versus irinotecan is interesting, as regimens containing these 
medicines have been found to have no difference in time to progression (7mnths vs. 7mnths) 
and overall survival (14mnths vs. 15mnths) [183]. In addition for patients that have 
experienced 1
st
 choice 5-FU treatment regimen failure, 2
nd
 choice regimens contained either 
FOLFIRI or FOLFOX4. These regimens however have shown no significant difference in 
overall survival [189]. The costs did differ for the different stages of the disease as the cost 
data structure for this research didn’t allow for the identification of 1st and 2nd line treatments 
for advanced CRC or 1
st
 and 2
nd
 choice regimens for early CRC. When comparing early CRC 
disease to advanced CRC disease however, oxaliplatin containing regimens are more costly. 
Early CRC disease shows that FOLFIRI is 13% cheaper (for the same number of cycles) and 
22% cheaper for advanced CRC disease (1 cycle less). The cost saving is due to the irinotecan 
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cost despite the inclusion of atropine for administration purposes. In this patient cohort, both 
early and advanced CRC, oxaliplatin regimens appear to be more frequently prescribed in the 
1
st
 line treatments for advanced CRC or as a 1
st
 choice in high-risk early CRC patients. This is 
seen in the high number of irinotecan-containing regimens in the 2
nd
 line of treatment for 
advanced CRC. Furthermore to this oxaliplatin can cause peripheral neuropathy therefore the 
increased number of irinotecan regimens in the 2
nd
 line may be due to intolerability of 
oxaliplatin and not necessarily be due to disease progression [48].  
 
In comparison to the theoretical pathways, it isn’t unexpected to see multiple treatment lines 
for advanced CRC disease however due to the observations made in the public sector; there is 
a likelihood of 2
nd
 choice treatment regimens for early CRC disease. The patients that did 
receive more than just 1
st
 choice treatment regimens were few and possibly were classified 
incorrectly on the database. The presence of adverse drug reactions can also not be ruled out. 
The advanced CRC disease group of patients had multiple treatment lines, more than was 
expected in the theoretical treatment pathways. This indicates the complexity of 
chemotherapy moreover the increased number of treatments available to these patients 
furthermore increases the level of complexity as oncologists and patients may well try as 
much as possible.    
 
4.4 Retrospective Drug Utilisation Review - patient cohort demographics 
 
4.4.1 Public healthcare sector 
 
4.4.1.1 Patient cohort characteristics 
 
The patient cohort for the oncology clinic is not necessarily reflective of all populations 
within South Africa as environmental and lifestyle factors play a major role in colorectal 
cancer development and is likely to differ with the country [24, 26]. This retrospective drug 
utilisation review does give insight into possible patient characteristics for a sub-population 
within South Africa. 
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4.4.1.2 Gender 
 
Although CRC is not a gender-specific cancer such as breast or prostate cancer, the disease 
affected more males for this cohort. Interestingly the patient cohort studied revealed that this 
is only the case for early CRC diagnoses. Advanced CRC disease incidence is more similar 
with nearly 50% of the population diagnosed being female thereby could indicate the increase 
in older females having a greater risk. This result was expected as previous research, albeit 
with larger cohorts, does reveal more males are affected [222]. When compared to the NCR 
statistics for 2012, more males were diagnosed than females however the percentage 
difference between the genders was only 8% for colorectal cancer [32].  
  
4.4.1.3 Age 
 
Published research has indicated that risk of CRC development increases over the age of 40 
with sharp increases over 50 years of age [24, 26, 223]. More recent research published by 
Siegel and colleagues (2014) [224] indicated that new CRC cases for 2014 peaked between 
the ages of 50 and 79 for both sexes. Other research indicated that patterns of incidence by 
age only displayed increases between 60 – 79 years for distal colon cancer and 60 - 69 years 
for rectal cancer [222, 224]. This pattern of incidence is similar to the data collected as the 
number of patients over 50 years show these increases where proximal cancer rates are much 
less and even show a decrease in males. Additional research has indicated that women over 
the age of 65 years have a greater risk of developing colorectal cancer however many more 
males were diagnosed than females in this patient cohort and although the risk is present it 
can’t be deduced that cancer will develop [11]. The median age of the patient cohort at 
CMJAH is no different to literature and was expected to be over 50 years of age [27]. This 
finding isn’t surprising and is most likely due to increased westernisation in South Africa and 
in particular the Johannesburg region. This might well differ in other LMICs within the Sub-
Saharan region. More than 60% of females and 70% of males from the patient cohort were in 
this age group, which is similar to the 60% and 71% seen by Siegel and colleagues (2014) 
[224] in the United States  [223, 224].  
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4.4.1.4 Tumour sub-sites – Left vs. Right-sided CRC 
 
Little research has been published with regard to patient diagnosis based on tumour sub-sites 
within the colorectal region but according to the National Cancer Institute, most colon cancers 
are left sided [225]. This is the case for this patient cohort whereby 38% of patients have left-
sided colon cancer however, Siegel and colleagues (2014) [224] as well as Murphy and 
colleagues [222] reported more proximal colon cases as with a mortality study conducted by 
Weiss and colleagues [222, 224, 226]. These studies also indicated that females were more 
likely to have right-sided cancers. Even if the 13% of unspecified colon cancer cases were to 
be confirmed as proximal cancers, this patient cohort would still indicate a greater incidence 
of distal colon cancer cases and males would still account for more of these cases. This 
finding should be investigated further as it is known that left and right-sided tumours have 
biological differences but there may be additional factors present in this population resulting 
in an increase of left-sided tumours. One such factor is a diet with increased red and processed 
meat consumption. Studies have indicated that distal colon cancers can be due to increased 
red meat consumption, bearing this is mind it could explain the increased number of distal 
colon and rectal cancer cases in this cohort [227-230]. South African’s are known to have 
higher consumptions of red and processed meat regardless of socioeconomic status [231]. In 
addition to this finding, 31% of the patient cohort was diagnosed with rectal cancer and is 
much more similar to the findings of Siegel and colleagues (2014) [224] (28%) but differs 
once again according to gender. Although more males were recorded in the Siegel et al. 
(2014) [224] study, by far more males were diagnosed with rectal cancer [224]. This patient 
cohort indicated more females were diagnosed with rectal cancer. Smoking has been found to 
be an important risk factor for the development of rectal cancer likewise with alcohol 
consumption [232]. This could possibly play a role in the cohort.  
 
Recent re-analysis of the FIRE-3 and CALGB/SWOG 80405 trials indicates the side the 
cancer originates may play a role in patient’s responsiveness to treatment. Patients with left-
sided cancer have an increased median overall survival regardless of the treatment regimen. 
Moreover right-sided cancer is more responsive to bevacizumab as opposed to cetuximab [97, 
98]. This is discussed in more detail in section 1.4.8.3.4.3. Although this could not be seen in 
this patient cohort as regimens containing cetuximab and bevacizumab are unavailable, it 
should be studied in the private sector.  
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4.4.1.5 Ethnicity  
 
Although ethnicity was not studied due to limitations in recording and multiple assumptions 
that would need to be made, studies such as those performed by Siegel et al. (2014) [224]  
have indicated that in the United States, the African American population has greater 
incidences of colorectal cancer while Asian/Pacific Islanders have the lowest for both 
genders. This difference was suggested to be due to the low socioeconomic status within the 
African American population thus should be studied further in South Africa as majority of the 
patients seen at clinics such as CMJAH are of low socioeconomic status [224].  
 
4.4.2 Private healthcare sector  
 
4.4.2.1 Patient cohort characteristics 
 
The patient cohort used for the private sector is more representative than the public sector 
cohort as the medical  scheme used has one of the largest memberships that covers patients 
countrywide and not only a region such as with the public sector cohort. Similarly to the 
public sector, this patient cohort can’t be used to standardise the characteristics of CRC in 
South Africa as there is only a small percentage within the population which subscribe to 
private medical insurance furthermore most of these subscribers are middle- and high-income 
earners [4].  
 
4.4.2.2 Gender 
 
Similarly to the public sector, more males are affected than females albeit a non-gender 
specific disease. Interestingly both early CRC and advanced CRC subgroups displayed this 
occurrence and does follow the risk data as seen in the SEER statistics [27]. This observation 
is no different to the public sector however the percentages differ but due to the large number 
of patients in the cohort, it is probably more accurate. As previously discussed the 
mechanisms associated with these phenomena are unknown but possibly related to the risk 
factors and sex hormones [222]. Interestingly the percentage of women affected by the 
disease is less in the advanced CRC group unlike the public sector; it suggests that women 
within these socio-economic groups are more lifestyle conscious thereby lowering their 
lifestyle risk for developing CRC. This result is similar to a prospective study conducted in 
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Denmark that found patients who do adhere to health recommendations and guidelines can 
reduce their risk considerably [233]. 
 
4.4.2.3 Age  
 
Similarly to the public sector data, patients aged between 50 and 79 years are the most likely 
to present with CRC in the private sector. Most of the cases are over the age of 60 and this is 
seen in the median age of the cohort and is similar to the literature for Sub-Saharan Africa 
[234]. In comparison to the public sector, the data indicates more than a 10% increase for the 
incidence of females in this age range and is similar to the males for the cohort but differs to 
the public sector. This result isn’t unexpected as patients making use of private healthcare in 
South Africa are higher income earners that are able to lower their risk factors particularly 
those related to lifestyle and research indicates that diets high in fruits and vegetables and 
dietary fiber intake make a difference. Together with an increase of physical activity CRC risk 
can be decreased [223]. Although the difference isn’t huge, it does illustrate the role lifestyle 
factors play in the development of CRC but also indicates that many factors that influence 
patients in the public sector also affect patients in the private sector. This is seen in the 
median age of the cohort, which is older for this sector when compared to the public sector, 
but is not as high as a developed country such as the USA [27]. 
 
4.4.2.4 Tumour sub-sites – Left vs. Right-sided CRC 
 
Due to suboptimal data capture of the private sector data, no sub-site evaluation could take 
place. Data from the public sector and literature indicates there is a need to gather data based 
on the origin within the colorectal region [222, 226]. Including such data will enhance the 
quality of not only private sector data but data for South Africa for all cancers. The 
importance of left vs. right-sided origin is discussed under section 1.4.8.3.4.3. 
 
4.4.2.5 Ethnicity 
 
Ethnicity wasn’t studied in this research thus no demographical data regarding race was 
received from the medical  scheme. As previously discussed race does play a role in CRC 
incidence with certain ethnic groups having greater incidences [224]. Siegel and colleagues 
(2014)  [224] noted an association between socio-economic status, race and the incidence of 
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the disease therefore it is an important aspect of demographical studies for a country such as 
South Africa and should be studied further [224]. Furthermore this data should be used to 
compare the two healthcare sectors and the population that makes use of each.  
 
4.4.3 Treatment costs 
 
4.4.3.1 Total cost for CRC treatment  
 
4.4.3.1.1 Public healthcare sector 
 
Costs associated with advanced CRC disease were expected to be more than for early CRC 
disease. This is because costs are influenced by disease state in that early CRC disease has 
better prognosis thus requiring fewer cycles of chemotherapy and possibly lower dosages. In 
addition, advanced CRC disease may be treated with newer therapies that tend to be costly for 
the public sector, treatment options are limited and therefore cost differences are generally 
due to cycle and dosage differences. Observed costs which are often lower than the theoretical 
costs, indicate the variability that occurs in a population and illustrates how difficult 
calculating costs for such a disease can be. The variability often results in lower doses and 
number of cycles than expected. The percentage changes for CAPOX range from 13% to 
179% for 1
st
 and 2
nd
 line treatment lines respectively when early CRC and advanced CRC 
disease is compared. However, when early CRC costs are compared to theoretical costs the 
costs are similar but advanced CRC disease is less than 5% in comparison to the theoretical 
costs (Table 3.19 and Table 3.21). These changes aren’t unforeseen however a regimen such 
as XELIRI indicates no percentage changes as irinotecan was not available at the time of the 
study to public sector patients nevertheless should irinotecan be included on the EML, the 
cost is expected to be less than the reported lowest SEP price for the private sector (Table 
3.19 and Table 3.21). This is due to the tender procurement process in the public sector. 
Although the total cost per cycle will be lower than the lowest calculated SEP cost, the costs 
to the Provincial Department of Health will increase as access to irinotecan by all public 
sector patients will remove the self-paying portion most patients currently cover, in other 
words patients who are currently self-funding for irinotecan will expect it to be freely 
available in the public sector. This nonetheless will increase access to patients who cannot 
afford the medicine.  
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When comparing early staged colon to rectal disease, rectal cancer costs are lower by half 
except for 1
st
 choice CAPOX. With regard to capecitabine costs, the theoretical costs have a 
range of costs due to the dosing range of the medicine. To simplify the comparison, the lowest 
theoretical cost i.e. the lowest dose was compared thus the percentage differences may be 
larger when comparing higher doses of capecitabine. Capecitabine was still on patent at the 
time of the study but is available in the public sector and is the most costly factor in the cost 
calculation for capecitabine-containing regimens. The change in cost is considerable when 
varying doses thus this research should be performed on various public sector cohorts in order 
to verify and understand the variations that will occur within a population. However, when the 
patent for capecitabine expires, the cost is likely to be reduced further and favour 
capecitabine-containing regimens even more.  
 
This is particularly important when comparing equivalent regimens such as 5-FU+LV and 
capecitabine. These regimens have previously been shown to differ in cost and favour the use 
of capecitabine due to its oral administration [169, 235-238]. This study is in line with 
previous research and indicates that although the medicine price of capecitabine was 
calculated to be double the cost of 5-FU+LV, administration costs are lower as patients spend 
less time receiving chemotherapy and don’t require the insertion of a port and pumps in 
addition to less administrative duties associated with capecitabine administration. This does 
indicate the complexity of economic-based decisions as medicine prices alone are not and 
should not be the only factors considered when determining the economic impact of 
treatment. In addition, there is a complexity to treatment and this can be seen in the variable 
adherence to these pathways.  
 
When comparing the advanced CRC theoretical costs to the patient cohort costs for advanced 
CRC disease little change is seen. The total public healthcare sector patient cohort had more 
patients with advanced CRC disease so variables such as the number of cycles and dosages 
are more accurate and represent what has previously been recorded in literature and clinical 
trials for advanced CRC disease. A similar study conducted for advanced CRC in Brazil 
indicated the lack of biological agents available in their public healthcare system but more 
noticeably regimens containing 5-FU were over budget and surpassed the monthly 
reimbursement amounts. Likewise with our study, administration costs contributed the most 
to the treatment costs but in Brazil, medicine costs were lower than in our study [239]. 
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4.4.3.1.2 Private healthcare sector 
 
Although the expectation was that advanced CRC disease costs would be higher than early 
CRC disease costs as seen with the public sector, the average cost per cycle is similar for the 
same regimens. This is essentially due to similar dosages, which is a result of the assumption 
that the claimed vials are the prescribed doses. However in clinical practice these doses may 
well be lower as vial wastage does occur in order to accommodate dosing based on BMI or 
body weight. Wastage cost unfortunately can’t be calculated from a claims database however 
these factors should be considered as a recent study published by Bach and colleagues (2016) 
[240] found that single-dose vials can lead to overspending as the vial sizes don’t match the 
prescribed doses for many newer medicines [240]. In addition to vial wastage, vial sharing 
may also occur. Vial sharing limits the wastage of viable medicines however, patients are still 
be billed for the entire vial thus in clinical practice the dose and cost don’t match. Bach and 
colleagues (2016) [240] do provide vial sharing as one method to curb costs however it is not 
recommended for all intravenous medicines [240]. Although vial sharing is likely to happen 
to limit chemotherapy wastage for a facility [241], due to the nature of the data collection and 
cost calculations, this practice won’t have such an effect as each patient is billed per vial 
regardless. The savings are therefore achieved by the oncology facility. Consequently the 
difference rests in the average number of cycles calculated for the patient cohort, which 
influence the average total cost per regimen.  
 
Additional costs are incurred in cases where patients received treatments that are neither 
conventional nor proven CRC treatments such as R 12 873,25 for 4 cycles of cisplatin (early 
CRC disease) or cisplatin with docetaxel at R 40 858,62 for 4 cycles (advanced CRC disease). 
Although these are regimens are not conventional nor proven for CRC, a secondary cancer 
cannot be ruled out.  
 
In comparison to the theoretical costs in the private sector in which only conventional 
regimens could be compared, the theoretical costs were substantially more in many instances. 
Of all the regimens that were compared only 5-FU+LV showed an increase of less than 50% 
between theoretical costs and observed costs. This trend is similar to the percentage changes 
(Table 3.24, Table 3.25) seen in the public sector nevertheless the changes are greater for 
many regimens within the private sector. This could be due to the vast number of treatment 
options available to patients and oncologists in the private sector thus lowering the number of 
cycles a patient will receive per regimen and increasing the number of treatment regimens. 
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Due to the patient data not specifying if an early CRC patient was diagnosed with colon or 
rectal cancer, the costs are most likely an average for regimens such as 5-FU+LV and 
capecitabine. Rectal cancer patients are likely to receive less chemotherapy thereby lowering 
the cost.  
 
The theoretical costs regarding capecitabine vary due to the dosing range however the lowest 
cost product was used for comparisons. Although 5-FU+LV and capecitabine are equivalent 
regimens and the costs should favour the use of capecitabine, [169, 235-238], it can be seen 
that many patients receive 5-FU in this sector. Although the chemotherapy costs are about 
double for capecitabine than 5-FU, the administrative costs are more than 70% for the I.V. 
regimen. This therefore may explain the increased use of 5-FU as facilities make more money 
when patients receive I.V. regimens as opposed to oral treatment although this only applies to 
monotherapy oral regimens. For multiple medicine regimens, the price of capecitabine is the 
largest contributor as all other medicines are averaged for all available products. Capecitabine 
regimens therefore are more expensive than 5-FU regimens but factors such as theatre time, 
ports and pumps were not included unlike in the public sector calculations. These costs should 
be included in order to allow for better comparisons especially once patents expire and 
generics become available to patients.  
 
4.4.3.1.2.1 Out-Of-Pocket Costs 
 
Out-of-Pocket costs are costs incurred by patients in the form of co-payments on medical 
scheme claims or expenses not covered for by the patient’s medical scheme. These out-of-
pocket expenses have rarely been studied in literature but it is well known that these costs 
vary based on the medical scheme coverage of the patient.  
 
A recent study, looking at Medicare patients in the USA, found that without additional 
insurance supplementation significant OOP costs would be incurred [242]. The study 
determined these OOP costs using a prospective survey of a cohort of Medicare beneficiaries, 
of which 1409 beneficiaries were diagnosed with cancer during the study period [242].  
 
While this body of research did not look at OOP costs, as OOP costs could not be determined 
using the claims database for the private sector as the data only reflects the actual costs paid 
for by the medical scheme, it would be beneficial to conduct a survey such as the previous 
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research mentioned above in order to quantify the OOP costs patients currently incur in the 
private sector.   
 
4.4.3.2 Supportive care medicine costs 
 
4.4.3.2.1 Public healthcare sector 
 
Supportive care medicine costs, although a small portion of the cost per cycle, were found to 
vary from the theoretical cost calculations. This was expected as the theoretical costs were 
bundled together into “baskets” and the average calculated for a regimen. Upon investigation, 
it was found that all patients on I.V. regimens receive the same medication except if 
irinotecan is administered. Thus regimens such as 5-FU + LV and FOLFOX have the same 
supportive medicine costs at R44.48 per cycle. If FOLFIRI is administered, patients receive a 
vial of atropine in addition to the anti-emetics and corticosteroids. This increases cost 
marginally to R46.20. Oral regimens are cheaper as less supportive care medicines are 
required thus the cost savings are nearly R20.00 per cycle.  
 
Other supportive care medicines that were unable to be included, due to a lack of clarity of 
cost, include Xeloda ® Cream (a lanolin-based cream), a donation from Roche, which is used 
for the hand-foot-skin (HFS) syndrome that may arise. Patients however do not always take a 
tub each month as not every patient uses it as much as the next. In addition to the cream, a 
mouthwash containing benzydamine hydrochloride such as Andolex® is usually prescribed. 
There is no EML price for 2014 but the cost, according to SEP, will range between R63.31 
and R78.32 per bottle. Once again this cost is not enough to change the percentage differences 
between the theoretical and cohort costs but should not be ignored. A similar study conducted 
by Kruse and colleagues (2008) [243] indicated that 3% of the total cost per visit for 
metastatic breast cancer in a US population is due to antiemetic’s and corticosteroids [243]. 
This is greater than for the South African public healthcare sector whereby the supportive care 
medicines contribute less than 1% for most regimens. This is also low as supportive care 
medicines are imitated in the public healthcare sector. 
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4.4.3.2.2 Private healthcare sector 
 
The supportive care medicine costs are minimal when compared to the chemotherapy and 
administrative costs in the private sector. The supportive care medicines are the same classes 
of medicines as used in the public sector, namely a corticosteroid and antiemetic. The 
difference in cost between the two sectors is at least 600% more per cycle in the private sector 
for advanced CRC disease. This difference is due to the increased price in the private sector 
for the same classes of medicines e.g. palonosetron (Onicit®) versus generic ondansetron or 
granisetron, as well as the increasing number of products available particularly newer 
antiemetic’s such as aprepitant, an NK-1 inhibitor. Most notably patients in the private sector 
would receive more than one class of antiemetic thus increasing the costs. Considering that 
CRC regimens have low to moderate emtogenicity, the recommended supportive care is a 
combination of a corticosteroid such as dexamethasone and one of the 5-HT3 receptor 
antagonists [244]. Thus the use of aprepitant for the (MEC) is not advised and should be 
reserved for highly emtogenic regimens (HEC) such as cisplatin or anthracycline + 
cyclophosphamide. In addition should oncologists prescribe generic ondansetron or 
granisetron in place of palonosetron, the cost savings of at least R 245,00 per cycle as only the 
originator of palonosetron (Onicit®) is available and the vial size is bigger. A recent review 
by Gyawali and colleagues (2016) [245] did indicate that there are many cheaper alternatives 
that could be prescribed for chemotherapy-induced nausea and vomiting (CINV) and it was 
stressed that this is of importance in low-resourced settings [245] however patients should be 
included in decisions such as this even in higher resourced settings. Another alternative is 
olanzapine. Olanzapine is an atypical antipsychotic which targets multiple receptors within 
the central nervous system and is advantageous as patients are only required to administer one 
medication as opposed to the current combinational therapy. The one disadvantage is the cost 
as many cheap generics are available for the medicines used in the combinational treatments 
[246]. Although this study clearly illustrates the contribution, albeit small, that these 
medicines have on total cost, it does also raise the question of ease of administration for the 
patient.     
 
When irinotecan was prescribed, atropine was included in the supportive care costs however 
the cost is marginal as with the public sector and has no effect on the total cost contribution. 
Claims on secondary supportive care medicines, these are medicines used in support of the 
cancer patient other than a corticosteroid and 5-HT3 receptor antagonist, were included in the 
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dataset however they were excluded in the final costs as it was unclear whether or not these 
medicines were for chronic co-morbidities or for the treatment of an adverse drug reaction. A 
few of these medicines included loperamide (diarrhea), lidocaine (irregular heart rhythms), 
lansoprazole (intestinal ulcers or esophagitis) and iron (iron deficiency or anaemia). The 
average cost for all medicines classified as secondary supportive care amounted to R 265,75 
for early CRC disease and R 306,69 for advanced CRC disease. Moreover this is an indication 
that advanced CRC patients have higher costs, which are not only due to chemotherapy.  
 
Use of pain medication was also considered from the database. Although it was initially not 
calculated for the public sector cohort, it become apparent in the private sector patient cohort 
that many patients receive pain management care particularly for advanced CRC patients. 
Pain management included medicines such as acetylsalicylic acid, codeine, ibuprofen, 
morphine and paracetamol. The cost contribution was much greater than the supportive care, 
secondary supportive care or administration costs and was calculated to be an average of R 
490,00 and R 692,56 per patient per cycle for early CRC and advanced CRC disease 
respectively. This should be studied further as it appears to contribute to the cost of 
chemotherapy but also to the best supportive care regimens many patients receive.  
 
4.4.3.3 Administration costs  
 
4.4.3.3.1 Public healthcare sector 
 
Administration costs refer to the costs associated with receiving chemotherapy such as 
admixture bags, needles, drip sets etc. These costs were calculated based on a previous study 
carried out in South Africa in 2011 [169] and adjusted by inflation. The costs however may be 
lower for regimens containing 5-FU+LV than recorded in this study as clinical practice 
reveals that administration ports are not inserted each cycle but patients may use a port for 
several cycles and this would reduce the average cost for a patient cohort. It does however 
still indicate a large cost contribution ( between 60% and 90%) to a regimen containing 5-
FU+LV and impacts the cost when comparing equivalent regimens such as 5-FU+LV and 
capecitabine. This does play a role in treatment choice in a resource-constraint environment 
such as the public healthcare sector in South Africa. Recent research published by Kruse and 
colleagues (2014) [247] indicated that chemotherapy administration costs for treating 
peripheral T-cell lymphoma account for 2 – 32% of the total costs [247]. This indicates much 
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variability in relative cost however when looking at the patient cohort in CMJAH, the 
administration costs vary between 0 and 62%. This is more than previously published 
literature for other cancers [247] and is partly due to the inclusion of a new port for each cycle 
administration of 5-FU+LV although patients may not necessarily receive a new port each 
cycle. These results are however in line with a study that compared CAPOX to FOLFOX in 
which administration costs can account for more than 70% due to the central vein catheter 
insertion and hospital stay [237]. The literature is limited thus comparisons such as this, is not 
that accurate nonetheless does indicate the need for further studies.  
 
4.4.3.3.2 Private healthcare sector 
 
The administration costs were based on the same cost components as for the public sector, 
namely drip bags i.e. carbohydrates or sodium chloride, antiseptics and other costs directly 
related to the administration of the chemotherapy, however, costs associated with 5-FU 
administration were difficult to ascertain in the private sector. These costs included the theatre 
time required for port insertion as well as the cost of the ports and pumps for 5-FU 
administration. All other materials such as the infusion drip sets, needles and swabs etc. are 
all included in the administrative costs for this sector. Therefore the administration costs 
appear to be negligible and much lower for 5-FU regimens when compared to the public 
sector. Due to this the administration costs don’t contribute more than 3% to the total cost per 
cycle and is on the lower side when compared to literature such as the Kruse study [247]. In 
addition the private sector costs were calculated for early CRC and advanced CRC patients 
unlike with the public sector due to the larger amount of data that was obtained. This can and 
has been shown to change the costs for components such as the administration and 
administrative costs depending on the disease state. A better understanding of the process by 
which patients receive chemotherapy in the private sector and insight into the coding for the 
claims and inclusions for each tariff is required in order to improve accuracy and enhance 
quality with both the administrative and administration costs in the private sector. Taking 
these factors into consideration, it is foreseen that capecitabine regimens will therefore also be 
lower in cost than the 5-FU regimens. This will most definitely be of benefit to both the 
patients and the medical scheme paying for the treatments.  
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4.4.3.4 Administrative costs 
 
4.4.3.4.1 Public healthcare sector 
 
Administrative costs for this sector had not previously been researched and the costs 
associated with delivering chemotherapy to a patient are unknown in the public healthcare 
sector of South Africa. Thus a time and motion study was performed at the oncology clinic. 
Previous research has indicated that administrative costs can account for over 70% of the total 
cost of a monotherapy regimen [237]. This unfortunately was not the case for most regimens 
in this sector as they are multiple medicine regimens.  Administrative costs accounted for as 
much as 13% for early CRC disease and 15% for advanced CRC disease. Observed cost 
indicated a greater contribution for intravenous regimens per cycle. A study conducted in 
Canada found that administrative costs contributed less for chemotherapy regimens 
containing expensive medicines and is similar to these findings in the public healthcare sector 
of South Africa [248]. The time and motion study was however very simplistic and should be 
expanded with more people recording the times in order to refine the costs for I.V. and oral 
therapies as well as if more than one medicine is administered. In addition to this, per patient 
recording could be more valuable but this does provide logistical problems in this setting. Per 
patient recording would allow more accurate time capture per patient as the patient would be 
followed through the process from arrival at the clinic until the time of departure moreover 
the time the patient spends at the clinic could be calculated and equated to a cost.  
 
Literature dose cite a lack of methodological standardisation for time and motion studies 
[249]. However, comparing the time and motion study conducted at CMJAH and other 
research, there is consistency within selecting steps based on a patient’s entire visit to a 
facility for chemotherapy. There are differences within the process for the various facilities so 
direct comparison is difficult [170, 171]. The limitations for the studies found in literature and 
those experienced during this research also don’t differ by much as timings and related costs 
were irrespective of chemotherapy regimens and dosing and may differ in the real-world 
between regimens and even cancers [170, 171]. The Schindler study also gathered timings in 
groups and not on a per patient basis however, the consistency of the timings is more 
important [170].  
 
These costs can furthermore be used in pharmacoeconomic studies such as cost of illness 
studies in order to determine the burden of disease in monetary terms [152]. This would 
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present a comprehensive picture of the cost of colorectal cancer for all stakeholders. This 
would however cause a logistical issue as the clinic is busy most days and could cause more 
issues trying to follow patients through the process in addition ethical approval may be 
difficult to obtain. Therefore the costs reported here are most likely higher than what was 
recorded. Over and above the limitations mentioned earlier, this study had multiple recording 
days which doesn’t ensure that the same staff employees are recorded but does indicate the 
inevitable variation. Also only one investigator was recording and monitoring the stopwatch 
therefore human error does play a role in readings.   
 
4.4.3.4.2 Private healthcare sector 
 
The administrative costs for this sector include the global fee and facility fees as set out by the 
medical  scheme tariffs but excluded the claims related to consultations as not every patient 
was charged a consultation fee for every cycle and in certain instances the consultations 
charged didn’t correspond to oncologists but a surgeon or radiologist. A consultation fee was 
included for some patients over and above the global and facility fee however was excluded 
from the administrative costs. The consultation cost is a substantial amount (R 747,10 per 
consult) and should be further investigated.   
In comparison to the time and motion study conducted in the public sector, the administrative 
costs are much higher and do have a contributing effect on the total costs as seen in the 
sensitivity analysis (Appendix Q). On average the cost contribution is between 10% and 45% 
of the total cost depending on the chemotherapy regimen. This is in line with previous 
research but is below the 70% threshold as found by Aitini and colleagues (2012) [237] in 
their economic comparison of CAPOX and FOLFOX [237]. On average for an I.V. regimen 
patients in the private sector will be charged 500% more and an oral regimen will be 600% 
more for administrative costs compared to the public sector. The public sector costs also 
include the time spent in a consultation with the specialist which were not included in the 
private sector calculations. Even though the salaries are higher in the private sector, a time 
and motion study should be undertaken in a similar manner to the public sector to validate the 
tariffs charged and to allow for a more accurate comparison.  
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4.4.3.5 Costs for multiple lines of therapies 
 
Colorectal cancer has fewer lines of therapy in comparison to other cancers i.e. breast cancer 
however many more treatments are becoming available to patients particularly in the private 
healthcare sector. These newer therapies are aimed at advanced stages of the disease and 
come at a substantial price for disease progression to be marginally prolonged nevertheless  
the emotional benefits i.e. the hope given to patients and their families is of value to the 
patients. As more lines of therapies are included in the treatment of colorectal cancer, the cost 
of treatment will increase further more. Research directly related to colorectal cancer cost for 
multiple lines of treatment is lacking but from breast cancer research it is known that 
advanced breast cancer chemotherapy treatment is complex and resource intensive thereby 
increasing the cost [250]. These will become concerns as colorectal cancer treatment develops 
more complexity and cost savings require greater considerations as this will limit the number 
of patients that will have access to all available treatment.  
 
4.5 Limitations  
 
4.5.1 The public healthcare sector 
 
Most limitations occurred in the retrospective drug utilisation reviews for each sector. For the 
public sector, there was no electronic data capturing system at the CMJAH oncology clinic – 
unit 495 thus the patient cohort might well be larger as the “new case” books were used to 
identify patients. If any incorrect entry was made into the “new case” books it would be 
overlooked. Also not all the “new case” books were attainable for the time period and as such 
approximately 10 months of new patients information was unknown. This was encountered a 
few times where patients weren’t CRC patients but initial records reflect this. Due to the 
alphabetical filing system used in the clinic, patient files that were mistakenly filed incorrectly 
weren’t located and were thus excluded. In addition, patient files weren’t accessible if the 
patient names were misspelt or the “new case” books were illegible or when the hospital 
number (GT number) and patient names didn’t match. Patient’s that are still receiving 
treatment at the clinic, which proved to be more often than not the more recently diagnosed, 
files were taken out in order for them to be seen thus had not been filed back in time for data 
collection.  
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For the data capture, files didn’t always contain all the necessary information such as co-
morbidities. This would be helpful for data analysis so as to examine the number of patients 
on certain regimens. Pathology results weren’t always available thus some instances required 
assumption of whether or not metastasis occurred. Photocopies of medical history or reports 
weren’t always clear or the doctors handwriting may have been illegible thus assumptions 
may have had to be made.   
 
Costing data in certain instances proved difficult and was unavailable for 2014 thus 2015 
costs were used. Non-EML medicine costs were determined from the lowest cost SEP 
however; these costs will be lower if the medicines were on the EML. The administrative 
costs were for 2015 for both sectors however; the time and motion study had several 
limitations in that times were recorded irrespective of cancer. The type of cancer may play a 
role in the administrative costs and should be considered. Also certain days appeared to be 
busier at the clinic and will impact the performance of tasks. The time and motion study was 
only conducted at the one clinic and would need to be performed at various public healthcare 
sectors in order to determine the true cost to the State. The cost of adverse drug reactions 
can’t be ignored when calculating the cost associated with chemotherapy but proves difficult 
as recording keeping and cross-referencing the diagnosis of patients presenting to emergency 
departments or doctors don’t always coincide with the chemotherapy.  
 
4.5.2 Private healthcare sector 
 
The use of claims data as opposed to patient records is limited in that the additional clinical 
information is not captured therefore information such as right vs. left sided colorectal cancer 
can’t be determined. Due to the type of the claims captured on the claims database, the 
average cost per regimen doesn’t account for the line of therapy but is the average for the 
either the advanced CRC or early CRC group within the cohort. A comprehensive breakdown 
of the cost and equipment inclusions for the administrative costs was unavailable thus clarity 
and accuracy is lacking with respect to these costs and the administration costs.  
 
4.5.3 Comparative analysis between the healthcare sectors 
 
The variation in the data collection and type of data from each sector limits the comparisons 
that can be made particularly with the administration and administrative costs.  
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4.6 Conclusion 
 
This study clearly illustrates the variation within chemotherapy treatment between the two 
South African healthcare sectors. Clinical practice guidelines and essential medicine lists may 
guide treatment. Although treatment pathways have shown cost savings such as reported by 
Feinberg and colleagues (2013) [123] that showed more than $ 8 million of savings, there has 
been debate as to whether or not these are essential. From this study it clearly indicates the 
need for treatment pathways as many regimens (approximately 30% - Table 3.24; Table 3.25) 
were prescribed unnecessarily and it seemed as though treatments lacked a “direction” or 
plan. This is particularly seen in the variation in both the chemotherapy and the supportive 
care medicines within the private sector. Treatment pathways should provide oncologists with 
evidence-based protocols thereby standardising treatments and limiting wastage and 
unnecessary financial strain.  
 
This study does provide insight into the cost components and the most costly components of 
cancer therapy for each sector but also highlights the fewer options available to patients and 
their oncologists in the South African public sector, based on the treatment regimens found to 
be used in this study. It highlights the vast differences in treatment access for the same disease 
within the South African healthcare sector as a whole (4 public sector regimens excluding 
irinotecan vs. 12 private sector regimens excluding aflibercept). This indicates a need for 
further resource utilisation studies in order to ensure effective use of the available resources 
and to limited resource wastage for the respective funders.  
 
4.7 Recommendations 
 
The public sector retrospective drug utilisation review and time and motion study should be 
replicated in several other oncology facilities within Gauteng. These results should be 
compared to other provinces in order to determine if treatment is equitable between all public 
sector patients. Non-medical costs should be incorporated into the costing model, as should 
surgery and radiation for a complete costing of colorectal cancer. Additional economic 
evaluations such as cost-effectiveness calculations should be performed to refine pathways 
but also increase resource utilization as this basic cost analysis is a primary step required prior 
to additional value-based economic analysis. In addition, a trial could be designed to compare 
a treatment pathway cohort to a current practice cohort in order to see if there is any cost 
savings.  In order for better comparisons, the methodology employed in the public sector 
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should be repeated at a private oncology clinic in order to ascertain data that is more 
comparable. This would particularly be with regard to the administration and administrative 
costs associated with receiving chemotherapy.  
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APPENDICES 
 
Appendix A Data collection sheet for Time and motion study                                          Date: ______________________ 
 
TASK 
TIME 1 TIME 2 TIME 3 
Start End Total Start End Total Start End Total 
Check-in          
 
Pink File          
 
Phlebotomy          
 
Lab          
 
Physician visit          
 
Pharmacy          
 
Drip administration and file 
completion 
         
 
Administration and 
Monitoring 
         
 
NOTES  
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Appendix B Data Collection Sheet for Drug Utilisation Study 
 
Patient information 
Patient identification code:  Date of Birth/ Age:  
Gender:   
Date of first diagnosis: Primary tumour site:  
Previous surgery: Y ☐  N ☐ 
Previous radiotherapy: Y ☐  N ☐ 
*for colorectal cancer 
 
ICD code:  ECOG status: 
Disease stage: Metastases: Y ☐  N ☐ 
If Yes where:  
and date of diagnosis:  
 
Treatment History 
Date Drug Dosage and Form Instructions 
    
 
Treatment plan 
No of cycles: 
Chemotherapy/Biologics: 
Drug 
 
 
Originator/Generic Dosage and Form Frequency Comments 
Supportive therapies: 
Drug 
 
 
Originator/Generic Dosage and Form Frequency Comments 
 
Treatment received 
No of cycles: 
Date of 
Administration 
Chemotherapy/Biologics: 
 
 
 
 
Drug 
 
 
 
Originator/Generic Dosage and Form Frequency Comments 
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Date of 
Administration 
Supportive therapies: 
 Drug 
 
 
Originator/Generic Dosage and Form Frequency Comments 
 
Pathology etc.:  
 
 
 
 
  
 196 
Appendix C Medicine list and classification for claimed medicines within private sector 
patient cohort grouped by class based on the ATC classification system 
 
ATC Classification ATC Description STRENGTH 
DOSAGE 
FORM 
Admin meds 
ANTISEPTICS AND 
DISINFECTANTS  
SLN 
Admin meds 
Carbohydrates – Dextrose OR 
Glucose  
INF/INJ 
Admin meds Cetrimide 
 
SLN 
Admin meds Chlorhexidine 
 
SLN/SPR 
Admin meds Povidone-iodine 
 
SLN/TUL 
Admin meds Silver nitrate 
 
STI 
Admin meds Sodium chloride 
 
INF/INJ/SLN 
Admin meds 
Solvents and diluting agents, 
incl. irrigating solutions - 
Water 
 
INJ/INF/SLN/
MLS 
Admin meds Chloroform water 
 
MLS 
Chemotherapy Azacitidine 100 INJ 
Chemotherapy Bevacizumab 400/100 INF 
Chemotherapy Calcium folinate 
300/200/100/1
75/50/25/15 
INJ/TAB 
Chemotherapy Capecitabine 500/150 TAB 
Chemotherapy Carboplatin 450 INJ 
Chemotherapy Cetuximab 5/2 INF 
Chemotherapy Cisplatin 50/10/0,5 INJ 
Chemotherapy Docetaxel 80/20 INF 
Chemotherapy Fludarabine 50 INJ 
Chemotherapy Fluorouracil 
5000/1000/500
/50/5 
INJ/OIN 
Chemotherapy Gemcitabine 200/10 INJ 
Chemotherapy Idarubicin 10/5 INJ 
Chemotherapy Irinotecan 100/40/20 INF 
Chemotherapy Mitomycin 10/2 INJ 
Chemotherapy Oxaliplatin 100/50 INF 
Chemotherapy Paclitaxel 300/30 INF 
Chemotherapy Regorafenib 40 TAB 
Chemotherapy Tegafur, combinations 
 
CAP 
Chemotherapy Tretinoin 10 CAP 
Pain management Acetylsalicylic acid 81 ECT 
Pain management Alfentanil 0,5 INJ 
Pain management Buprenorphine 20/10/5/0,2 TAB/PTD 
Pain management Celecoxib 200/100 CAP 
Pain management Codeine 30 TAB 
Pain management Diclofenac 100/50 DSP/SUP 
Pain management Dihydrocodeine 30 TAB 
Pain management Etoricoxib 90/60 TAB 
Pain management Fentanyl 
100/75/50/25/1
2 
INJ/PTD 
Pain management Hydromorphone 8/4 TAB 
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Pain management Ibuprofen, combinations 
 
CAP/TAB 
Pain management Lornoxicam 8 TAB 
Pain management Meloxicam 15/7,5 TAB 
Pain management Morphine - MST 60/30/10 SRT 
Pain management Morphine 15/10 PDR/INJ 
Pain management Oxycodone 80/40/20/10/5 SRT/CAP 
Pain management Paracetamol 500/1 TAB/CAP/INF 
Pain management 
Paracetamol, combinations 
excl. psycholeptics  
TAB/CAP 
Pain management Tramadol 
200/150/100/5
0 
SRT/CAP/INJ 
Pain management Tramadol, combinations 
 
TAB 
Pain management Tramadol, combinations 
 
TAB 
Pain management Tramadol, combinations 
 
TAB 
Supportive meds Aprepitant 
 
KIT-CAP 
Supportive meds Aprepitant 125/80 CAP 
Supportive meds Betamethasone 6/5/4/0,6/0,5 INJ/TAB/SYR 
Supportive meds Cyclizine 100/50 SUP/TAB 
Supportive meds Dexamethasone 4 INJ 
Supportive meds Diazepam 10 INJ 
Supportive meds Domperidone 10 TAB 
Supportive meds Granisetron 3/2/1 TAB/INJ 
Supportive meds Haloperidol 5 TAB 
Supportive meds Hydrocortisone 100 INJ 
Supportive meds Lorazepam 2,5/1 TAB/SLT 
Supportive meds Methylprednisolone 
500/125/40/16/
4 
TAB/INJ/OIN 
Supportive meds Metoclopramide 10/5 TAB/INJ/SYR 
Supportive meds Ondansetron 8/4 INJ/TAB/DSP 
Supportive meds Palonosetron 50 INJ 
Supportive meds Prednisone 20/5 TAB 
Supportive meds Prochlorperazine 25/12,5/5 TAB/SUP/INJ 
Supportive meds Promethazine 25/10/2,5 INJ/CRE/TAB 
Supportive meds 
(additional) 
Atropine 1/0,6/0,5 INJ/OPD 
 
 
 
 
 
 
 
 
 
 
 
 
 198 
Appendix D Pivot table builders  
 
 
Figure 1 Pivot table builder for initial summary of data set A4 in order to determine 
treatment pathways - Based on the treatment pathways, patients were excluded if the treatment claimed/received 
was for other cancers such as breast, prostrate, lymphoma, ovary and myeloma to name a few.  
 
 
 
Figure 2 Pivot table builder for initial summary of data set A7 in order to determine 
claimed costs 
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Figure 3 Pivot table builder for cost adjustment data in order to calculate the average 
costs and number of cycles – Filter will be either advanced CRC or early CRC  
 
 
Figure 4 Pivot table generated in order to calculate the number of cycles per regimen 
and subsequently the average number of cycles per regimen – Each column used for the 
treatment pathways was denoted as 1, 2 etc. 
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Appendix E Medicine Lists 
 
Table 1 Public healthcare sector - Chemotherapy (Essential Medicine List, 2014) 
MEDICINE NAME ATC DOSAGE/S PRODUCT NAME 
CONTRACT 
NUMBER 
PRICE (Rands) 
LEVEL 
OF 
CARE 
5-FLUOROURACIL L01BC 50mg/ml 5-Fluorouracil 50 mg/mL 10 mL vial HP04-2012Onc 15,05 TER 
 
CAPECITABINE 
 
L01BC 
 
150mg Capecitabine 150 mg 60 tablets HP04-2012Onc 413,54 [per tab = 6,89] TER 
500mg Capecitabine 500 mg 120 tablets HP04-2012Onc 2 782,42 [per tab = 23,19] TER 
 
FOLINIC ACID 
(Sodium or Calcium folinate/ 
Folinic acid) 
 
 
V03AF 
 
 
 
10mg/ml Calcium folinate 10 mg/mL 20 mL vial HP04-2012Onc 120 TER 
15mg Calcium folinate 15 mg 10 tablets HP04-2012Onc 1 46,89 TER 
300mg/30ml Calcium folinate 300 mg/30mL 30 mL vial HP04-2012Onc 180 TER 
50mg/vial Calcium folinate 50 mg/vial 1 vial HP04-2012Onc 30 TER 
 
OXALIPLATIN 
 
L01XA 
 
50mg/ml Oxaliplatin 50 mg/vial 1 vial HP04-2012Onc 702,68 TER 
100mg/ml Oxaliplatin 100 mg/vial 1 vial HP04-2012Onc 1 405,34 TER 
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Table 2 Public healthcare sector – Supportive care medicines (Essential Medicine List, 2014) 
MEDICINE  NAME ATC DOSAGE/S PRODUCT NAME 
CONTRACT 
NUMBER 
PRICE (Rands) 
LEVEL OF 
CARE 
5HT3 INHIBITORS A004AA 
4mg Ondansetron 4 mg 10 tablets HP04-2012ONC-01 
15,38 
[per tab = 1,54] 
HOSP 
4mg vial Ondansetron 4 mg/2mL 2 mL ampoule HP04-2012Onc 4,45 HOSP 
8mg Ondansetron 8 mg 10 tablets HP04-2012ONC-01 
16,90 
[per tab = 1,69] 
HOSP 
8mg vial Ondansetron 8 mg/4mL 4 mL ampoule HP04-2012Onc 7,15 HOSP 
1mg Granisetron 1 mg 10 tablets HP04-2012Onc 
201,78 
[per tab = 20,18] 
TER 
3mg vial Granisetron 1 mg/mL 3 mL ampoule HP04-2012Onc 63,28 TER 
 
CORTICOSTEROIDS H02AB 
4mg vial Dexamethasone 4 mg/mL 1 mL ampoule HP06-2012SVP 4,01 HOSP 
5mg Prednisone 5 mg 100 tablets HP09-2012SD 
10,51 
[per tab = 0,11] 
HOSP 
5mg Prednisone 5 mg 40 tablets HP09-2012SD 
4,00 
[per tab = 0,10] 
HOSP 
5mg Prednisone 5 mg 500 tablets HP09-2012SD 
41,53 
[per tab = 008] 
HOSP 
5mg Prednisone 5 mg 5000 tablets HP09-2012-01 
410,11 
[per tab = 0,08] 
HOSP 
 
DOPAMINE 
INHIBITORS 
 
 
10mg Metoclopramide 10 mg 100 tablets HP09-2012SD 
6,63 
[per tab = 0,07] 
HOSP 
10mg Metoclopramide 10 mg 500 tablets HP09-2012SD 
19,45 
[per tab = 0,04] 
HOSP 
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Table 3 Public healthcare sector - Chemotherapy (Single exit price, 2014) 
MEDICINE NAME ATC DOSAGE/S PRODUCT NAME NAPPI CODE SEP (Rands) 
LOWEST COST 
(Rands) 
HIGHEST 
COST (Rands) 
AVERAGE 
COST (Rands) 
5-
FLUOROURACIL 
L01BC 50mg/ml 
Floracor 50mg/ml Injection 711364001 15,66 
15,66 28,30 21,98 
Floracor 50mg/ml Injection 711366001 28,30 
 
BEVACIZUMAB L01XC 
100mg/4ml Avastin 100Mg 4Ml [251] 706042002 3 682,56 3 682,56 3 682,56 3 682,56 
400mg/16ml Avastin 400Mg 16Ml [251] 706041002 14 730,25 14 730,25 14 730,25 14 730,25 
 
CAPECITABINE L01BC 
150mg Xeloda 150 [251] 870072005 743,93 743,93 743,93 743,93 
500mg Xeloda 500 [251] 870080008 5 005,51 5 005,51 5 005,51 5 005,51 
 
Price per tab Xeloda 150: 12,40 12,40 12,40 
Price per tab Xeloda 500: 41,71 41,71 41,71 
 
CETUXIMAB L01XC 
2mg/ml (not 
available) 
Erbitux 2Mg/Ml (Merck) 710034001 2 897,69 2 897,69 2 897,69 2 897,69 
5mg/ml (20ml vial) Erbitux 5Mg/Ml (Merck) 715052001 2 897,69 2 897,69 2 897,69 2 897,69 
 
IRINOTECAN L01XX 
20mg/ml Irinotas (Accord) 712643001 370,50 370,50 370,50 370,50 
40mg/2ml 
Campto 40mg/2ml (Pfizer) 829560009 1 025,44 
374,40 1 025,44 494,94 
Irinotecan Safeline 40 Mg/2 Ml 718488001 375,00 
Sandoz Irinotecan 40 711903001 380,00 
Mylan Irinotecan 40mg/2ml 
(Xixia) 
717026001 412,70 
Accord Irinotecan 40 712603001 374,4 
Cipla Irinotecan 40 mg/2 ml 716182001 402,12 
100mg/5ml 
Campto 100mg/5ml (Pfizer) 829579001 2 563,58 
934,80 2 563,58 1 194,13 
Irinotecan Safeline 100 Mg/5 Ml 718489001 937,50 
Sandoz Irinotecan 100 711902001 950,00 
Mylan Irinotecan 100mg/5ml 
(Xixia) 
717027001 1 031,75 
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Accord Irinotecan 100 712872001 936 
Irinotas 100 (Accord) 712873001 934,80 
Cipla Irinotecan 100 mg/5 ml 716183001 1 005,29 
 
FOLINIC ACID 
(Sodium folinate) 
V03AF 
10mg/ml 
Leucovorin Faulding 10mg/ml 
(Pharmaplan) 
781525004 76,18 76,18 76,18 76,18 
15mg 
Rescuvolin Tab (Pharmachemie) 
10 TABS – NOT OFTEN USED 
788503006 198,70 198,70 198,70 198,70 
15mg/vial 
Rescuvolin Pfi 
15(Pharmachemie) 
827541018 32,24 32,24 32,24 32,24 
50mg/vial Rescuvolin Vial (Pharmachemie) 788511017 107,46 107,46 107,46 107,46 
100mg/10ml 
Abic Leucovorin 100mg/10ml 
(Teva) 
704608001 184,00 184,00 184,00 184,00 
200mg/20ml 
Abic Leucovorin 200mg/20ml 
(Teva) 
704609001 368,00 368,00 368,00 368,00 
300mg/30ml 
Abic Leucovorin 300mg/30ml 
(Teva) 
704610001 552,00 552,00 552,00 552,00 
 
OXALIPLATIN L01XA 
50mg/10ml (5mg/ml) 
Oxaliplatin Pch 50 717567001 1 061,34 
974,13 1 794,62 1 418,11 
Eloxatin 50mg/10ml RTU (Sanofi 
Aventis) 
707494001 1 300,44 
Oxaliwin 50mg/10ml RTU 
(Winthrop) 
710319001 980 
Intas Oxaliplatin 50 (Accord) 717829001 974,13 
Accord Oxaliplatin 50 718138001 980,00 
Exiplat 50 (Pharmaplan) 716224001 1 794,62 
100mg/20ml 
(5mg/ml) 
Oxaliplatin Pch 100 717569001 2 122,60 
1 948,26 3 589,22 3 228,19 
Eloxatin 100mg/20ml RTU 
(Sanofi Aventis) 
707495001 2 600,89 
Oxaliwin 100mg/20ml RTU 
(Winthrop) 
710317001 1 960,00 
Intas Oxaliplatin 100 (Accord) 717830001 1 948,26 
Accord Oxaliplatin 100 718139001 1 960,00 
Exiplat 100 (Pharmaplan) 716225001 3 589,22 
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PANITUMUMAB – 
Not registered – 
Section 21 Price 
(Registered in 2016) 
 100mg/5ml Vectibix 5ml 714612001 7 170,97 7 170,97 7 170,97 7 170,97 
 
REGORAFENIB - 
Registered Dec 2014 
 
40mg Stivarga 40 mg (28 tabs) 720787001 52 782,91 52 782,91 52 782,91 52 782,91 
 Price per tab Regorafenib: 1 885,10 1 885,10 1 885,10 
 
AFLIBERCEPT – 
International price 
March 2014 
 
100mg/vial Zaltrap 100mg N/A 5280,31 5280,31 5280,31 5280,31 
200mg/vial Zaltrap 200mg N/A 10560,62 10560,62 10560,62 10560,62 
 205 
Table 4 Public healthcare sector – Supportive care medicines (Single exit price, 2014) 
MEDICINE NAME DOSAGE/S PRODUCT NAME NAPPI CODE SEP (Rands) 
LOWEST 
COST (Rands) 
HIGHEST 
COST (Rands) 
AVERAGE 
COST (Rands) 
ONDANSETRON 
4mg/2ml 
Alepet 4 717049001 85,00 
51,30 247,08 178,24 
Sabax Ondansetron injection 4mg/2ml 711904001 231,00 
Nausetron 4,0 Mg Injection 705078001 168,08 
Ondansetron Fresenius 2mg/ml (4mg/2ml) 718557001 51,3 
Zofran 4mg Injection 785806008 240,53 
Mylan Ondansetron 4 Mg/2 Ml 705537001 71,64 
Aspen Ondansetron 4Mg/2Ml 705458001 247,08 
Zofer 4 Mg Injection 705941001 102,11 
Dantron 4 Injection 708105001 154,13 
Ondansetron - Hexal 4Mg Injection 710419001 164,93 
Danset 4 Mg 710908001 88,92 
Zydus-Ondansetron 4 mg Injection 711906001 177,63 
8mg/4ml 
Alepet 8 717050001 170,00 
102,60 494,16 321,97 
Sabax Ondansetron injection 8mg/4ml 711905001 462,01 
Nausetron 8,0 Mg Injection 705079001 336,19 
Ondansetron Fresenius 2mg/ml (8mg/4ml) 718558001 102,6 
Zofran 8mg Injection 785822003 481,07 
Mylan Ondansetron 8 Mg /4 Ml 705538001 143,2 
Aspen Ondansetron 8 Mg/4Ml 705460001 494,16 
Zofer 8 Mg Injection 705943001 204,21 
Dantron 8 Injection 708106001 308,35 
Ondansetron - Hexal 8Mg Injection 710420001 303,53 
Danset 8 Mg 710909001 177,84 
Vomiz 8 mg Injection 711533001 325,26 
Zydus-Ondansetron 8 mg Injection 711907001 355,22 
4mg (pack-5) Austell Ondansetron 4mg Tablets (pack-5) 716720001 96,19 6,41 per tab 44,38 per tab 21,13 per tab 
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 Dantron (pack-5) 704858002 150,43 
4mg (pack-10) 
 
Cipla-Ondansetron 4 (pack-10) 716801001 153,16 
Zofer 4 Mg Tablets (pack-10) 705944001 182,02 
Vomiz 4 mg Tablets (pack-10) 711531001 144,72 
4mg (pack-15) 
Zofran 4 (pack-15) 785814019 665,66 
Dantron (pack-15) 704858001 451,30 
4mg (pack-30) Austell Ondansetron 4mg Tablets (30) 716720002 192,39 
8mg (pack-5) 
 
Austell Ondansetron 8mg Tablets (pack-5) 717154001 192,33 
12,82 per tab 70,04 per tab 35,60 per tab 
8mg (pack-10) 
 
Vomiz 8 mg Tablets (pack-10) 711532001 289,47 
Cipla-Ondansetron 8 (pack-10) 716802001 306,32 
Zofer 8 Mg Tablets (pack-10) 705945001 364,03 
8mg (pack-15) 
 
Zofran 8 (pack-15) 785830006 1 050,65 
Dantron (pack-15) 706703001 709,74 
8mg (pack-30) Austell Ondansetron 8mg Tablets (30) 716154002 384,66 
 
GRANISETRON 
1mg/ml 
Granitril Injection 715706001 168,86 
151,62 425,53 225,26 
Kytril Iv 1Ml 861863003 425,53 
Sandoz Granisetron 1Mg/1Ml 714500001 191,45 
Granisetron Teva 1 718524001 151,62 
Adco Granisetron 1 Mg/1 Ml 712891001 188,83 
3mg/3ml 
Kytril Iv 3Ml 787019003 854,78 
545,63 854,78 635,31 
Mylan Granisetron 3 Mg/3 Ml 714109001 545,63 
Sandoz Granisetron 3Mg/3Ml 714501001 574,34 
Adco Granisetron 3 Mg/3 Ml 712892001 566,49 
1mg 
Granitril 1Mg Tablet (pack-10) 715707001 256,04 
17,88 per tab 77,92 per tab 38,90 per tab 
Kytril Oral (pack-10) 812374003 779,24 
Granicip 1mg (pack-10) 716740001 178,84 
Aspen Granisetron 1 Mg 713782001 342 
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2mg 
Kytril Oral (pack-5) 701453001 799,75 
58,20 per tab 159,95 per tab 91,32 per tab Granicip 2 mg (pack-5) 715305001 291,01 
Aspen Granisetron 2 Mg 713784001 279 
 
DOLASETRON 
100mg/20ml Zamanon 100 mg IV 869961004 1 232,01 1 232,01 1 232,01 1 232,01 
200mg Zamanon 200 mg Tablets (pack-3) 869988018 379,57 126,52 per tab 126,52 per tab 126,52 per tab 
 
TROPISETRON 
5mg/5ml Navoban 806641010 1 463,95 1 463,95 1 463,95 1 463,95 
5mg Navoban (pack-5) 806633018 625,07 125,01 p/tab 125,01 p/tab 125,01 p/tab 
 
PALONOSETRON 50mcg/ml Onicit 708388001 465,14 465,14 465,14 465,14 
 
DEXAMETHASONE 4mg/ml 
Decasone Injection 4Mg/Ml 818763019 441,38 
76,00 441,38 173,59 
Pharma-Q  Dexamethasone Phosphate Injection 4Mg/1Ml 701589001 92,44 
Mylan Dexamethasone 4 Mg/Ml 718224001 84,55 
Fresenius Dexamethasone 4 mg/1 ml 720206001 76,00 
 
PROCHLORPERAZINE 
12,5mg/ml Stemetil 1.25% M/V Inj 1 ml 766461009 129,32 129,32 129,32 129,32 
5mg (pack-25) Stemetil (pack-25) 766542009 70,68 
0,16 per tab 2,83 per tab 1,52 per tab 5mg (pack-250) 
Stemetil 5 mg Tablets (pack-250) 766542017 617,88 
Mitil (pack-250) 744182026 169,53 
5mg (pack-500) Scripto-Metic 5Mg (pack-500) 762849126 82,46 
 
METOCLOPRAMIDE 
10mg (pack-20) 
Setin (pack-20) 783285019 3,34 
0,09 per tab 2,12 per tab 0,62 per tab 
Maxolon t (pack-20) 740519018 42,47 
Sandoz Metoclopramide (pack-20) 757845002 4,58 
10mg (pack-
100) 
Setin (pack-100) 783285027 16,71 
Maxolon t (pack-100) 740519026 212,28 
10mg (pack- Adco Contromet Tablet (pack-500) 715875124 56,91 
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500) Betaclopramide (pack-500) 787817023 62,49 
Bio Metoclopramide (pack-500) 717891001 44,97 
Merck-Metoclopramide (pack-500) 701430001 65,27 
Clopamon (pack-500) 714828017 143,48 
10mg (pack-
1000) 
Setin (pack-1000) 783285035 131,81 
10mg/2ml 
Sabax Metoclopramide 10Mg/2Ml 856134007 25,35 
25,35 92,94 54,94 
Pramalon 832839019 29,64 
Clopamon Injection 10 mg/2 ml 714836001 68,88 
Maxolon i 2ml (pack-10) 740535005 92,94 
Pharma-Q Metoclopramide Injection 10Mg/2Ml 705973001 32,58 
 
APREPITANT 
80mg Emend (pack-5) 705301001 1 191,18 
238,24 238,24 238,24 125mg Emend (pack-5) 705302001 1 191,18 
COMBO PACK Emend Combi Pack (1x125 + 2x80) 716467001 714,71 
 
ATROPINE 
0,5mg/ml 
Sabax Atropine 0.5mg/ml (1ml) 798428007 22,11 
22,11 43,23 29,91 Atropine Sulphate Fresenius 0.5Mg/1Ml 705551008 43,23 
Pharma-Q  Atropine  Injection 0,5Mg/1Ml 700218001 24,38 
1mg/ml 
Sabax Atropine 1 Mg/Ml 798436018 29,64 
29,64 43,43 32,14 
Atropine Sulphate Fresenius 1Mg/1Ml 705578003 43,43 
Mylan Atropine 832758019 24,84 
Pharma-Q  Atropine  Injection 1 Mg/1 Ml 700226001 30,63 
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Appendix F Review articles used to identify the relevant clinical trials 
Author/s Title Journal and Publication 
date 
doi PubMed or 
SCOPUS 
Tol and Punt (2010) 
[175] 
Monoclonal antibodies in the treatment 
of metastatic colorectal cancer: a 
review 
Clin Ther. 2010 
Mar;32(3):437-53 
10.1016/j.clinthera.20
10.03.012. 
PubMed and 
SCOPUS 
Edwards et al. 
(2012) [176] 
A systematic review of treatment 
guidelines for metastatic colorectal 
cancer 
Colorectal Dis. 2012 
Feb;14(2):e31-47 
10.1111/j.1463-
1318.2011.02765.x. 
PubMed and 
SCOPUS 
Bekaii-Saab and Wu 
(2014) [179] 
Seeing the forest through the trees: a 
systematic review of the safety and 
efficacy of combination chemotherapies 
used in the treatment of metastatic 
colorectal cancer 
Crit Rev Oncol Hematol. 
2014 Jul;91(1):9-34 
10.1016/j.critrevonc.2
014.01.001. Epub 
2014 Jan 15. 
PubMed 
Kordatou, 
Kountourakis and 
Papamichael (2014) 
[178] 
Treatment of older patients with 
colorectal cancer: a perspective review 
Ther Adv Med Oncol. 2014 
May;6(3):128-40 
10.1177/17588340145
23328. 
PubMed and 
SCOPUS 
Heinemann et al. 
(2013) [177] 
Targeted therapy in advanced CRC 
colorectal cancer-an example of 
personalised medicine in action 
Cancer Treat Rev. 2013 
Oct;39(6):592-601 
10.1016/j.ctrv.2012.12
.011. Epub 2013 Jan 
31. 
PubMed 
Fakih (2015) [180] Metastatic colorectal cancer: current 
state and future directions 
J Clin Oncol. 2015 Apr;33 
[online] 
10.1200/JCO.2014.59.
7633 
PubMed 
Golfinopoulos, 
Pentheroudakis and 
Pavlidis (2006) 
[174] 
Treatment of colorectal cancer in the 
elderly: A review of the literature 
Cancer Treat Rev. 2006 
32:1-8 
10.1016/j.ctrv.2005.10
.002. 
SCOPUS 
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Appendix G Sample of early CRC group of patients stratified by site of origin of the colorectal cancer – The site of origin starts with general 
diagnosis of colon [252], followed by all right sided colon cancer diagnosis (purple), left sided colon cancer diagnosis including rectal cancer 
(pink/red) and lastly if more than one site was diagnosed (green). Treatment regimens are colour coded based on the treatment line, 1
st
 line: Blue, 2
nd
 
line: Green, Maintenance: Orange, BSC: Yellow and if no therapy was administered: White. These tables are not the full data set but give an 
indication as to what data was recorded and analysed for the 2012 year at the CMJAH Oncology Clinic.  
Patient ID 
Code 
G Age  Treatment lines 
2012_001 M 63 5FU + LV         
2012_042 F 52 NONE         
2012_093 F 73 CAPOX CAPECITABINE       
2012_069 F 56 CAPOX         
2012_046 F 72 5FU + LV         
2012_055 M 40 CAPOX         
2012_066 M 78 NONE         
2012_079 M 70 CAPOX         
2012_080 F 46 NONE         
2012_082 M 38 CAPECITABINE         
2012_107 M 60 CAPOX         
2012_108 M 63 CAPOX CAPECITABINE       
2012_117 F 34 CAPOX CAPECITABINE       
2012_119 F U CAPOX         
2012_137 F 44 CAPOX CAPECITABINE       
2012_148 M 80 NONE         
2012_024 F 69 NONE         
2012_026 M 64 CAPOX         
2012_048 F 55 NONE         
2012_064 F 60 CAPOX CAPECITABINE       
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Appendix H Sample of advanced CRC group of patients stratified by site of origin of the colorectal cancer – The site of origin starts with 
general diagnosis of colon [252], followed by all right sided colon cancer diagnosis (purple), left sided colon cancer diagnosis including rectal cancer 
(pink/red) and lastly if more than one site was diagnosed (green). Treatment regimens are colour coded based on the treatment line, 1
st
 line: Blue, 2
nd
 
line: Green, Maintenance: Orange, BSC: Yellow and if no therapy was administered: White. These tables are not the full data set but give an 
indication as to what data was recorded and analysed for the 2012 year at the CMJAH Oncology Clinic.  
Patient ID 
Code 
G Age Treatment Pathways 
2012_030 F 67 CAPOX BSC           
2012_040 F 43 BSC             
2012_070 F 60 NONE             
2012_099 M 59 CAPOX XELIRI  CAPECITABINE + MITOMYCIN       
2012_127 F 74 CAPECITABINE CAPOX CAPECITABINE XELIRI CAPECITABINE + MITOMYCIN CAPECITABINE 
2012_136 M 46 CAPOX             
2012_023 F 50 CAPOX CAPECITABINE           
2012_114 M 53 CAPOX CAPECITABINE XELIRI         
2012_129 M 58 CAPOX XELIRI CAPECITABINE         
2012_143 F 26 NONE             
2012_149 M 52 CAPOX             
2012_004 M 51 CAPOX CAPECITABINE CAPOX         
2012_131 M U BSC             
2012_009 F 56 CAPOX CAPECITABINE FOLFIRI CAPECITABINE + MITOMYCIN BSC   
2012_016 M 62 CAPOX CAPECITABINE           
2012_144 M 62 CAPOX CAPECITABINE CAPECITABINE + MITOMYCIN       
2012_150 F 59 CAPOX BSC           
2012_151 M 38 CAPECITABINE CAPOX           
2012_025 F 65 CAPOX CAPECITABINE           
2012_106 F 47 CAPOX XELIRI  CAPECITABINE + MITOMYCIN CAPECITABINE BSC   
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Appendix I Sample of treatment pathways and total claimed medical cost per early CRC patient – G: Gender, A: Age, METS: Advanced CRC 
status, CRC SURG: Colorectal surgery. Treatment pathway colour coding relates to the treatment line, Blue: 1
st
 line, Green: 2
nd
 line, Red: 3
rd
 line, 
Turquoise: 4
th 
line, Purple: 5
th
 Line, White: NONE (no treatment but claims include diagnostic/radiation medicines etc.), Yellow: Best Supportive Care 
(BSC) and Orange: Maintenance therapy. Any non-conventional treatment line is indicated in one shade lighter for respective line.  These tables are 
not the full data set but give an indication as to what data was recorded and analysed for the medical scheme claims database. 
PATIENT 
COHORT 
CODE 
G Age 
CRC 
SUR
G. 
TOTAL 
MEDICAL 
COST 
TREATMENT PATHWAYS 
B0001 M 68 Y R99 291,48 FOLFOX (6 CYCLES) 
    
B0002 M 73 Y R769,61 BSC 
    
B0004 M 69 Y R2 300,04 NONE 
    
B0011 F 55 Y R116 987,64 5FU (9 CYCLES) FOLFOX (7 CYCLES) FOLFIRI (12 CYCLES) 
  
B0027 M 47 Y R107 995,20 5FU (2 CYCLES) FOLFOX (8 CYCLES) 
CAPECITABINE (2 
CYCLES) 
IRINOTECAN (6 
CYCLES)  
B0046 M 52 Y R100 950,28 CAPOX (6 CYCLES) 
CAPECITABINE (1 
CYCLE) 
XELIRI (1 CYCLE) 5FU (1 CYCLE) 
FOLFIRI (1 
CYCLE) 
B0094 M 74 Y R157 510,04 
IRINOTECAN (1 
CYCLE) 
FOLFIRI (1 CYCLE) 
CAPECITABINE (7 
CYCLES) 
FOLFOX (6 CYCLES) 5FU (2 CYCLES) 
FOLFIRI (8 CYCLES) 
    
B0173 M 56 Y R45 015,29 CAPOX (1 CYCLE) 5FU (15 CYCLES) 
   
B0400 M 64 Y R138 931,86 CAPOX (4 CYCLES) 
IRINOTECAN (1 
CYCLE) 
FOLFIRI (2 CYCLES) 
IRINOTECAN (1 
CYCLE) 
FOLFIRI (7 
CYCLES) 
B0401 F 68 Y R4 495,04 BSC 
    
B0402 M 56 Y R16 261,34 CAPOX (1 CYCLE) 
    
B0403 M 58 Y R42 074,14 FOLFOX (4 CYCLES) CAPOX (1 CYCLE) 
   
B0407 F 57 Y R3 300,78 NONE 
    
B0408 M 58 Y R76 366,38 CAPOX (7 CYCLES) 
CAPECITABINE (1 
CYCLE)    
B0409 M 56 Y R83 849,07 CAPOX (8 CYCLES) 
    
B0517 M 75 Y R344 114,95 FOLFOX (11 CYCLES) FOLFIRI (17 CYCLES) CAPOX (1 CYCLE) FOLFOX (11 CYCLES) 
 
B0569 F 66 Y R3 667,34 BSC 
    
B0690 F 36 Y R74 994,89 FOLFOX (3 CYCLES) 
FOLFOX + 
FLUDARABINE (1 
CYCLE) 
5FU (8 CYCLES) 
  
 213 
B0692 M 52 Y R58 291,89 
CAPECITABINE (7 
CYCLES)     
B0696 F 65 Y R53 087,95 CAPOX (4 CYCLES) 5FU (12 CYCLES) 
   
B0795 F 72 Y R105 239,27 
FOLFIRI (12 CYCLES) 5FU (1 CYCLE) FOLFIRI (1 CYCLE) 5FU (1 CYCLE) 
FOLFIRI (2 
CYCLES) 
CAPOX (1 CYCLE) 
    
B0818 F 91 Y R1 131,35 NONE 
    
B0821 F 70 Y R3 337,46 BSC 
    
B0862 F 53 Y R101 149,08 5FU (1 CYCLE) 
CAPECITABINE (7 
CYCLES) 
CISPLATIN (4 CYCLES) CAPOX (1 CYCLE) 
 
B0961 F 76 Y R98 612,61 FOLFOX (6 CYCLES) 
OXALIPATIN (1 
CYCLE) 
FOLFOX (3 CYCLES) 
  
B0991 M 40 N R925,23 NONE 
    
B1162 F 68 Y R101 229,28 
OXALIPLATIN + 
TEGAFUR INCL. CA 
FOLINATE (7 
CYCLES) 
    
B1267 M 73 Y R231 350,50 
CAPECITABINE (20 
CYCLES) 
IRINOTECAN (4 
CYCLES) 
CAPOX (8 CYCLES) 
CAPECITABINE (7 
CYCLES)  
B1283 M 63 Y R38 011,75 CAPOX (2 CYCLES) 
IRINOTECAN (5 
CYCLES)    
B1285 M 71 Y R4 142,28 5FU (1 CYCLE) 
    
B1326 M 60 N R318 213,95 CAPOX (6 CYCLES) 5FU (1 CYCLE) FOLFIRI (19 CYCLES) 
OXALIPLATIN (1 
CYCLE) 
FOLFIRI (5 
CYCLES) 
B1327 F 68 Y R91 823,88 CAPOX (2 CYCLES) FOLFOX (5 CYCLES) 
   
B1350 F 54 Y R107 220,21 FOLFOX (11 CYCLES) 
    
B1351 M 67 Y R122 886,73 CAPOX (6 CYCLES) 
CAPECITABINE (11 
CYCLES)    
B1393 M 68 Y R14 392,47 
CAPECITABINE (1 
CYCLE) 
CAPECITABINE + 
MITOMYCIN (1 
CYCLE) 
CAPECITABINE (2 
CYCLES) 
CAPECITABINE + 
MITOMYCIN (1 
CYCLE) 
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Appendix J Treatment pathways and total claimed medical cost per advanced CRC patient – G: Gender, A: Age, METS: Advanced CRC status, 
CRC SURG: Colorectal surgery. Treatment pathway colour coding relates to the treatment line, Blue: 1
st
 line, Green: 2
nd
 line, Red: 3
rd
 line, Turquoise: 
4
th 
line, Purple: 5
th
 Line, Teal: 6
th
 line, White: NONE (no treatment), Yellow: Best Supportive Care (BSC) and Orange: Maintenance therapy. Any 
non-conventional treatment line is indicated in one shade lighter for respective line.  These tables are not the full data set but give an indication as to 
what data was recorded and analysed for the medical scheme claims database. 
PATIENT 
COHORT 
CODE 
G Age 
CR 
SURG. 
TOTAL 
MEDICAL 
COST 
TREATMENT PATHWAYS 
B0003 F 59 Y R373 466,69 FOLFOX (3 CYCLES) FOLFIRI (10 CYCLES) 
FOLFOX + BEV (9 
CYCLES) 
FOLFOX (1 
CYCLE)  
B0008 M 69 Y R214 314,01 
FOLFOX + BEV (4 
CYCLES) 
FOLFOXIRI + BEV (1 
CYCLE) 
IRINOTECAN (1 
CYCLE) 
FOLFIRI (29 
CYCLES) 
IRINOTECAN (1 
CYCLE) 
B0010 M 69 N R94 789,42 FOLFIRI (3 CYCLES) 
IRINOTECAN (1 
CYCLE) 
FOLFIRI (7 CYCLES) 
CAPOX (2 
CYCLES)  
B0014 M 66 Y R747 629,05 CAPOX (8 CYCLES) 
XELIRI + BEV (16 
CYCLES)    
B0015 M 70 Y R293 055,60 FOLFOX (1 CYCLE) 
FOLFOX + BEV (11 
CYCLES) 
CAPECITABINE (1 
CYCLE)   
B0018 M 57 Y R225 066,20 CAPOX (8 CYCLES) 
CAPECITABINE (15 
CYCLES) 
XELIRI (2 CYCLES) 
  
B0019 M 68 Y R125 658,72 CAPOX (1 CYCLE) 
CAPOX + BEV (3 
CYCLES) 
XELIRI (1 CYCLE) 
  
B0022 M 68 Y R381 349,71 
FOLFOX + BEV (6 
CYCLES) 
FOLFOX (1 CYCLE) 
FOLFOX + BEV (1 
CYCLE) 
FOLFOX (1 
CYCLE) 
FOLFOX + BEV 
(4 CYCLES) 
FOLFIRI (12 CYCLES) 
    
B0118 F 80 N R200 724,72 FOLFIRI (15 CYCLES) FOLFOX (12 CYCLES) XELIRI (8 CYCLES) 5FU (10 CYCLES) 
 
B0121 M 60 Y R399 114,72 
CAPOX + BEV (7 
CYCLES) 
CAPOX (1 CYCLE) 
IRINOTECAN (2 
CYCLES) 
FOLFIRI (1 
CYCLE) 
IRINOTECAN (3 
CYCLES) 
FOLFIRI (1 CYCLE) 
    
B0123 F 49 N R939 820,04 
CAPOX + BEV (6 
CYCLES) 
FOLFIRI + BEV (1 
CYCLE) 
FOLFIRI (1 CYCLE) 
FOLFIRI + BEV (11 
CYCLES)  
B0124 F 64 Y R81 955,97 FOLFOX (11 CYCLES) 
    
 
 
 
B0155 
 
 
M 58 Y R230 315,57 
CAPECITABINE (4 
CYCLES) 
CAPOX (4 CYCLES) FOLFIRI (1 CYCLE) 
FOLFIRI + BEV (5 
CYCLES) 
CAPECITABINE 
(1 CYCLE) 
FOLFIRI (2 CYCLES) 
FOLFIRI + BEV (1 
CYCLE)    
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B0170 M 58 Y R475 803,94 
CAPOX + BEV (4 
CYCLES) 
OXALIPLATIN (1 
CYCLE) 
FOLFIRI (15 CYCLES) 
FOLFOXIRI (6 
CYCLES) 
CAPECITABINE 
+ BEV (3 
CYCLES) 
BEV (1 CYCLE) 
CAPECITABINE + BEV 
(1 CYCLE) 
BEV (1 CYCLE) 
REGORAFENIB (1 
CYCLE)  
B0174 M 57 Y R107 222,09 FOLFOX (9 CYCLES) 5FU (3 CYCLES) 
   
B0205 F 55 Y R166 197,93 FOLFOX (6 CYCLES) FOLFIRI (3 CYCLES) 
CARBOPLATIN + 
PACLITAXEL (3 
CYCLES) 
CISPLATIN + 
GEMCITABINE (1 
CYCLE) 
CARBOPLATIN + 
PACLITAXEL (1 
CYCLE) 
B0332 F 58 Y R95 340,09 CAPOX (3 CYCLES) 
OXALIPLATIN (1 
CYCLE) 
TEGAFUR, COMBO + 
IRINOTECAN (2 
CYCLES) 
  
B0346 F 72 Y R264 471,93 
TEGAFUR, COMBO (1 
CYCLE) 
XELIRI (7 CYCLES) 
OXALIPLATIN (6 
CYCLES) 
OXALIPLATIN + 
BEV (6 CYCLES)  
B0351 F 59 Y R768 518,83 
FOLFOX + CET (5 
CYCLES) 
FOLFIRI (1 CYCLE) 
FOLFIRI + BEV (4 
CYCLES) 
5FU + BEV (5 
CYCLES) 
BEV (1 CYCLE) 
FOLFOX + CET (1 
CYCLE)     
B0382 F 46 Y R497 547,15 
FOLFOX (4 CYCLES) BEV (5 CYCLES) XELIRI (5 CYCLES) 
IRINOTECAN + 
BEV (7 CYCLES) 
CAPOX + CET (1 
CYCLE) 
CAPOX (1 CYCLE) 
CAPOX + CET (1 
CYCLE)    
B0383 F 59 N R608 323,18 
CAPOX + BEV (4 
CYCLES) 
OXALIPLATIN + BEV (3 
CYCLES) 
CAPECITABINE + 
BEV (10 CYCLES) 
CAPECITABINE (5 
CYCLES)  
B0388 M 40 Y R248 240,05 FOLFOX (10 CYCLES) 
IRINOTECAN + CET (3 
CYCLES)    
B0390 M 38 Y R756 363,48 
CAPOX (6 CYCLES) 
OXALIPLATIN (1 
CYCLE) 
FOLFIRI (9 CYCLES) 
IRINOTECAN + 
CET (2 CYCLES) 
FOLFIRI + CET 
(3 CYCLES) 
CAPECITABINE + CET 
(1 CYCLE) 
IRINOTECAN + BEV (3 
CYCLES) 
FOLFOX + CET (1 
CYCLE)   
B0392 F 61 Y R144 328,15 FOLFOX (6 CYCLES) 
    
B0395 M 55 Y R132 083,10 
OXALIPLATIN (1 
CYCLE) 
FOLFOX + BEV (5 
CYCLES)    
B0404 M 70 Y R253 027,45 FOLFOX (10 CYCLES) 
FOLFIRI + BEV (7 
CYCLES)    
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Appendix K Theoretical costs calculated from costing model for public healthcare sector 
 
Table 5 Theoretical chemotherapy costs for early CRC colon cancer in the public healthcare sector 
Chemotherapy costs for early CRC colon costs 
Chemotherapy cost per cycle is based on cost per vial, not on cost per mg.    
  5-FU LV Capecitabine Capecitabine Capecitabine Oxaliplatin Rationale / Reference 
No. of cycles 6 6 8 8 8 6 
*see pvt sector SAOC primary 
LOC 
No. of administration 
per cycle 
1 1 28 28 28 1   
Average BSA (m2) 1,73 1,73 1,73 1,73 1,73 1,73 
Av BSA for cancer patient (Heaf, 
2007; McIntosh et al., 1928) 
Dose (mg/m2) 2800 400 850 1050 1250 85 
Clinical trial data and treatment 
guidelines (NCCN) 
Dose per 
administration (mg) 
4844 692 1470,5 1816,5 2162,5 147,05   
Dose per cycle (mg) 4844 692 41174 50862 60550 147,05   
No. of vials (tabs) per 
cycle 
10 4 84 102 122 2   
(500mg x 10) 
(300mg x 2), 
(50mg x 2) 
(500mg x 82), 
(150mg x 2) 
(500mg x 102) 
(500mg x 121), 
(150mg x 1) 
(100mg x 1), 
(50mg x 1) 
  
Medicine price / vial 
(tab) R 15,05 R 180,00 
R6,89 R23,19 R6,89 
R 702,68 
EML Feb 2014 
(medicine 1, medicine 
2 ect)  R 30,00 
R23,19 
 
R23,19 
R 1 405,34 
Medicine costs per 
cycle 
R150,50 R420,00 R1 915,36 R2 365,38 R2 812,88 R2 108,02   
Total medicine costs 
(x cycles) 
R903,00 R2 520,00 R15 322,88 R18 923,04 R22 503,04 R12 648,12   
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Table 6 Theoretical chemotherapy costs for early CRC rectal cancer in the public healthcare sector 
Chemotherapy costs for early CRC rectal cancer 
Chemotherapy cost per cycle is based on cost per vial, not on cost per mg. 
  5-FU LV Rationale / Reference 
No. of cycles 4 4 
*see pvt sector SAOC primary LOC 
(2+2) 
No. of administration 
per cycle 
1 1   
Average BSA (m2) 1,73 1,73 
Av BSA for cancer patient (Heaf, 
2007; McIntosh et al., 1928) 
Dose (mg/m2) 2800 400 
Clinical trial data and treatment 
guidelines (NCCN) 
Dose per 
administration (mg) 
4844 692   
Dose per cycle (mg) 4844 692   
No. of vials per cycle 
10 4   
(500mg x 10) 
(300mg x 2), 
(50mg x 2) 
  
Medicine price / vial R 15,05 R 180,00 
EML Feb 2014 (medicine 1, medicine 
2 ect)  R 30,00 
Medicine costs per 
cycle 
R150,50 R420,00   
Total medicine costs 
(x cycles) 
R602,00 R1 680,00   
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Table 7 Theoretical chemotherapy costs for advanced CRC in the public healthcare sector 
Chemotherapy costs for advanced CRC 
Chemotherapy cost per cycle is based on cost per vial, not on cost per mg. 
  5-FU LV Capecitabine Capecitabine Capecitabine Oxaliplatin Rationale / Reference 
No. of cycles 6 6 8 8 8 6 *see pvt sector SAOC primary LOC 
No. of administration 
per cycle 
1 1 28 28 28 1   
Average BSA (m2) 1,73 1,73 1,73 1,73 1,73 1,73 
Av BSA for cancer patient (Heaf, 
2007; McIntosh et al., 1928) 
Dose (mg/m2) 2800 400 850 1050 1250 85 
Clinical trial data and treatment 
guidelines (NCCN) 
Dose per 
administration (mg) 
4844 692 1470,5 1816,5 2162,5 147,05   
Dose per cycle (mg) 4844 692 41174 50862 60550 147,05   
No. of vials (tabs) per 
cycle 
10 4 84 102 122 2   
(500mg x 10) 
(300mg x 2), 
(50mg x 2) 
(500mg x 82), 
(150mg x 2) 
(500mg x 102) 
(500mg x 121), 
(150mg x 1) 
(100mg x 1), 
(50mg x 1) 
  
Medicine price / vial 
(tab) R15,05 R180,00 
R6,89 R23,19 R6,89 
R702,68 
EML Feb 2014 
(medicine 1, medicine 
2 ect)  R30,00 
R23,19 
 
R23,19 
R1 405,34 
Medicine costs per 
cycle 
R150,50 R420,00 R1 915,36 R2 365,38 R2 812,88 R2 108,02   
Total medicine costs 
(x cycles) 
R903,00 R2 520,00 R15 322,88 R18 923,04 R22 503,04 R12 648,12   
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Appendix L Theoretical costs calculated from costing model for private healthcare sector 
 
Table 8 Theoretical chemotherapy costs for early CRC (colon) in the private healthcare sector 
Chemotherapy costs for early CRC colon (lowest SEP) 
Chemotherapy cost per cycle is based on cost per vial, not on cost per mg. 
  5-FU LV Capecitabine Capecitabine Capecitabine Oxaliplatin Irinotecan Rationale / Reference 
No. of cycles 6 6 8 8 8 6 6 
SAOC Aug 2014 
Guidelines (Std LOC) 
No. of administration 
per cycle 
1 1 28 28 28 1 1   
Average BSA (m2) 1,73 1,73 1,73 1,73 1,73 1,73 1,73 
Av BSA for cancer patient 
(Heaf, 2007; McIntosh et 
al., 1928) 
Dose (mg/m2) 2800 400 850 1050 1250 85 180 
Clinical trial data and 
treatment guidelines 
(NCCN) 
Dose per administration 
(mg) 
4844 692 1470,5 1816,5 2162,5 147,05 311,4   
Dose per cycle (mg) 4844 692 41174 50862 60550 147,05 311,4   
No. of vials per cycle 
10 3 84 102 122 2 4   
(500mg x 10) 
(100mg x 1), 
(300mg x 2) 
(500mg x 82), 
(150mg x 2) 
(500mg x 102) 
(500mg x 121), 
(150mg x 1) 
(100mg x 1), 
(50mg x 1) 
(20mg X 1) 
(100mg X 3) 
  
Medicine price / vial R 15,66 R 184,00 R 12,40 R 12,40 R 12,40 R 974,13 R370,50 
SEP Aug 2014 (medicine 1, medicine 2 
etc.)  
R 552,00 
R 41,71 R 41,71 R 41,71 R 1 948,26 
R934,80 
Medicine costs per 
cycle 
 R 156,61   R 1 288,00   R3 445,02   R4 254,42   R5 059,31   R 2 922,39  R3 174,90   
Total medicine costs (x 
cycles) 
 R 939,68   R 7 728,00   R27 560,16   R34 035,36   R40 474,48   R 17 534,34  R19 049,40   
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Table 9 Theoretical chemotherapy costs for early CRC (rectal) in the private healthcare sector 
 
Chemotherapy costs for early CRC (lowest SEP) 
Chemotherapy cost per cycle is based on cost per vial, not on cost per mg. 
  5-FU LV Rationale / Reference 
No. of cycles 4 4 SAOC Aug 2014 Guidelines (Std LOC) - (2+2) 
No. of administration per 
cycle 
1 1   
Average BSA (m2) 1,73 1,73 
Av BSA for cancer patient (Heaf, 2007; McIntosh et al., 
1928) 
Dose (mg/m2) 2800 400 Clinical trial data and treatment guidelines (NCCN) 
Dose per administration 
(mg) 
4844 692   
Dose per cycle (mg) 4844 692   
No. of vials per cycle 
10 3   
  
(500mg x 10) 
 
(100mg x 1), 
(300mg x 2) 
  
Medicine price / vial R 15,66 R 184,00 SEP Aug 2014 
(medicine 1, medicine 2 
ect)  
R 552,00  
Medicine costs per cycle  R 156,61   R 1 288,00    
Total medicine costs (x 
cycles) 
 R 626,45   R 5 152,00    
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Table 10 Theoretical chemotherapy costs for advanced CRC in the private healthcare sector 
Chemotherapy costs for advanced CRC (lowest SEP) 
Medicine cost per cycle is based on cost per vial (tab), not on cost per mg. 
  5-FU LV Capecitabine Capecitabine Capecitabine Oxaliplatin Irinotecan 
Rationale / 
Reference 
No. of cycles 6 6 8 8 8 6 12 
(SAOC Aug 2014 
Guidelines) 
No. of administration per 
cycle 
1 1 28 28 28 1 1   
Average BSA (m2) 1,73 1,73 1,73 1,73 1,73 1,73 1,73 
Av BSA for cancer 
patient (Heaf, 
2007; McIntosh et 
al., 1928) 
Dose (mg/m2) 2800 400 850 1050 1250 85 180 
Clinical trial data 
and treatment 
guidelines (NCCN) 
Dose per administration 
(mg) 
4844 692 1470,5 1816,5 2162,5 147,05 311,4   
Dose per cycle (mg) 4844 692 41174 50862 60550 147,05 311,4   
No. of vials (tabs) per 
cycle 
10 3 84 102 122 2 4   
(500mg x 10) 
(100mg x 1), 
(300mg x 2) 
(500mg x 82), 
(150mg x 2) 
(500mg x 102) 
(500mg x 121), 
(150mg x 1) 
(100mg x 1), 
(50mg x 1) 
(100mg x 3), 
(20mg x 1) 
  
Medicine price / vial R15,66 R184,00 R12,40 R12,40 R12,40 R974,13 R370,50 
SEP Aug 2014 (medicine 1, medicine 2 
ect)  
R552,00 
R41,71 R41,71 R41,71 R1 948,26 R934,80 
Medicine costs per cycle R156,61 R1 288,00 R3 445,02 R4 254,42 R5 059,31 R2 922,39 R3 174,90   
Total medicine costs (x 
cycles) 
R939,68 R7 728,00 R27 560,16 R34 035,36 R40 474,48 R17 534,34 R38 098,80   
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Table 11 Theoretical biological medicine costs for advanced CRC in the private healthcare sector 
Chemotherapy costs for advanced CRC (biologics) NB! Only originators available 
Medicine cost per cycle is based on cost per vial (tab), not on cost per mg. 
  
Bevacizumab 
(1st line) 
Bevacizumab 
(2nd line) 
Cetuximab 
(loading dose) 
Cetuximab Panitumumab Aflibercept Regorafenib 
Rationale/Reference  
No. of cycles 
10 10 1 8 8 9 3 
(SAOC Aug 2014 Guidelines)/ 
Literature for unreg/newly reg 
No. of 
administration per 
cycle 1 1 1 2 1 1 21 
Av BSA for cancer patient (Heaf, 
2007; McIntosh et al., 1928), 
Average BSA 
(m2) or BW (kg) 70 70 1,73 1,73 70 70 
Flat dose 
Conventional ideal BW [164] 
Dose (mg/m2) 
5 10 400 250 6 4 
Clinical trial data and treatment 
guidelines (NCCN) 
Dose per 
administration 
(mg) 350 700 692 432,5 420 280 160   
Dose per cycle 
(mg) 350 700 692 865 420 280 3360   
No. of vials (tabs) 
per cycle 
1 4 7 9 5 3 84   
(4oomg x 1) 
(400mg x 1), 
(100mg x 3) (100mg x 7) (100mg x 9) (100mg x 5) 
(100mg x 1), 
(200mg x 1) (40mg)   
Medicine price / 
vial R3 682,56 R3 682,56 R2 897,69 R2 897,69 R7 170,97 R5 280,31 R628,37 
SEP Aug 2014/ SEP Mar 2015/ 
Section 21 2014 (Amgen) 
(medicine 1, 
medicine 2 ect) R14 730,25 R14 730,25       R10 560,62   
Medicine costs 
per cycle R14 730,25 R25 777,94 R20 283,83 R26 079,21 R35 854,85 R15 840,93 R52 782,80   
Total medicine 
costs (x cycles) R147 302,49 R257 779,40 R20 283,83 R208 633,68 R286 838,80 R142 568,37 R158 348,40   
      
Therefore for CET: Loading 
dose +         
      Cycle doses =          
      R228 917,51         
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Appendix M Total theoretical treatment pathways costs for advanced CRC in the private healthcare sector for RAS mutant type patients– 
Due to all the possible dose combinations for regimens comprised of Capecitabine (Cape), CAPOX and XELIRI doses are seen at the top of the 
columns for the costs and CAPOX/Bev doses are in brackets behind regimen.  
Total 
Pathway 
costs RAS 
mutant type 
(average for 
two type of 
facilities): 
CAPOX + XELIRI dose 
combinations 
(850 +850) (1050+850) (1250+850) (850 +1050) (1050+1050) (1250+1050) (850 +1250) (1050+1250) (1250+1250) 
CAPOX, XELIRI, 
FOLFOX/BEV, 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R755 958,54 R762 433,74 R768 872,86 R762 433,74 R768 908,94 R775 348,06 R768 872,86 R775 348,06 R781 787,18 
CAPOX, XELIRI, 
CAPOX/BEV (850), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R775 962,60 R782 437,80 R788 876,92 R782 437,80 R788 913,00 R795 352,12 R788 876,92 R795 352,12 R801 791,24 
CAPOX, XELIRI, 
CAPOX/BEV (1050), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R784 056,60 R790 531,80 R796 970,92 R790 531,80 R797 007,00 R803 446,12 R796 970,92 R803 446,12 R809 885,24 
CAPOX, XELIRI, 
CAPOX/BEV (1250), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R792 105,50 R798 580,70 R805 019,82 R798 580,70 R805 055,90 R811 495,02 R805 019,82 R811 495,02 R817 934,14 
CAPOX, XELIRI, 
FOLFIRI/BEV, 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R737 020,29 R743 495,49 R749 934,61 R743 495,49 R749 970,69 R756 409,81 R749 934,61 R756 409,81 R762 848,93 
CAPOX dose 850 1050 1250 
 
CAPOX, FOLFIRI, 
FOLFOX/BEV, 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R772 376,98 R778 852,18 R785 291,30 
      
CAPOX, FOLFIRI, 
CAPOX/BEV (850), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
 
R792 381,05 R798 856,25 R805 295,37 
      
CAPOX, FOLFIRI, 
CAPOX/BEV (1050), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
 
R800 475,05 R806 950,25 R813 389,37 
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CAPOX, FOLFIRI, 
CAPOX/BEV (1250), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R808 523,95 R814 999,15 R821 438,27 
      
CAPOX, FOLFIRI, 
FOLFIRI/BEV, 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R753 438,73 R759 913,93 R766 353,05 
      
 
FOLFOX, FOLFIRI, 
FOLFOX/BEV, 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R786 348,11 
        
FOLFOX, FOLFIRI, 
CAPOX/BEV (850), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R806 352,17 
        
FOLFOX, FOLFIRI, 
CAPOX/BEV (1050), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R814 446,17 
        
FOLFOX, FOLFIRI, 
CAPOX/BEV (1250), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R822 495,07 
        
FOLFOX, FOLFIRI, 
FOLFIRI/BEV, 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R767 409,86 
        
XELIRI dose 850 1050 1250 
 
FOLFOX, XELIRI, 
FOLFOX/BEV, 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R769 929,66 R776 404,86 R782 843,98 
      
FOLFOX, XELIRI, 
CAPOX/BEV (850), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R789 933,73 R796 408,93 R802 848,05 
      
FOLFOX, XELIRI, 
CAPOX/BEV (1050), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R798 027,73 R804 502,93 R810 942,05 
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FOLFOX, XELIRI, 
CAPOX/BEV (1250), 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R806 076,63 R812 551,83 R818 990,95 
      
FOLFOX, XELIRI, 
FOLFIRI/BEV, 
FOLFIRI/AFLIBERCEPT, 
REGORAFENIB 
R750 991,41 R757 466,61 R763 905,73 
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Appendix N Total theoretical treatment pathways costs for advanced CRC in the private healthcare sector for RAS wildtype patients – Due to 
all the possible dose combinations for regimens comprised of Capecitabine (Cape), CAPOX and XELIRI doses are seen at the top of the columns for 
the costs and CAPOX/Bev doses are in brackets behind regimen.  
Total 
Pathway 
costs RAS 
wildtype 
(average 
for two 
type of 
facilities): 
CAPOX dose 850 1050 1250 
 
CAPOX, FOLFIRI, 
FOLFIRI/CET, 
FOLFOX/BEV, 
FOLFIRI/AFLIBER
CEPT, 
REGORAFENIB 
R1 403 389,32 R1 409 864,52 R1 416 303,64 
      
CAPOX, FOLFIRI, 
FOLFOX/PAN, 
FOLFIRI/BEV, 
FOLFIRI/AFLIBER
CEPT, 
REGORAFENIB 
R1 100 226,28 R1 106 701,48 R1 113 140,60 
      
CAPOX + XELIRI 
dose combination 
(850 +850) (1050+850) (1250+850) (850 +1050) (1050+1050) (1250+1050) (850 +1250) (1050+1250) (1250+1250) 
CAPOX, XELIRI, 
FOLFIRI/CET, 
FOLFOX/BEV, 
FOLFIRI/AFLIBER
CEPT, 
REGORAFENIB 
R1 386 970,87 R1 393 446,07 R1 399 885,19 
R1 393 446,0
7 
R1 399 921,2
7 
R1 406 360,39 
R1 399 885,
19 
R1 406 360,3
9 
R1 412 799,5
1 
CAPOX, XELIRI, 
FOLFOX/PAN, 
FOLFIRI/BEV, 
FOLFIRI/AFLIBER
CEPT, 
REGORAFENIB 
R1 083 807,84 R1 090 283,04 R1 096 722,16 
R1 090 283,0
4 
R1 096 758,2
4 
R1 103 197,36 
R1 096 722,
16 
R1 103 197,3
6 
R1 109 636,4
8 
 
FOLFOX, 
FOLFIRI, 
FOLFIRI/CET, 
FOLFOX/BEV, 
FOLFIRI/AFLIBER
CEPT, 
REGORAFENIB 
 
R1 417 360,44 
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FOLFOX, 
FOLFIRI, 
FOLFOX/PAN, 
FOLFIRI/BEV, 
FOLFIRI/AFLIBER
CEPT, 
REGORAFENIB 
R1 114 197,41 
        
XELIRI dose 850 1050 1250 
 
FOLFOX, XELIRI, 
FOLFIRI/CET, 
FOLFOX/BEV, 
FOLFIRI/AFLIBER
CEPT, 
REGORAFENIB 
R1 400 942,00 R1 407 417,20 R1 413 856,32 
      
FOLFOX, XELIRI, 
FOLFOX/PAN, 
FOLFIRI/BEV, 
FOLFIRI/AFLIBER
CEPT, 
REGORAFENIB 
R1 097 778,96 R1 104 254,16 R1 110 693,28 
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Appendix O Theoretical chemotherapy costs per healthcare sector - Ramucirumab and TAS-102 are unavailable in South Africa, 5FU/LV is 5-
fluorouracil and folinic acid, Cape – capecitabine, CAPOX – capecitabine and oxaliplatin, FOLFOX - 5-fluorouracil, folinic acid and oxaliplatin. 
XELIRI – capecitabine and irinotecan, FOLFIRI – 5-fluorouracil, folinic acid and irinotecan, Bev – bevacizumab, Pani – panitumumab, CET – 
cetuximab. 
 
Public sector chemotherapy costs* 
 5-FU + LV FOLFOX Cape (850) Cape (1050) Cape (1250) CAPOX (850) CAPOX (1050) CAPOX (1250) 
Cost per cycle  R570,50 R2 678,52 R1 915,36 R2 365,38 R2 812,88 R4 023,38 R4 473,40 R4 920,90 
Private sector chemotherapy costs – early CRC  
 5-FU + LV FOLFOX Cape (850) Cape (1050) Cape (1250) CAPOX (850) CAPOX (1050) CAPOX (1250) 
Cost per cycle  R1 444,61 R4 367,00 R3 445,02 R4 254,42 R5 059,31 R6 367,41 R7 176,81 R7 981,70 
Private sector chemotherapy costs – advanced CRC♯ 
 CAPOX 
(850) + Bev 
CAPOX 
(1050) + Bev 
CAPOX 
(1250) + Bev 
FOLFOX + 
Bev 
FOLFOX + 
Bev (2
nd
 line) 
FOLFIRI + 
Aflibercept 
FOLFOX + 
Pani 
Regorafenib 
Cost per cycle  R21 097,66 R21 907,06 R22 711,95 R19 097,25 R30 144,94 R20 460,44 R40 221,85 R158 348,40 
 FOLFIRI + 
Cet 
FOLFIRI + 
Bev (2
nd
 line) 
XELIRI (850) XELIRI 
(1050) 
XELIRI 
(1250) 
FOLFIRI  
Cost per cycle  R50 982,55 R30 397,45 R6 619,92 R7 429,32 R8 234,21 R4 619,51 
* Costs are the same for both early and advanced CRC as the regimens are the same 
♯ 
Costs for regimens that differ
 
from early  
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Appendix P Time and Motion Study Results 
 
Time and Motion Study - Data Points  
Day 1: 28/9/2015 
Task Time 1 Time 2 Time 3 Time 4 Time 5 Time 6 Time 7 Time 8 Time 9 Average  
Check-in 00:01:06 00:01:35 00:02:00 00:02:02 00:01:54 00:02:05 00:02:44 00:01:11 00:01:51 00:01:50 
Pink file  00:00:45 00:01:20 00:00:40 00:00:52 00:01:01 00:00:58 00:01:08 00:00:47 00:01:07 00:00:58 
Phlebotomy 00:04:28 00:05:00 00:03:50 00:02:31 00:04:31 00:04:34 00:04:10 00:03:35 00:04:36 00:04:08 
Lab 2 - 2,5 hrs. = 120 - 150 min 02:15:00 
(MIDPOINT) 
Physician visit 00:05:39 00:08:36 00:06:29 00:13:37 00:08:47 00:05:11 00:04:38 00:09:33 00:09:03 00:07:57 
Pharmacy - oral 00:02:10 00:03:05 00:01:18 00:02:39 00:02:54 00:06:28 00:01:39 00:03:48 00:04:04 00:03:07 
Pharmacy - mixing 00:09:40 00:10:35 00:08:48 00:10:09 00:10:24 00:13:58 00:09:09 00:11:18 00:11:34 00:10:37 
(ORAL 
SCRIPT PREP 
+ MIDPOINT 
MIXING 
TIME 
00:07:30) 
Drip admin + file update 00:02:17 00:03:25 00:02:37 00:03:25 00:03:11 00:02:59 00:03:39 00:03:32 00:04:14 00:03:15 
Administration + Monitoring 2 - 2,5 hrs. = 120 - 150 min 02:15:00 
(MIDPOINT) 
 
Time and Motion Study - Data Points 
Day 2: 6/10/2015 
Task Time 1 Time 2 Time 3 Time 4 Time 5 Time 6 Time 7 Time 8 Time 9 Average  
Check-in 00:01:17 00:01:52 00:01:44 00:01:39 00:02:32 00:01:04 00:01:02 00:00:58 00:01:51 00:01:33 
Pink file  00:01:02 00:01:22 00:00:58 00:01:31 00:01:11 00:01:17 00:01:11 00:01:17 00:01:08 00:01:13 
Phlebotomy 00:02:40 00:02:27 00:02:31 00:03:23 00:02:04 00:03:59 00:02:48 00:03:07 00:06:38 00:03:17 
Lab 2 - 2,5 hrs. = 120 - 150 min 02:15:00 
(MIDPOINT) 
 230 
Physician visit 00:34:42 00:06:59 00:07:18 00:03:38 00:06:25 00:08:39 00:05:48 00:18:21 00:16:57 00:12:05 
Pharmacy - oral 00:02:28 00:02:59 00:03:15 00:05:48 00:02:08 00:01:50 00:04:25 00:04:05 00:02:20 00:03:15 
Pharmacy - mixing 00:09:58 00:10:29 00:10:45 00:13:18 00:09:38 00:09:20 00:11:55 00:11:35 00:09:50 00:10:45 
(ORAL 
SCRIPT PREP 
+ MIDPOINT 
MIXING 
TIME 
00:07:30) 
Drip admin + file update 00:05:05 00:04:06 00:03:05 00:03:05 00:03:40 00:03:02 00:03:23 00:03:07 00:03:12 00:03:32 
Administration + Monitoring 2 - 2,5 hrs. = 120 - 150 min 02:15:00 
(MIDPOINT) 
 
Time and Motion Study - Data Points  
Day 3: 7/10/2015 
Task Time 1 Time 2 Time 3 Time 4 Time 5 Time 6 Time 7 Time 8 Time 9 Average  
Check-in 00:01:54 00:02:43 00:01:11 00:02:35 00:02:13 00:01:09 00:01:00 00:00:27 00:00:30 00:01:31 
Pink file  00:01:15 00:01:40 00:01:23 00:00:46 00:01:07 00:01:05 00:01:10 00:01:15 00:01:19 00:01:13 
Phlebotomy 00:04:39 00:04:56 00:05:01 00:05:44 00:05:07 00:04:12 00:04:40 00:02:51 00:04:17 00:04:36 
Lab 2 - 2,5 hrs. = 120 - 150 min 02:15:00 
(MIDPOINT) 
Physician visit 00:05:36 00:06:48 00:08:45 00:03:56 00:05:52 00:15:44 00:03:12 00:20:57 00:11:13 00:09:07 
Pharmacy - oral 00:02:04 00:03:34 00:04:40 00:02:00 00:02:03 00:02:32 00:01:49 00:00:58 00:01:25 00:02:21 
Pharmacy - mixing 00:09:34 00:11:04 00:12:10 00:09:30 00:09:33 00:10:02 00:09:19 00:08:28 00:08:55 00:09:51  
(ORAL 
SCRIPT PREP 
+ MIDPOINT 
MIXING 
TIME 
00:07:30) 
Drip admin + file update 00:04:59 00:03:06 00:02:32 00:05:48 00:01:23 00:03:30 00:03:08 00:03:30 00:03:29 00:03:29 
Administration + Monitoring 2 - 2,5 hrs. = 120 - 150 min 02:15:00 
(MIDPOINT) 
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Salaries for professionals (www.govpage.co.za)  
Profession Lowest pa Highest pa Average pa *Average ph Average pm 
Medical Specialist R859 086,00 R1 139 958,00 R999 522,00 R480,54 R8,01 
Pharmacist R533 496,00 R679 986,00 R606 741,00 R291,70 R4,86 
Nurse R294 861,00 R362 655,00 R328 758,00 R158,06 R2,63 
Admin Clerk R132 399,00 R155 961,00 R144 180,00 R69,32 R1,16 
*For an average 40 hour work week, the total number of hours worked is 40 X 52 = 2080 hours 
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Appendix Q Sensitivity analysis tables  
 
Table 12 Sensitivity analysis for the public healthcare sector - Each variable was varied by -50%, -20%, 20% and 50%. The number of cycles was 
rounded up to the nearest whole number if a decimal number was calculated for the variation. The table indicates the lowest and highest total costs 
when the respective variable was changed.   
 
Variable 
Theoretical CRC Regimens 
5FU+LV FOLFOX Capecitabine CAPOX 
Chemotherapy costs R42 743,58 R47 878,09 R98 598,33 R146 811,69 R8 756,26 R31 740,58 R20 727,18 R69 007,74 
Supportive care medicine costs R44 379,46 R44 606,37 R114 305,92 R115 396,49 R16 316,85 R16 619,40 R36 578,35 R37 305,40 
Administrative costs (TM study) R42 927,49 R47 510,29 R111 614,25 R120 779,85 R15 971,14 R17 310,82 R34 783,90 R40 894,30 
Administration costs  R25 542,28 R82 280,71 R76 824,57 R190 359,21 R16 417,70 R16 417,70 R36 783,02 R36 896,06 
Number of cycles R22 227,55 R88 910,19 R57 334,72 R229 338,89 R8 208,85 R32 835,40 R18 410,35 R73 641,40 
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Table 13 Sensitivity analysis for early CRC disease in the private healthcare sector - Each variable was varied by -50%, -20%, 20% and 50%. The 
number of cycles was rounded up to the nearest whole number if a decimal number was calculated for the variation. The table indicates the lowest and 
highest total costs when the respective variable was changed.   
Variable 
Theoretical CRC Regimens 
5FU+LV FOLFOX Capecitabine CAPOX 
Chemotherapy costs R20 164,99 R33 166,52 R62 233,70 R140 839,77 R21 659,48 R62 999,72 R49 490,76 R125 899,68 
Supportive care medicine costs R24 456,52 R26 636,55 R86 166,40 R97 080,52 R34 470,66 R37 377,37 R73 447,52 R80 723,60 
Administrative costs (av. of two 
facilities) 
R17 994,29 R39 560,99 R75 426,64 R118 560,04 R32 468,76 R41 381,16 R66 287,68 R95 043,28 
Administration costs  R24 841,01 R25 867,55 R89 120,08 R91 173,16 R35 439,56 R35 439,56 R75 416,64 R76 785,36 
Number of cycles R12 591,60 R50 366,39 R44 902,22 R179 608,89 R17 719,78 R70 879,13 R37 936,44 R151 745,76 
Variable 
Theoretical CRC Regimens 
 
FOLFIRI XELIRI 
Chemotherapy costs R66 960,56 R150 111,81 R52 642,00 R132 081,04 
Supportive care medicine costs R90 861,76 R102 309,40 R76 459,20 R83 735,28 
Administrative costs (av. of two 
facilities) 
R79 556,14 R124 920,64 R69 040,68 R99 283,68 
Administration costs  R93 993,28 R96 046,36 R78 665,44 R80 034,16 
Number of cycles R47 338,82 R189 355,29 R79 121,68 R79 121,68 
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Table 14 Sensitivity analysis for advanced CRC disease in the private healthcare sector - Each variable was varied by -50%, -20%, 20% and 50%. 
The number of cycles was rounded up to the nearest whole number if a decimal number was calculated for the variation. The table indicates the lowest 
and highest total costs when the respective variable was changed.   
Variable 
Theoretical CRC Regimens 
Capecitabine CAPOX + Bevacizumab FOLFOX + Bevacizumab FOLFIRI + Aflibercept 
Chemotherapy costs R21 659,48 R62 999,72 R136 595,00 R453 059,88 R126 592,96 R413 051,75 R123 301,91 R399 517,89 
Supportive care medicine costs R34 470,66 R37 377,37 R239 051,59 R248 146,69 R219 047,53 R228 142,63 R211 028,43 R224 064,84 
Administrative costs (av. of two 
facilities) 
R32 468,76 R41 381,16 R230 101,79 R266 046,29 R210 097,73 R246 042,23 R204 590,55 R236 940,60 
Administration costs  R35 439,56 R35 439,56 R241 543,14 R243 163,59 R221 539,08 R223 159,53 R214 887,77 R216 346,17 
Number of cycles R17 719,78 R70 879,13 R121 041,65 R484 166,58 R111 039,61 R444 158,45 R119 652,17 R430 747,80 
Variable 
Theoretical CRC Regimens 
FOLFOX + Panitumumab Regorafenib FOLFIRI + Cetuximab FOLFIRI + Bevacizumab 
Chemotherapy costs R187 755,97 R670 418,22 R240 477,39 R953 045,19 R695 070,40 R2 530 442,33 R112 012,30 R385 589,38 
Supportive care medicine costs R346 218,03 R353 494,11 R477 636,65 R478 726,68 R1 295 273,13 R1 330 036,88 R200 307,68 R208 998,62 
Administrative costs (av. of two 
facilities) 
R338 066,59 R369 796,99 R476 885,94 R480 228,09 R1 278 105,44 R1 364 372,24 R196 015,76 R217 582,46 
Administration costs  R348 211,27 R349 507,63 R477 999,99 R477 999,99 R1 305 564,68 R1 309 453,76 R202 880,57 R203 852,84 
Number of cycles R174 321,69 R697 286,78 R318 666,66 R955 999,98 R653 430,52 R2 613 722,09 R101 602,33 R406 409,32 
Variable 
Theoretical CRC Regimens 
XELIRI CAPOX FOLFIRI FOLFOX 
Chemotherapy costs R54 239,60 R133 678,64 R50 355,00 R126 763,92 R69 356,96 R152 508,21 R63 530,06 R142 136,13 
Supportive care medicine costs R76 856,64 R88 444,56 R73 399,28 R80 675,36 R91 280,08 R108 661,96 R86 094,04 R97 008,16 
Administrative costs (av. of two 
facilities) 
R71 134,08 R99 889,68 R66 239,44 R94 995,04 R82 696,24 R125 829,64 R75 354,28 R118 487,68 
Administration costs  R80 287,16 R81 583,52 R75 392,52 R76 688,88 R96 425,86 R98 370,40 R89 083,90 R91 028,44 
Number of cycles R40 359,64 R161 438,56 R37 912,32 R151 649,28 R48 537,02 R194 148,09 R44 866,04 R179 464,17 
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Appendix R Ethical Clearance for study 
 
 
